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Abstract
Cysteine proteases are ubiquitous throughout nature as proteolytic machinery that are
responsible for key physiological processes. Unregulated, uncontrolled or undesired prote-
olysis is often a key process in many disease states. As such, specific inhibitors of cysteine
proteases offer a unique therapeutic target for chemotherapeutic intervention. This is
particularly true in many diseases caused by parasitic infections, such as Malaria, Schis-
tosomiasis and Chagas disease, as the parasitic lifecycle is often highly dependent upon
cysteine proteases.
The majority of attempts at conferring specificity of covalent inhibitors have been derived
from classical structure activity relationship (SAR) studies. Such studies place emphasis
on the primary non-covalent interaction with little optimisation of the electrophillic trap,
which forms the covalent bond, being attempted. In this work a new class of electrophillic
traps, the thiosulfonates, will be developed as cysteine protease inhibitors. This aims to
take advantage of the differing chemistry observed for cysteine proteases, with a sulfur
centred nucleophile, rather than the oxygen centred nucleophile which is present in all
other protease classes. When combined with classical SAR this two pronged attack should
greatly increase inhibitor specificity and reduce off target effects, adding to the chemical
toolkit available to medicinal chemists.
Throughout this work the synthesis, reactivity profiles and biological evaluation of thiosul-
fonates as cysteine protease inhibitors will be explored. Computational modelling studies
will be incorporated, highlighting the synergy between classical SAR and electrophilic trap
optimisation. This will culminate in the application of thiosulfonates towards schistoso-
miasis, the second biggest neglected tropical disease after malaria.
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Chapter 1
Introduction
1.1 Cysteine Proteases: Structure, Mechanism and Role
in Disease
Proteases are ubiquitous throughout nature as one of the largest, most important enzyme
classes. This proteolytic machinery is involved in a vast range of physiological processes
including blood coagulation, digestion, fertilization, wound healing, cell differentiation
and growth, the immune response, cell signalling, apoptosis and protein turnover. Unde-
sired, unregulated and uncontrolled proteolysis can result in many disease states including
stroke, emphysema, cancer, viral infections, Alzheimer’s disease, arthritis and inflam-
mation.1 Furthermore, many pathogenic species depend upon proteases for a successful
lifecycle, including those which cause neglected tropical diseases (NTDs) such as Malaria,
Schistosomiasis, Leishmaniasis and Trypanosomiasis. As such, proteases have become in-
teresting targets for therapeutic intervention in a range of disease states, especially where
current therapies are limited and resistance is emerging. There are five main classes of
protease which are classified according to their catalytic site: serine, threonine, cysteine,
aspartic and metallo-proteases. This work focuses on the cysteine proteases, aiming to
exploit subtle differences in their chemistry to generate novel, class specific, inhibitor con-
structs - the thiosulfonates.
Cysteine proteases (CPs) are ubiquitous in nature, being found in all living organisms.
These CPs are categorised based on sequence homology into clans, containing one or more
CP families that have arisen from a single evolutionary origin. Furthermore, the families
are categorised based on three key features: (i) common sequence motifs surrounding the
catalytic residue, (ii) the order of catalytic residues in their sequence and (iii) by their
similar tertiary structure. The most abundant among all CPs is clan CA, encompassing
1
the calpain and papain families. The next most abundant clan is CD, which contains the
caspase, separases, legumain, gingipain and clostripain families.2,3 At present, 21 different
families of CPs have been identified, with almost half of these being found in viruses.4,5
Many of these proteases are also found in plants,6 fungi,7 bacteria and protozoa.8–11 The
mammalian CPs fall into two main groups; The cytosolic calpains and the lysosomal
cathepsins, both members of clan CA.12,13
Some of the best characterised, most widely studied cysteine proteases are the papain like
cysteine proteases (belonging to clan CA, family C1). The papain like cysteine proteases
are structurally related to papain (figure 1.1), which is isolated from the latex of papaya
fruit. The papain family includes CPs of mammals (e.g. the cathepsins) as well as CPs of
parasites such as Leishmania, Trypanosomatids, Schistosoma, Fasciola, Giardia and other
parasites.14,15
1.1.1 Structure
(a) Pro-Cathepsin L: PDB code 1HUC (b) Papain: PDB code 9PAP
Figure 1.1: (a) Structure of pro Cathepsin L with the pro-peptide highlighted in yellow running
up the active site cleft between cathepsin L’s left and right domains and (b) Structure of Papain.
Looking towards papain, as a representative protease within the papain family, it is char-
acterised by a single polypeptide chain of 212 amino acids, split into two domain of roughly
equal size (figure 1.1, right). The space between between the right domain (R) and a left
domain (L) forms the active site binding cleft, which is common to all members of the
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papain family. This V-grooved cleft houses the active site catalytic dyad of Cys25 (found
on the L domain) and His159 (found opposite on the R domain), which are evolutionary
preserved in all cysteine proteases. The R domain forms a β-barrel like structure with a
shorter α-helical motif appended to it, whilst the most distinct feature of the L domain is
the central α helix comprising approximately 30 residues.16
To prevent undesired protein degradation, cysteine proteases are synthesised as zymogens
(inactive precursors). The zymogens of CPs contain a prodomain that masks the active
site, blocking access to substrates, as shown for pro-cathepsin L in figure 1.1.17 It can
be noted that, alike papain, cathepsin L comprises a single polypeptide chain with two
distinct domains forming the active site binding cleft between them. The pro-peptide
of cathepsin L can be seen binding along this active site cleft, masking the catalytic
function until activation takes place. Whilst these pro-peptides function as an endogenous
inhibitor,18,19 the prodomain may also have roles in intracellular sorting and / or protein
folding.18,20,21 Transformation of the zymogen to the enzymes active form usually takes
place within a subcellular compartment, or the extracellular environment in which the
protease fulfils its biological role, with multiple modes of activation being reported.22,23
Zymogen conversion to the active form may occur auto catalytically (usually requiring
a significant drop in pH),24 by another protease or molecule of the same enzyme (trans-
activation),25 or by an uncommon mechanism such as that displayed for Schistosome
cathepsin B1 (SmCB1). SmCB1 exhibits a mode of activation that is part auto catalytic,
begining with autocatalysis of part of the prodomain, followed by a structural change
induced by a sulfated polysaccharide, before final trans-activation by another protease
(SmAE).26
Based on the early proposal of Schechter & Berger,27 the active site of papain (and related
proteases) comprises seven subsites (S4-S3’) which can accommodate the corresponding
amino acids of the substrate (commonly denoted P4-P3’). As shown in figure 1.2 the sub-
sites on the C-terminal side of the scissile bond are denoted the primed (’) sites, with the
subsites on the N-terminal side denoted as non-primed. The later work of Turk et al . re-
vised the definition of these substrate binding sites, highlighting that the three substrate
binding sites of S2-S1’ were of the greatest improtance, with binding contributing from
both the substrate backbone as well as amino acid side chains.16 Beyond these regions,
interaction at the S3 and S2’ subsites with substrate is dependent on the substrate amino
acid side chains, with no contribution from the substrate backbone. Furthermore, it was
defined that beyond the S3 and S2’ subsites the location and definition of binding sites be-
comes questionable, which was in keeping with Schechter & Berger’s original assessment.27
Hence, it can be reasoned that (for inhibitor design) the key sites to consider for successful
target engagement are the S2-S1’ regions.
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Figure 1.2: Papain subsite nomenclature and corresponding substrate residues. Substrate N-
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thiolate is shown in red adjacent to the scissile bond.
Proteases can be further classified depending on where in the peptidic substrate the scis-
sile bond lies. Endopeptidases represent the basis of the papain superfamily, cleaving
a scissile bond within the main chain of the peptide. Conversly, exopeptidases cleave
amino acids off the end of the peptide. Further to this, amino peptidases cleave from the
N-terminus while carboxy peptidases cleave from the C-terminus. This is an important
consideration as the mammalian papain like cysteine protease (cathepsin B) exhibits a
dipeptidyl carboxypeptidase activity, cleaving selectively two amino acids back from the
C-terminus. This activity is additional to the endopeptidase activity which is common
amongst the papain like proteases. It is the presence of a unique structural feature, termed
the occluding loop, which facilitates this function in cathepsin B. As shown in figure 1.3,
the occluding loop is an amino acid chain which extends beyond the C-terminal region
of the substrate (shown with a blue carbon backbone). Importantly, the occluding loop
houses two key hydrogen bonding partners (His110 and His111) which effectively anchor
the C-terminal carboxylic acid through a -COO-· · ·+H-Im hydrogen bond pairing with
both His residues. This activity is in addition to the endopeptidase activity exhibited for
all other papain like CPs and operates in a highly pH dependant manner.28
Rather than offer a full description of the structure of all papain-like cysteine proteases,
papain will be discussed as a representative example. Furthermore, Cathepsin B and
Cathepsin L will be discussed for comparison. Due to the high homology between papain
like cysteine proteases, it is commonplace in literature to describe cysteine proteases as
either cathepsin B or cathepsin L like, with the remaining structural features comparable
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Figure 1.3: Cathepsin B (PDB code: 1HUC) active site binding cleft highlighting subsites S3-
S2’ (cyan box), notable residues (yellow box) include the catalytic dyad of Cys29 and His199 and
also His110 and His111 of the occluding loop. Occluding loop is displayed with a blue carbon
backbone (towards the right of binding cleft as viewed)
to the parent papain enzyme. Thus, exploring the key structural elements of these three
key proteases will give a good understanding of the specificity and activity of multiple
papain like cysteine proteases. The three key regions will be discussed (S2-S1’), largely
based on the work of Turk et al . which provides a good overview of all binding sites.16
In the following description of the subsites, papain numbering has been used throughout,
thus residue numbers in figures may vary slightly if different proteases are presented to
highlight structural differences.
Begining with the S1 site, this lies completely within the L domain of the enzyme. For
reference, the S1 pocket of cathepsin B is shown in figure 1.4, which highlights both the
general features of this region as well as Cathepsin B specific additions of interest. As this
subsite is located directly next to the active site Cys29 (Cys25 in papain numbering) the
5
Figure 1.4: S1 site of cathepsin B highlighting key structural features. Based on papain num-
bering, the pocket is formed between residues 21-23 (pink carbon backbone) along the left side
as pictured, connected by a Cys22-Cys63 disulfide bridge at the base with the right side formed
by the broad turn of residues 63-66 (yellow carbon backbone). The oxyanion hole is formed by
th amide protons of Cys29 (25 in papain numbering) and Glu19 (papain numbering). Active site
catalytic dyad of Cys29 and His199 can also be seen (residues 25 and 159 in papain numbering)
backbone carbonyl of the substrate is able to interact with a region known as the oxyan-
ion hole. The oxyanion hole is a feature common to many protease classes, comprising
a local H-bond network which is thought to stabilise the oxyanion tetrahedral intermedi-
ates during peptide hydrolysis (see the later discussion on the catalytic cycle, figure 1.8).
As such, the backbone carbonyl of the substrate amide bond being hydrolysed offers an
important interaction within this region. This H-bonding takes place through the amide
protons of Cys25 and the Gln19 sidechain, forming the oxyanion hole. Moving along into
the S1 subsite, the binding region for the P1 side chain is created by the Ser21, Cys22 and
Gly23 loop along one side (left side as shown by pink carbon backbone in figure 1.4). The
Cys22 residue lies at the bottom of the S1 pocket, forming the base of the pocket with a
disulfide bridge accross to Cys63. Moving back down the other side of the S1 pocket is
a broad turn, shown with a yellow carbon backbone in figure 1.4, which is formed from
Cys63,Asn64, Gly65 and Gly66. Combined, this forms a relatively shallow binding pocket
for the majority of papain like proteases, with the P1 side chains running along the surface
and pointing towards solvent facing regions. In the case of papain, the backbone carbonyls
of the Ser21 and Cys23 are directed towards the P1 sidechain offering potential H-bond ac-
ceptors, which may account for the preference of an arginine side chain in this position.29
In the case of cathepsin B, an additional structural feature known as the occluding loop
is present, which further encloses this binding pocket. As shown in figure 1.4, Glu122
(with cyan carbons) extends out from the occluding loop and folds over the top of the
S1 pocket. This residue rests towards the bottom of the S1 pocket and further enhances
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the electrostatically negative character of this binding site. As a result, cathepsin B has
an increased preference towards basic residues binding in this region compared to papain,
although both can process basic P1 residues. Furthermore, the Glu122 residue restricts the
size of the S1 binding pocket of cathepsin B, reducing the steric bulk of P1 residues that
can be accommodated when compared with other papain like cysteine proteases, such as
papain or cathepsin L.30
Figure 1.5: S2 site of cathepsin B highlighting key structural features. View is along the
binding cleft with the active site Cys29 in the foreground. Key H-bond partner of Gly74 anchors
peptidic backbone amides allowing the side chain to stretch into the S2 binding pocket in the
right domain. Glu245 can be found at the bottom of the S2 pocket, offering a H bonding partner
for basic residues.
Moving on to the S2 site this offers the most well defined subsite of papain like CPs. This
binding site forms a deep pocket with contributions from both the L and R domains of the
protease. Figure 1.5 displays the S2 binding site for cathepsin B, which is representative of
papain-like CPs with some notable additions which will be discussed. The S2 site begins
from Gly74 (Gly66 in papain numbering) in the L domain that presents its carbonyl and
amide N-H towards the active site binding cleft, forming an excellent anti-parallel H bond
partner for peptidic substrates. With the anti-parallel H bonding of Gly74 anchoring the
substrate backbone, the side chain can then extend down into the S2 pocket, which takes
the form of a cavity penetrating into the R domain (moving from right to left away from
Gly74 and into binding pocket in figure 1.5). In general, this pocket is hydrophobic in
character being surrounded by aliphatic and methionine residues resulting in a preference
for hydrophobic residues such as phenylalanine in the P2 position.16 In the case of cathep-
sin B, the base of the S2 pocket houses a glutamic acid (Glu245, figure 1.5), replacing the
serine residue of papain (Ser205, papain numbering) and offers an H-bonding partner for
basic residues. As such, Cathepsin B and cathepsin B like proteases have been reported to
efficiently process arginine as well as phenylalanine in this position.31,32 Interestingly Turk
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et al . concluded that for the parasitic protease cruzipain, which is cathepsin B like in this
region, the glutamic acid adjusts its position in order to process different substrates in the
P2 position, swinging in towards the binding pocket to process basic residues, or outwards
away from the binding pocket to process hydrophobic residues based on the structures
published by Mcgrath et al . and Gilmor et al .32,33
Figure 1.6: The S1’ binding site of papain.
Finally, the S1’ site will be considered. The S1’ site is formed entirely within the R domain.
as shown in figure 1.6, lying directly within the base of the active site binding cleft is Trp177
(in papain numbering), which is highly conserved throughout all papain like CPs. The
NH of tryptophans NE1 atom offers a potential H bonding partner towards backbone
carbonyl of a substrate binding along the active site cleft before the P1’ sidechain extends
out towards the S1’ region. The main surface for interaction with P1’ side chains is created
by the loop between Gln135 and Gln142. The character of this binding site accepts both
small hydrophobic (up to three methylene units) as well as hydrophillic P1’ side chains.34
This dual functionallity may be attributed to the hydrophobic contact patch created by
Ala136 and Ala137, while Gln135 and Gln142 are thought to contribute to the hydrophilic
character. In the case of Cathepsin L there is a key alteration when compared with
papain to include two acidic residues (Glu141 and Asp137), which may explain its ability to
bind basic residues such as lysine in this position.35 Cathepsin L is also able to catalyse
substrates with an arginine in the P1’ position, which has been attributed to the (Asp137)
residue.
In the case of Cathepsin B this pocket is significantly larger and more hydrophobic in
character. This is likely due to the key structural change induced by deletion of Cys153
(papain numbering), which prevents disulfide formation to Cys240 (Cys200 in papain num-
bering).16 The loss of this disulfide effectively allows the chain between Tyr188 and Gly198
to fold forward over the top of the S1’ site (figure 1.7, increasing the size and contact patch
8
Figure 1.7: Cathepsin B S1’ binding site. The conserved loop, common to papain, is shown
with a pink carbon backbone. The additional peptide chain which overlaps the top of the binding
site is shown with a cyan carbon backbone. The top image shows a stick representation of key
residues, the bottom image shows a cartoon which highlights the nature of the additional peptide
chain in overlapping the conserved binding region
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of this binding region and allowing larger residues to be processed. This also enhances the
hydrophobic character of Cathepsin B’s S1’ region by overlapping it with Met196. Apart
from the contribution of the additional peptide chain, the original binding surface also
shows an increased hydrophobic character, replacing Gln135 and Gln136 (in papain) with
Val176 and Tyr177 in cathepsin B. The combination of cathepsin B’s key changes results in a
larger, more hydrophobic region which is in keeping with the observation by Menard et al .
that larger, hydrophobic P1’ residues (leucine, phenylalanine, tyrosine and tryptophan)
are accepted in this region.35
1.1.2 Mechanism
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Figure 1.8: Catalytic cycle of cysteine proteases
The enzymatic activity of cysteine proteases is highly dependent on the active site catalytic
dyad between Cys25 and His159, which exist as the ion pair -S-· · ·+H-Im.36,37 Figure 1.8
illustrates the catalytic cycle, which begins with the active site thiolate of Cys25 performing
a nucleophilic attack on the scissile bond (a) forming the tetrahedral intermediate (b),
which is stabilised by a local hydrogen bond network termed the oxyanion hole (figure 1.8,
left). Upon collapse of this intermediate protonated His159 acts as an acid, protonating
the amine moiety and forming the thioester-enzyme intermediate (c). The thioester then
undergoes hydrolysis (d) generating the corresponding carboxylic acid and restoring the
catalytic cysteine residue.
Mechanistically, the catalytic cycle of cysteine proteases shares many similarities with
other protease classes, including the common sequence of nucleophilic attack, tetrahedral
intermediate formation and collapse to the respective amine and carboxylic acid moieties.
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In many instances, this also involves similar catalytic dyad, or triads utilising histidine as
a catalytic residue. However, cysteine proteases are unique in that the catalytic histidine
first acts as a general acid in the catalytic cycle (proton donor). This is in contrast to
other protease classes, such as serine proteases, which first utilise their active site histidine
as a general base. As such, cysteine proteases offer a unique hydrogen bond partner at
the active site (protonated His), which can be targeted to enhance the selectivity towards
cysteine proteases over other protease classes. Furthermore, all other protease classes
operate through an oxygen centred nucleophile (i.e. the OH of serine and threonine, or
by polarising a water molecule in metallo proteases). As such, cysteine proteases offer a
softer nucleophile (sulfur centred) than the harder (oxygen centred) nucleophiles of other
protease classes. By considering these unique catalytic features, it can be hypothesised
that a softer electrophilic centre, which can take advantage of the the unique hydrogen
bond network of a cysteine protease, will be intrinsically more selective towards cysteine
proteases over other protease classes.
1.1.3 Cysteine Proteases Role in Disease
Table 1.1: Cysteine proteases, their host organism and associated disease state.
Cysteine Protease Organism Assosiated disease state
Mammalian Proteases
Cathepsin B Human Cancer
Cathepsin L Human Cancer
Cathepsin K Human Osteoporosis / Rheumatoid arthritis
Parasitic Proteases
Plasmodium
Falcipain-1 P. falciparum Malaria
Falcipain-2 P. falciparum Malaria
Falcipain-3 P. falciparum Malaria
Trypanosoma
Cruzipain T. cruzi Chagas disease
Rhodizane T. rhodesiense Acute African trypanosomiasis
Brucipain T. bruci Chronic African trypanosomiasis
Schistosoma
SmCB1 S. mansoni Schistosomiasis
SmCB2 S. mansoni Schistosomiasis
As papain-like CPs are ubiquitous throughout nature, they are responsible for a vast num-
ber of biochemical and physiological processes in living organisms. Members of the papain
family (clan CA, family C1) have been identified from plant, viral, parasitic and mam-
malian origin. The primary function of CPs in their respective organisms is metabolic
degradation of peptides and proteins. As such, disregulation of cysteine proteases has
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been implicated in many disease states. Mammalian CPs have been linked to the pro-
gression and development of diseases involving abnormal protein turnover.29,38–40 Table
1.1 displays a few notable members of the papain superfamily including the some mam-
malian lysosomal cathepsin (Cathepsins B,L and K) and their associated disease states.
Table 1.1 also displays some notable parasitic CPs related to plasmodium (responsible for
Malaria), Trypanosoma (responsible for Chagas disease and African sleeping sickness) and
schistosoma (responsible for schistosomiasis).
Mammalian Cysteine Proteases in Disease
The main focus of this work will be on parasitic cysteine proteases, however there are some
noteworthy mammalian proteases (the cathepsins) which will be briefly discussed. The
cathepsins are implicated in a range of human disease states such as osteo-arthritis,41,42
rheumatoid arthritis,43 immune system and inflammation related diseases44 and can-
cer.45
The Role of Cathepsins in Cancer
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Figure 1.9: Role of cathepsins B and L in tumour progression and metastasis. After initial
tumour formation (Tumourogenesis, step 1), the following seven key steps of metathesis involve
either cathepsin B, cathepsin L or both. These steps are; Proliferation (step 2), Epithelial-
mesenchymal transition (EMT, step 3), dissemination (step 4) Extracellular matrix (EM) degra-
dation (step 5), migration (step 6), invasion (step 7) and angiogenesis (step 8). Adapted from
Tan et al.45
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Cathepsins B and L are of particular interest as they show promise in the area of can-
cer treatment. Figure 1.9 displays some of the key areas in which cathepsins B and L
have been implicated in cancer.45 In general tumour metastasis and progression requires
proteolysis of the surrounding environment for spatial expansion,46 for angiogenesis (for-
mation of blood vessels aiding tumour growth)47 and for migration of transformed cells
(metastasis).48 The tumourigenesis stage is not thought to be reliant upon cathepsin B
or L, although other cathepsins are thought to be involved.45 Following on from this, the
cancer cells proliferate and undergo a process known as epithelial-mesenchymal transition
(EMT). EMT induces cellular changes in the cytoskeleton as well as protein expression
and is common to processes such as wound healing, embryonic development and tumour
metastasis.49
After EMT, dissemination of the cancer cells occurs. Cathepsin B has displayed a potential
role in dissemination of squamous carcinoma cells and pancreatic cancer cells.50,51 Vasil-
jeva et al . have shown that a reduction in invasion and migration of cancer cells correlated
with reduced cathepsin B levels, which may offer circumstantial evidence of cathepsin B’s
role in dissemination of cancer cells.52 According to the work of Tao et al . cathepsin
L, along with multiple other lysosomal proteins, may be important for dissemination of
cancer cells via the lymphatic system.53
Dissemination increases the motility of the cancer cells, however, degradation of the ex-
tracellular matrix (ECM) is required to allow migration throughout the body. Cathepsin
B can degrade components of the basement membrane and ECM, facilitating tumour
progression,46 whilst inhibition studies have demonstrated reduced cathepsin B activity
correlated with reduced ECM degradation and, in turn, the invasiveness of inflammatory
breast cancer.54 Similarly, Withana et al . found that administration of a cathepsin B
inhibitor (CA-074) reduced metastasis in tumour bearing animals.55 It has also been pro-
posed that the increased anaerobic glycolysis in cancer cells results in acidification of the
local environment, which facilitates extracellular activity of cathepsin L.45
The final stages of invasion and angiogenesis complete the process of metastasis of can-
cer cells. Cathepsin B is necessary for fibroblast mediated invasion in esophageal cancer,
with strong links between overexpression and angiogenesis in restricted colon adenocar-
cinoma,47,56 while cathepsin L has been reported to increase the invasiveness of ovarian
cancer cells in vitro.48 Furthermore, a cathepsin L knockout study (murine model) signif-
icantly reduced tumour invasion and proliferation.57
As a whole, the data present in the literature supports the cathepsins as a potential
therapeutic target in cancer.55,58 Indeed, a recent study has linked Cathepsin B inhibition
to reduced bone metastasis in breast cancer,55 which is significant as metastasis to the bone
is recognised as a major cause of morbidity. With this in mind, novel cysteine protease
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inhibitors such as the thiosulfonates explored in this work may find future applications in
this area.
The Role of Cathepsins in Bone Resorption and Osteoporosis
Figure 1.10: The role of Osteoclasts and Cathepsin K in bone resorption.44
Bone development and homeostasis is a complex process, which is highly reliant on the
balance of bone formation and resorption processes. Osteoblasts and osteoclasts are the
key cells responsible for the fine balance between bone formation and resorption.59 Osteo-
clasts are the specialised cells that attach to the bone surface during remodelling cycles
and facilitate bone resorption as shown in figure 1.10. Osteoclasts form a cavity or depres-
sion in the bone (known as the lacuna) by demineralising the bone through creating a local
acidic environment at their site of attachment. This unveils the organic matrix (approxi-
mately 90% type I collagen) to be degraded by proteases released by the osteoclasts, before
osteoblasts refill the lacuna with new bone, completing the remodelling cycle.60
Early inhibition studies linked cysteine protease activity with bone matrix degradation.61,62
For the most part, both cathepsins B and L have been found in bone tissue and are
proposed to have roles in collagen degradation.63,64 However, the later discovery that
cathepsin K is selectively expressed by osteoclasts and secreted into the resorption la-
cunae,65,66 suggests that cathepsin K is central in degrading the organic component of
the bone matrix.67,68 Additionally, Li et al . found that under physiologically relevant
conditions cathepsin K represented the only lysosomal collagen degrading activity.69 The
observations of Li et al . also correlate with the finding that inhibiting cathepsin K, both
in vivo and in vitro, reduced bone resorption.70
Understanding the role of cathepsin K led to questioning its role in disease states that are
characterised by loss of bone density. Osteoporosis is a progressive disease characterised
by loss of bone density and microstructural deterioration, resulting in an increased risk
of bone fractures due to skeletal fragility.71 The work of Kiviranta et al . displayed that
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Cathepsin K accelerated the turnover of metaphysical trabecular bone in a transgenic
murine model, which is an indicator of osteoporosis.72 Furthermore, Morko et al . used
a transgenic mouse model to highlight the effect of overexpressing cathepsin K, which
led to increased osteoclastic bone resorption. This resulted in an increased porosity of
the diaphyseal cortical bone and osteopenia (a common osteoporosis pre-cursor) of meta-
physeal trabecular bone.73 Under conditions that increased bone resorption is known to
occur, such as with bone resorption agents or during imobilisation (lack of movement,
often related to paralysis or bed rest in humans), the expression of cathepsin K is seen
to be up-regulated.74,75 Leading on from this, osteoperosis patients have been found to
have significantly higher cathepsin K levels than their corresponding controls.76 In these
patients the serum level of cathepsin K correlated with markers of bone turnover, bone
mineral density and the insidence of nontraumatic fractures. As a whole, the data present
in the literature validates cathepsin K as a suitable target for disease states involving
increased bone resorption and degradation, such as osteoporosis.77,78 Indeed, more recent
clinical trials have unveiled the successful application of a cathepsin K inhibitor for treat-
ment of osteoporosis,79 with three other cathepsin K inhibitors reported for osteoporosis
treatment (odanacatib, relacatib and balicatib).80–82
Although mammalian cysteine proteases (namely the cathepsins) will not be specifically
targeted in this work, the involvement of cysteine proteases in such a broad range of
human disease states, such as cancer and osteoporosis, has resulted in their interest as
therapeutic targets.83 Thus, this work on the development of thiosulfonates as cysteine
protease inhibitors may find application in these areas in future.
Cysteine Proteases and Neglected Tropical Diseases
Globally, parasitic disease has placed a burden on both domestic animals and humans
alike. Combined with emerging drug resistance, the development of new chemotherapeu-
tics is of the utmost importance. Cysteine proteases, which play a key role in the life
cycle of helminth and protozoan parasites, offer a key target for the development of new
chemotherapies. A common trend amongst these disease states is a high dependance on
CPs within the papain-like family (Clan CA, family C1). In this section, three key ne-
glected tropical diseases (NTD’s) will be discussed. This will begin with Chagas disease,
for which a cysteine protease inhibitor was developed playing a pivotal role in progressing
cysteine protease inhibitors as therapeutic targets of NTD’s. Next, the role of papain like
CPs will be discussed in Malaria and finally Schistosomaiasis. This will highlight the par-
asitic lifecycles and reliance on papain like cysteine proteases, validating CPs as suitable
chemotheraputics in each disease state. It is worth noting that multiple other (related)
parasitic diseases such as Leishmaniasis, African sleeping sickness and Giardiasis offer
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equally valid targets for similar reasons discussed herein. There are a number of reviews
which cover the role of cysteine proteases in parasitic organisms, providing substantial
background information and outlining the roles specific proteases play.11,44,84,85
The Role of Cathepsin Like Proteases in Schistosomiasis
Figure 1.11: Lifecycle of Schistosoma In both the snail vector (left, red) and human (right,
blue) stages. (Centre for disease control and prevention [CDC], 2019).
Schistosomiasis (bilharzia) is a chronic, debilitating neglected tropical disease (NTD) that
is second only to malaria in terms of public health importance. There are an estimated
200 million people infected, with a total of 400 million at risk. The disease is caused by
blood flukes belonging to the genus Schistosoma with the majority of human infections
caused by Schistosoma japonicum, S. haematobium and S. mansoni. In each case, the
blood flukes have a complex life cycle (shown in figure 1.11) that involves an intermediate
hosts (snails) and a final vertebrate host (often humans). During the life cycle, eggs are
shed from their vertebrate host through urine or faeces to enter into fresh water. These
eggs hatch (in an aqueous environment) and infect the intermediate snail host where they
mature to the infective cercariae stage. The cercariae are free swimming, allowing them
to come into contact with and infect their vertebrate host by penetration through the
skin. Upon entering the final host the cercariae lose their tail, becoming schistosomulae
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before maturation to adult schistosomes. The adult schistosomes lay eggs, completing
the parasites life cycle. It is during the final stages that the most significant damage
occurs to the host tissues, with schistosomes penetrating the walls of the small intestine or
veins (S. japonicumand, S. mansoni) or urinary bladder (S. haematobium). This results
in chronic and debilitating symptoms such as growth stunting, cognitive impairment and
lassitude.86
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Figure 1.12: Structure of praziquantel, the only actively administered schistosomiasis medica-
tion.
Large-scale elimination activities are ongoing and praziquantel, the only schistosomia-
sis medication, is widely deployed by mass drug administration programs (figure 1.12).
Praziquantel is effective against all species of schistosomes which infect humans, however
juvenile parasites are less susceptible to treatment than adults.87–89 Despite the current
success of praziquantel, relying on a single drug for treatment of 200 million people is con-
cerning.90 As such, new anti-schistosomal drug candidates are urgently needed, especially
since reduced susceptibility to praziquantel has been reported for many decades.91,92
Many steps of the schistosomes life cycle are highly dependent upon papain-like cysteine
proteases. For example, cathepsin B-like and cathepsin L-like activities have been de-
scribed at different stages of trematode development.93 Furthermore, the cercariae utilise
proteolytic activities to penetrate the human skin and evade the immune response. In
the case of S. japonicum cathepsin B activity has been found in the cercarial secretions,94
with a cathepsin B2-like cysteine protease being identified as the main penetration tool.95
Schistosomes have also been reported to utilise papain-like cysteine proteases such as legu-
main, cathepsin B, D, C and L to degrade the hemoglobin of hosts, which is required for
nutrition growth, development and reproduction of the parasite.93 In S.mansoni two iso-
forms of cathepsin L have been isolated (SmCL1 and SmCL2),96,97 as well as a cathepsin
B-like protease (SmCB1 and SmCB2).98,99 SmCB1 has been reported as having high
hemoglobinase activity in infected mammals, representing the major proteolytic activity
of S.mansoni.100
Due to the parasites dependence on cysteine proteases throughout its life cycle, cysteine
protease inhibitors offer valuable therapeutic targets. Indeed work by Abdulla et al . has
highlighted that the cysteine protease inhibitor K11777 (structure shown in figure 1.16),
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which was originally developed for treatment of Chagas disease, offers a novel chemother-
apeutic for schistosomiasis.101
The Role of Falcipains in Malaria
.
Figure 1.13: Lifecycle of Plasmosium In both mosquito (left, red) and human (right, blue)
stages. Infective species of protozoa is trypomastigote. (Centre for disease control and prevention
[CDC], 2019).
Human malaria represents the most prevalent neglected tropical disease, with an esti-
mated 219 million cases claiming more than 435,000 lifes in 2017.102 Malaria is caused
by one of four Plasmodium protozoa (Plasmodium malariae, P. vivax, P. ovale and P.
falciparum).103–106 P. falciparum is responsible for the majority of malaria deaths, partic-
uarly in children under the age of 5.107 The lifecycle of malaria is shown in figure 1.13,
comprising both vector stages (in the female anopheles mosquito) and host stages (hu-
man). Infection begins when a mosquito vector takes a blood meal, injecting sporozoites
into the host. These sporozoites relocate to and infect liver cells (hepatocytes), where
they undergo maturation as part of the exo-erythrocytic cycle. Following on from this the
hepatocytes rupture, which is likely to involve cysteine proteases,108 releasing merozoites.
The merozoites go on to infect red blood cells (erythrocytes), signifying the begining of
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the human blood stage of the infection. It is this erythrocytic life cycle (part of the hu-
man blood stage) which is responsible for the characteristic symptoms of malaria such
as jaundice, fever, anemia and paroxysm.44 A secondary stage of the life cycle occurs in
tandem with the erythrocytic stage, whereby gametocytes replicate in the blood plasma.
These gameocytes sustain the infection and allow transmission back to the vector stage
(mosquito) completing the parasitic life cycle.
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Figure 1.14: Structure of Quinine, Chloroquine and Mefloquine used for treatment of Malaria.
Current antimalarial drugs include quinine, chloroquine and mefloquine (figure 1.14),
which Plasmodium are beginning to display resistance towards, especially in P. falci-
parum.109 Methods to overcome resistance include combination therapies, with current
artemisinin based combination therapies (ACTs) leading the way.110 In addition to ACTs,
haemoglobin degrading cysteine proteases are emerging as new promising drug targets in
the treatment of P. falciparum.111,112 Plasmodium falciparum expresses three key papain-
like CPs, falcipain 1, 2, and 3, which are central in providing amino acids and nutrition
through hemoglobin hydrolysis, facilitating parasitic development.113,114 The falcipains
which are most closely related to hemoglobin hydrolysis are falcipain 2 and 3, being ex-
pressed in the acidic food vacuole of the parasite where hydrolysis occurs.115,116
Due to the parasitic life cycles dependence on CPs, cysteine protease inhibitors have
been recognised as potential chemotherapeutics.117 After identifying the falcipains as
key proteases for heamoglobin degradation,118 Rosenthal et al . went on to show the
antimalarial effects of vinyl sulfone based cysteine protease inhibitors.119 As such, this
work on the development of thiosulfonates as novel cysteine protease inhibitors may lead
on to new anti-malarial chemotherapeutics.
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The Role of Cruzipain in Chagas disease
Figure 1.15: Lifecycle of T.Cruzi. In both triatomine bug (left, red) and human (right, blue).
Infective species of protozoa is trypomastigote. (Centre for disease control and prevention [CDC],
2016).
Chagas disease is a neglected tropical disease that affects approximately 8 million people
worldwide.120 Chagas was previously confined to Latin America, where the disease is now
considered endemic, however an increase in the number of worldwide cases has resulted in
the disease being recognised as a global challenge.121 Chagas is caused by the Trypanosoma
cruzi protozoa, which is mainly transmitted through vector means (figure 1.15), namely
the triatomine bug. After a brief acute phase, Chagas causes neurological disorders, results
in megaorgans (enlargement of mainly the colon and oesophagus) and damages the heart
muscle (leading cause of infectious myocarditis in latin america).122
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Figure 1.16: Structure of Beznidazole, Nifurtimox and K11777.
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Current therapeutics, such as benznidazole and nifurtimox (figure 1.16), have limited
efficacy and severe side effects hence alternatives are desired.123 The cysteine protease
cruzipain (also known as cruzain) is a cathepsin L-like protease and the major proteolytic
enzyme present at all stages of the parasitic life cycle.124 The highest levels of cruzi-
pain are found in the epimastigote stage and the omnipresent nature of cruzipain makes
this an enticing target, with potential to halt the parasite at any stage of its develop-
ment.125 Thomas et al . have shown that the overexpression of cruzipain is linked with
metacyclogenesis (the process of parasitic maturation into the highly infective metacyclic
trypomastigote form).126 Cruzipain has also been implicated in the kinin cascade, which
favours parasitic invasion in host cells that express kinin receptors.127
The realisation that T. cruzi was highly dependent on the cysteine protease cruzipain
led on to inhibition studies. Inhibition of cruzipain has been shown to arrest cellular
development by impairing in vitro host cell invasion, blocking amastigote replication and
preventing amastigote and trypomastigote differentiation.128,129 Following on from this, a
vinyl sulfone inhibitor of cruzipain (K11777, figure 1.16) has been developed and toxicolog-
ical, ADME and pharmacodynamics data has been reported in non-human primates.130,131
One of the key attributes of K11777 is its selectivity for cruzipain over the mammalian
cysteine proteases. Displaying this selectivity was a significant step forward in validat-
ing CPs as therapeutic targets of parasitic infections, due to the high homology between
parasitic and mammalian CPs. With the current success of cysteine protease inhibitors
in the treatment of Chagas disease, this work on the development of thiosulfonates as a
novel class of cysteine ptorease inhibitors may find future applications in this area.
1.2 Current Cysteine Protease Inhibitors
As the catalytic mechanism is dependent upon an active site nucleophile, a common in-
hibitor design is to incorporate an electrophile on a small scaffold or ‘backbone’, often
designed to confer specificity, in order to trap the active site nucleophile. This is of-
ten termed an electrophilic trap, or warhead. Many warheads are present in the litera-
ture, falling into three broad categories: (1) the 1,4-Michael acceptors (e.g. fumarates,134
vinyl α-keto esters, amides and acids135 and vinyl sulfones).136 (2) Irreversible inhibitors
(e.g. tetrafluorophenoxymethyl ketones,137 aziridine-2,3-dicarboxylates,138 epoxyketones,
epoxyamides, α-alkoxyketones and diacyl-bis-hydrazides)139 and finally (3) reversible in-
hibitors (e.g. nitriles,140 aldehydes141 and thiosemicarbazones).142
An example of an inhibitor from each of the three broad categories is given in figure 1.17.
These include the Cathepsin K inhibitor Odanacatib, designed for treatment of osteoporo-
sis, as well as the vinyl sulfone inhibitor K11777, designed for the treatment of Chagas
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Figure 1.17: Current cysteine protease inhibitors, from top to bottom: The cruzipain inhibitor
(α-alkoxyketone warhead, irreversible inhibitor, top).132 The cathepsin K inhibitor Odanacatib
(Nitrile warhead, reversible inhibitor, middle).133 The cruzipain inhibitor K11777 (Vinyl sulfone
warhead, 1,4-Michael acceptor, bottom).130
disease. Interestingly, an analysis conducted in 2018 found that Michael acceptors domi-
nate the landscape of cysteine protease inhibitors, accounting for approximately 70% of the
published compounds.143,144 Furthermore, the dependence on a specific warhead sub class
is placing more emphasis on the initial non-covalent binding interactions, with warheads
being viewed as ‘off the shelf’ reactive moieties for installation and generation of covalent
inhibitors. This is resulting in a design paradigm whereby inhibitors are being designed
purely on the basis of reversible inhibitors, with a known binding mode, placing reactive
warheads in the correct spacial positioning. This is a process which placed all optimisation
on the non-covalent interactions, preventing optimisation of the covalent interactions. As
the overall inhibitor design has contributions from both the non-covalent scaffold and the
warhead, current methods are preventing the parallel optimization of the non-covalent and
covalent interactions. As a result, the literature is becoming increasingly biased towards
proven chemistries for covalent bond formation, potentially ignoring valuable character-
istics such as exploring new chemical space, chemically selective reactions and tunable
reactivity profiles. This is exemplified when looking towards natural products, which offer
a significantly wider range of covalent inhibition mechanisms such as oxidations, substi-
tutions, nucleophilic additions, addition-eliminations, non-Michael additions as well as
Michael additions.145 This work aims to expand the chemical toolbox, focusing on the
thiosulfonates as a novel electrophilic trap with inherent chemical selectivity towards its
target, the cysteine proteases. In a similar manner to natural products, the thiosulfonates
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move into the underexplored chemical space of substitution-based electrophilic traps. Fur-
thermore, the thiosulfonates display a highly tunable nature in their reactivity profiles.
This is particularly interesting when considering the recent study by Abranyi et al ., which
highlights that warheads operating through a substitution mechanism cover the same range
of reactivity in a biological environment as the ubiquitous Michael acceptors. Furthermore,
this study recognised the potential to access differing levels of selectivity towards biolog-
ically relevant nucleophiles by exploring under-developed chemistries and control of the
reactivity profiles.143
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1.3 The Thiosulfonate Moiety
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Figure 1.18: The thiosulfonate, methyl methane thiosulfonate (MMTS, 1), simple symmet-
rical thiosulfonates explored by Santos et al . (2,3 and 4)146 and the ’switch on’ thiol sensing
fluorophore by Ge et al . (BODIPY-TS, 5).147
There are few examples of the use of thiosulfonates as cysteine protease inhibitors in the
literature other than the simple methyl methanethiosulfonate (MMTS). MMTS can be
found in many plants and was isolated from cauliflower extracts by Nakamura et al . in
1996.148 After its isolation Reddy et al . went on to show its chemo-preventive effect
on colon cancer, demonstrating the link between thiosulfonates in diet and therapeutic
potential.149 There has also been further interest in the link between diet and cancer
risk, such as exploring the various sulfur compounds (including thiosulfonates) of garlic
and their cytotoxic effect in oesophageal cancer cells.150 MMTS itself is regularly used
as a reversible thiolating reagent in studies of the natural thiol-disulfide oxidation state
of proteins,151 for studying protein S-nitrosylation,151,152 and for evaluation of the role of
both catalytic and structural cysteine residues on enzyme activities.153–155 A significant
next step was the use of functionalised methane thiosulfonate derivatives by Matsumoto
et al .156 in post translational modifications of subtilisin mutants, which incorporated a
cysteine by directed site mutagenesis. Since these early discoveries some exploration into
thiosulfonates as protease inhibitors has been carried out with Santos et al . correlating
insecticidal activity with reduced protease activity upon treatment with simple thiosul-
fonates, although no efforts were made to specifically target cysteine proteases (figure
1.18, compounds 2, 3 and 4).146 The thiosulfonate moiety has also been explored as a
bioisostere of the mesylate group for use in structure activity relationships by Gabriele
et al . in order to improve the stability of compounds and avoid the multiple potential
alkylations, facilitated by the mesylate group.157 More recently, thiosulfonates have found
an interesting application as ‘turn on’ fluorescent probes for thiol sensing (figure 1.18,
BODIPY-thiosulfonate, 5).147
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Figure 1.19: Proposed thiosulfonate inhibitor constructs building on the success of K11777,
with a warhead inspired by methyl methane thiosulfonate (MMTS).
As a moiety that appears to be abundant in nature, it would be interesting to harness this
potential electrophilic trap in the design of specific cysteine protease inhibitors. The afore-
mentioned applications exploited the nature of the thiosulfonate as an excellent thiophile
for highly chemoselective targeting of protein thiols. This is in part due to the soft elec-
trophillic centre of the thiosulfonates (a bivalent sulfur), offering chemoselectivity towards
sulfur centred nucleophiles (figure 1.18). In this work, inspiration has been drawn from
MMTS, which serves as an SH specific electrophile, combined with the successful vinyl
sulfone inhibitor K11777 (6) serving as a lead compound (figure 1.19). It was intended
to use the backbone of K11777 as a foundation for thiosulfonate inhibitors, with K11777
its self offering a valid reference compound. From this starting point, rational modifica-
tions to both the backbone and warhead design will be made. It has been hypothesised
that modification of the primed side residue R’ (figure 1.19) group can be used to con-
trol reactivity resulting in highly tunable and specific cysteine protease inhibitors. The
underlying hypothesis was that by modifying the substitution of aromatic analogues, the
electrophilicity of the bivalent sulfur could be altered (compounds 7-10 and 13-16. This
trend will then be further explored by moving away from aromatic R’ substituents and on
to aliphatic ones, such as cyclohexane (compounds 11 and 17) or the benzylic derivatives
(compounds 12 and 18).
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Chapter 2
DrawToDock : Development of a
Virtual Screening Platform to Guide
Rational Design.
Aim of DrawToDock : Making Computational Techniques More Accessible for
Synthetic Chemists
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Figure 2.1: DrawToDock : A schematic representation. DrawtoDock allows for direct conversion
of multiple two dimensional ligands, generated by common chemistry drawing software, to 3D
docked models with target proteins.
Procedures which rapidly explore the complementarity between target binding sites and
potential ligands present indispensable tools for medicinal chemists.158 Medicinal chemists
are living in an information age whereby 3D coordinates of potential drug targets, or closely
related analogues, are readily available from crystal structures. As such, molecular mod-
elling techniques allow for identification, optimisation and prioritisation of small molecule
drug candidates. However, the knowledge required for the complex underlying protocols,
and relevant experience in computational chemistry, may create a barrier between medic-
inal chemists and these highly valuable in silico methods. As such, a new tool has been
developed named DrawToDock (Figure 2.1), which aims to overcome the barrier between
these powerful predictive modelling techniques and the persons who require them most.
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This is done by facilitating docking and virtual screening through recognisable chemistry
drawing software, such as ChemDraw.
The fundamentals, advantages and limitations of docking are beyond the scope of this work
with numerous reviews available to the interested reader.158–162 Although many docking
software packages are available, DrawToDock has been developed specifically to allow an
intuitive link between chemistry drawing software, docking and virtual screening. This
offers users a more direct route towards screening novel inhibitor constructs, which was
desired in the development of thiosulfonates as cysteine protease inhibitors.
2.1 DevelopingDrawToDock : A Virtual Screening Plat-
form Directly From Chemdraw Files
As DrawToDock is targeted towards chemists with little computational background a short
note on computer specific nomenclature and the underlying principles is warranted. Bash
shell scripting has been used to create the DrawToDock script, comprising a series of
commands stored as a plain text document. The individual commands in a Bash script
can also be executed individually through Command line on Windows operating systems
(Win OS) or terminal for Macintosh Operating systems (Mac OS). These are in essence
the process of operating a PC with strings of text rather than through a graphical user
interface (GUI). A Graphical User Interface (GUI) is the collection of graphics, such as
windows and toolbars, commonly used to control a software package. Through using
Bash shell scripting, 2D images (such as a ChemDraw file) have been converted to 3D
ligand constructs followed by docking of those ligands to a protein of interest. In order
to achieve this, the correct software for each required process (i.e. transformation from
2D to 3D structures, docking, generating new directories for output files etc.) has been
collated and contained within one convenient script. This avoids the need for users to
jump between multiple software packages and GUI’s to achieve the same outcome. Herein
is presented the process of collating the required software and developing a script to
automate the required processes, facilitating a virtual screen from 2D ChemDraw images,
named DrawToDock.
After a survey of the freely available docking software, AutoDock Vina was identified
as the optimal platform on which to base DrawToDock.163 This was primarily due to
the speed and accuracy with which Autodock Vina performs predictions, as well as the
developer friendly way in which the software has been presented.163 Moreover, Autodock
Vina is executable through Bash shell scripting, allowing a direct route towards virtual
screening with a Bash script. The required software for file conversions was identified
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and combined into one Bash script, ending with the docking process which automatically
performs iteratively for multiple ligands, offering what is commonly referred to as a virtual
screen. There are three key steps to the docking process: (1) generating the ligands
(small molecules) of interest, (2) obtaining the macromolecule of interest and (3) Bringing
both together in the docking process. The following will outline each individual step to
aid understanding, then the DrawToDock script, which automates the process, will be
presented.
Generating Ligands of Interest
Figure 2.2: Generating ligands for docking with Chemdraw
The first step in any docking study involves obtaining ligands of interest. Often this can
be achieved by downloading 3D structures from a database such as ZINC, the Cambridge
structural database (CSD) or the Protein data bank (PDB).164–166 Database methods are
a convenient source of 3D ligand constructs however, they are limited to known small
molecules and thus do not cover much of the chemical space available by newly developed
chemistry and novel constructs. An alternative method is to generate 3D ligands by
computational techniques, which requires greater user input and time. However, this
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method allows for the introduction of novel chemical motifs and rational modifications
to lead compounds. It was hypothesised that developing a method for generation of
ligands by common chemistry drawing software such as ChemDraw (Figure 2.2) would
bridge the gap between the convenience of database derived methods and the flexibility
of computationally generated ligands.
With the easily available 2D images to hand generated through ChemDraw (figure 2.2)
the next step was to generate 3D coordinates. The available methods for this fall into
three main catagories: Firstly, commercially available options such as advanced versions
of ChemDraw, Corina and Discovery Studio.167,168 Although these options undoubtedly
function well they present both a financial barrier as well as the need to navigate addi-
tional software packages, increasing the time taken for ligand generation. Secondly, there
are freely available web server based techniques such as PRODRG.169 Such web based
techniques are not suitable for use in virtual screening as they often place a limit on the
daily number of submissions and incur a time delay when awaiting results to be sent back
to the user. Third and finally are freely available, open source software packages such as
Ghemical and Avogadro.170,171 Not only do these remove the financial barrier imposed by
commercial softwares but they often facilitate and encourage developers to modify and
build on these techniques providing the ideal starting point for a virtual screening tool
such as DrawToDock.
Figure 2.3: Using Avogadro to convert 2D .mol files to 3D .pdb files.
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Initially, 3D coordinates were generated with the use of Avogadro, a freely available soft-
ware which allows for the creation of 3D coordinates followed by energy minimisation from
.mol files (figure 2.3).171 Avogadro functioned well and allowed early docking studies to
take place, however two main drawbacks were identified for improvement. Firstly input
files were required in a .mol format, which required conversion from the native file format
(.cdx in this instance), adding an additional step to the process. Secondly, the generation
of 3D coordinates had to be conducted manually, through a graphical user interface (GUI),
and then saved as a new output (.pdb) file. Although this process is possible, it becomes
time consuming and laborious for multiple ligands.
Figure 2.4: Using Open Babel to convert 2D .cdx files to 3D .pdb files through terminal
(MacOS). The terminal window (top) is overlayed with the file directory (bottom). Colour coding
illustrated the function of each line of text in the terminal window and shows the corresponding
file in the file directory where appropriate as follows: File directory (pink), Command to use
Open Babel (red), input file name (blue), Output file name (green), Generate 3D coordinates
(yellow), protonate ligand at pH 6.5 (purple), energy minimise over a defined number of steps
with a steepest descending algorithm (brown)
Having identified the time consuming steps an approach to streamline the process was
outlined. Looking into the inner workings of Avogadro it was apparent that Open Babel,
a freely available chemistry file conversion software, was the underlying process respon-
sible for generating 3D structures.172,173 As such, Open Babel was explored and found
to be executable directly through Bash scripting which is illustrated in figure 2.4. This
removed the time consuming GUI dependent steps of Avogadro. Moreover, Open Babel
offers a wide range of possible transformations which are well documented on the Open
Babel Wiki.174 This allowed for greater flexibility dependent on the desired docking pa-
rameters, in this instance pH dependent protonation states were employed. This allows
the user to define a pH representative of the environment in which the target protein is
located, thus accessing relevant ligand protonation states. The 3D coordinates were gen-
erated and then energy minimised with Molecular Force Fields (MFF94), allowing fast
and accurate generation of 3D constructs.175 Energy minimisation was performed to best
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represent reasonable bond lengths and angles, and was conducted over 3000 steps with a
steepest descending algorithm. Furthermore Open Babel facilitated direct conversion from
ChemDraw (.cdx) files, removing additional conversion steps, which greatly decreased the
time taken for file conversions. It is worth noting that Open Babel can also facilitate the
above transformation from other common formats such as .mol or SMILES meaning that
there is inherent flexibility for users of all backgrounds using differing chemistry drawing
software (not just ChemDraw).
Figure 2.5: Converting ligand format from .pdb to .pdbqt with AutoDockTools GUI
Continuing on from generation of the 3D coordinates, software specific manipulations
were required. Autodock Vina requires an input format known as .pdbqt, which is spe-
cific to AutoDock. As such this transformation was accomplished through AutoDock-
Tools, a GUI provided by the makers of AutoDock shown in figure 2.5. Again, work-
ing through another GUI greatly increased the time taken to convert between file for-
mats. As such, a python script provided by the developers of AutoDock, which can
be found in the installation package of AutoDockTools, is available to convert from
.pdb to .pdbqt formats. Executing this python script can be conducted through Bash
scripting, again greatly decreasing the required user input time. This is achieved in
a similar way to executing the previously discussed Open Babel command and is dis-
played in figure 2.4 by navigating through terminal to the correct directory and typing
the following: python ./prepare_ligand4.py -l Ligand_X.pdb. Where ‘python’ calls on
python to be used to execute the script (./) named prepare_ligand4.py with the input file
Ligand_X.pdb which will generate the required .pdbqt output file.
An important feature with the above techniques is the ability to bypass GUI’s. Although
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GUI’s are a welcome and intuitive method for conducting many computational tasks they
come with associated time penalties such as installation, learning and execution. This
poses a significant barrier towards their use for synthetic chemists and is one of the major
drawbacks in exploring ‘free’ software packages. Thus users are faced with the option of
either a ‘computational’ barrier, involving greater time taken searching for the correct se-
lection of software and learning how to use it, or a financial barrier in paying for a software
package which can address this issue. Either of these barriers are often enough to pre-
vent many chemists from using computational techniques, which could potentially enhance
their work. This is the fundamental issue DrawToDock ultimately aims to overcome by
providing a free, fast and convenient docking solution based on open source software.
Obtaining the Target Macromolecule
Figure 2.6: Defining the search space for docking with AutodockTools.176 The search space is
visualised with a 3D grid box and the corresponding coordinates, which define the search space,
can be noted down for docking.
Obtaining the 3D coordinates of the macromolecule of interest was achieved by down-
loading a crystal structure from the protein data bank (PDB).166 Subsequent preparation
of the macromolecule was then conducted. This involved removing any unbound atoms
such as counter ions and water molecules as well as any covalently bound inhibitors in
the active site. This is a simple ‘highlight and delete’ procedure using Pymol,177 although
other molecular visualisation software, such as AutodockTools, would suffice.176 Once the
macromolecule had been prepared it then had to be saved as a .pdbqt file, again this is
an AutoDock specific format and was therefore carried out thought AutodockTools GUI.
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AutoDock Vina operates by searching a defined space, which is defined by visual assess-
ment in AutoDockTools as shown in figure 2.6. The corresponding coordinates were then
saved in a configuration file (a simple text document defining the macromolecule file, coor-
dinates to search, and ligand to dock). It is worth noting that this was a one time process
for the macromolecule of interest and all subsequent docking simulations use the same
macromolecule and configuration files, hence this is highly time efficient.
Running Docking
Figure 2.7: Running AutoDock Vina, an example. Image displays directory containing the
required files in the background: macromolecule (clean1cvzwithH.pdbqt), AutoDock Vina exe-
cutable (Vina), Ligand (Ligand.pdbqt) and the configuration file (config.txt). A Log file (log.txt)
is also generated upon running docking. The foreground shown AutoDock Vina running, giving
live updates in the shell window.
Finally docking was conducted; the method for this depends on the chosen docking soft-
ware. In this instance Autodock Vina was chosen which is always executed through shell
scripting (it does not carry its own GUI). Direct execution through bash shell also made
the later incorporation into a bash script intuitive and seamless. In short, the user must
include all of the necessary files in one directory (ligand, macromolecule, configuration file
and AutoDock Vina executable), navigate to this directory through their respective bash
shell and execute AutoDockVina. The docking process will then take place with updates
given through the shell window (Figure 2.7).
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Upon completion a results file is generated which contains the top 8 docked conformations.
A log file is also generated which defines the relative predicted binding affinities of each
docked conformation serving as AutoDock Vinas ‘scoring function’. Unless there is a
considerable difference observed in the predicted binding energies all should be considered
possible and user discretion is often required to determine the most likely binding pose.
This process should be guided by known inhibitor binding modes where possible allowing
the user to give greater weight to predicted binding modes by comparison with known
binding modes. In the absence of such information, the lowest energy conformation should
be considered the most likely binding mode. Of course, these are predictive models of
a complex system so caution should be exercised by the user, especially to avoid over
interpretation of computational results. It is for this reason that a combinatorial approach
has been taken in the work to follow whereby docking studies are used to help guide rational
modifications leading on to empirical results to solidify the findings.
The DrawtoDock Script
As discussed, all of the previous steps were carefully chosen in such a way to be easily
executable through shell scripting. Hence, all steps have been incorporated into one conve-
nient script forming the DrawToDock script, as shown in figure 2.8 (this is for illustration
purposes only; a full text copy has also been provided in the appendix for ease of read-
ing). Furthermore, DrawToDock has been written to execute iteratively for all provided
ChemDraw files named Ligand_‘X’, where ‘X’ is a variable name chosen by the user. As
such, all that is required by the user is to include the relevant docking files (ChemDraw
files of all desired ligands named with the convention Ligand_‘X’, macromolecule file and
configuration file) along with the DrawToDock script and DrawToDock will complete the
whole process upon execution. Importantly, once complete for one ChemDraw file it auto-
matically continues on to the next facilitating time efficient screening. The DrawToDock
script has also been written to sort all of the various files generated at each step into folders
dependent upon their file type to make accessing results, or intermediate files, easy. This
reduces the overall user input time from approximately 30 minutes per ligand of interest
when compared with the ’manual’ options presented previously to the time taken for the
user to draw the ligand in ChemDraw which, as a conservative estimate, is ca. 2 minutes.
It is envisioned that DrawToDock will prove a valuable means for both time and cost
efficient virtual screening to be utilised by medicinal chemists with little to no experience
of computational techniques. As such, DrawToDock has been used extensively throughout
the following work.
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Figure 2.8: DrawtoDock script. The script has been fully annotated to aid user understanding
of the process and further development if desired. This is for illustration purposes only, a full
text version can be found in the appendix.
2.2 Summary and Future Work
A virtual screening script has been developed, named DrawToDock, which offers a fantas-
tic collection of free, openly available software to facilitate rapid virtual screening with
minimal user input and importantly no upfront cost. As such, this represents a valuable
tool for time and cost efficient virtual screening however, further steps are possible to
improve the user experience. Namely, integrating all of the described script into a clean
user interface. It was determined that building a GUI for DrawToDock was beyond the
scope of this work however, in the current iteration of DrawToDock, the user must navi-
gate through shell to execute the script. Although this is not a major challenge, it may be
off-putting to users with little computational experience. Rather, developing a clean user
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interface with user prompts such as ‘select ligand files’ and ‘select save location’ as well
as the option to directly draw structures for docking is certainly possible and may prove
useful. This is particularly true in realising the philosophy of overcoming computational
barriers for synthetic chemists and would be a valuable addition in future work.
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Chapter 3
First Generation Thiosulfonate
Inhibitors
3.1 Docking Study: Are Thiosulfonates Viable War-
heads?
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Figure 3.1: Comparison of the site of nucleophilic attack on a natural peptidic substrate (top)
compared with a Michael acceptor (middle) and a thiosulfonate (bottom). Red dashed line
highlights the site of attack on the carbonyl of the natural substrate and vinyl sulfones. Blue
dashed line highlights site of attack on thiosulfonates which, as shown, is shifted towards the
bivalent sulfur one position further along.
There are many factors to consider when designing a novel electrophilic trap. An im-
portant consideration for covalent inhibitors is the kinetics related to covalent bond for-
mation. One kinetic implication which was immediately apparent for the thiosulfonates
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in peptidomimetic inhibitors was the site of nucleophilic attack, as shown in figure 3.1.
Introducing thiosulfonates into peptidomimetic inhibitor constructs effectively translates
the site of attack one position along the inhibitor backbone (towards the natural sub-
strate’s C terminus) when compared with the natural site of attack on the carbonyl of
peptidic amide bonds. Furthermore, this natural site of attack is well mimicked by cur-
rent Michael acceptors such as the vinyl sulfones, which offer well established covalent
inhibitor constructs (figure 3.1). Of course, proteins are complex flexible structures and
as such it may be reasonable to suggest that altering the site of attack by such a small
margin may be well tolerated. Indeed, previous work within the Liskamp group towards
sulfonyl fluorides as inhibitors of the proteasome,178–181 serine proteases182 and prolyl oligo
peptidase inhibitors,182–184 has demonstrated that such a shift in the site of attack can be
well tolerated and should be of little concern. It is however prudent to consider that such
a change may be kinetically detrimental towards covalent bond formation. An obvious
solution would be to develop chemistry which accounts for this, in effect shifting the site
of attack back to the ‘natural’ position. Although this may be possible, this would involve
functionalising next to a stereogenic centre which would greatly increase the complexity
of the chemistry required. In order to address this issue, a modelling study was con-
ducted to better understand the possible binding mode of the thiosulfonate constructs
and rationalise if altering the site of attack would be detrimental to the binding mode of
thiosulfonate derived peptidomimetic inhibitors.
It was hypothesised that the inherent flexibility of the target proteins would be sufficient
to account for this difference as has been displayed previously within the Liskamp group
with the sulfonyl fluorides. However, if this could be further supported by modelling
studies then efforts to develop the more complex chemistry, functionalising adjacent to
a stereogenic centre, could be reasonably considered to be unnecessary. Importantly, it
was believed that developing chemistry which was robust and readily accessable would be
fundamental to the future success and uptake of thiosulfonate derived inhibitors. Hence,
exploring the synthetic complexity vs inhibitor potential is a critical consideration which
was further explored before synthesis was conducted.
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Figure 3.2: Vinyl sulfone inhibitor K11777 (6, left) and the thiosulfonate mimic ( 8, right).
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Papain was taken as a prototypical cysteine protease for this study as it is representative
of Clan CA family C1 cysteine proteases and has been well studied in the literature. It
was decided that modelling K11777 (6, figure 3.2) against its closest thiosulfonate mimic
(compound 8, figure 3.2) would allow investigation of the relative binding modes of the
two inhibitor constructs, which was conducted with the use of DrawToDock (discussed in
chapter 2).
(a) Docked K11777 6 (b) Docked Thiosulfonate 8
(c) Overlay of 6 and 8 (d) RMS line representation
Figure 3.3: Docking binding mode of (a) K11777 6, (b) Thiosulfonate mimic 8, (c) overlay of
both 6 and 8, (d) RMS calculation between binding modes of 6 and 8, line representation with
paired atoms highlighted in yellow.
Firstly, the observed binding mode of K11777 (compound 6) was evaluated to determine
if this modelling study was producing reasonable, reliable data as shown in figure 3.3.
K11777 was docked into papain (PDB code 1CVZ)185 which gratifyingly gave an overall
binding mode representative of the known binding mode for K11777. The known binding
mode was determined by examination of the crystal structure of K11777 with two other
clan CA cysteine proteases, Cruzain (PDB code 2OZ2)186 and S. mansoni Cathepsin B1
(SmCB1, PDB code 3S3R).187 In both of these crystal structures, the aromatic ring of
the warhead occupies the S1’ pocket with the homophenylalanine residue occupying the
S1 pocket, the phenylalanine residue occupies the S2 pocket and the N-methyl piperazine
cap occupies the S3 region. The same trend was observed in docking K11777 with papain
in this study, with the phenyl ring of the warhead occupying the S1’, homophenylalanine
side chain occupying the S1, phenylalanine side chain occupying the S2 and N-methyl
piperazine cap solvent facing in the S3 region. This gave further confirmation that a
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reasonable prediction had been generated before further interpretation.
Confident that DrawToDock had generated a reasonable predicted binding mode, by com-
parison with literature crystal structures, the thiosulfonate warhead was then analysed.
As shown in figure 3.3 the overall binding mode of the thiosulfonate mimic 8 was largely
in agreement with that observed for the vinyl sulfone 6 (K11777). The greatest variability
between 6 and 8 was observed for the N -methyl piperazine cap in the S3 region, which
was expected as this region is solvent facing and anticipated to be freely rotatable in the
solvated environment. To further highlight the agreement in the binding modes between
each inhibitor construct the RMS deviation, determined by Pymol align function, was
0.320Å (overlay of 28 atom pairs as shown in figure 3.3). The N -methyl piperazine cap
was not included in the RMS determination as it is considered to be freely rotating in the
solvated environment thus does not contribute significantly towards the primary binding
event.
Importantly, this modelling study also suggested that moving the position of the elec-
trophilic trap further along the inhibitor backbone, as shown in figure 3.2 was not detri-
mental to the overall binding mode. It was found that the bivalent sulfur of the thiosul-
fonate was positioned 3.2Å from the active site nucleophile (Cys-25) whereas the β sp2
carbon of the vinyl sulfone was 3.7Å from the active site thiolate. Furthermore, the angle
of attack could also be assessed. As the thiosulfonates operate through an SN mechanism
the optimal angle of attack by the active site nucleophile would be 180◦. This modelling
study suggests that in the bound conformation the angle of attack is aproximately 128◦
as shown in figure 3.4. comparitively, the vinyl sulfone, being sp2 hybridised, would be
expected to have an optimal attack angle of ca. 107◦ in accordance with the Bürgi-Dunitz
angle.188,189 In this study an angle of ca. 127◦ was observed. Of course, considerations
involving distance between nucleophile and electrophile as well as angle of attack can offer
valuable insight into potential mechanistic advantages an inhibitor construct may have.
On the other hand, these considerations tend to assume reactivity dependent on random
collision and do not take into account the local, relatively constrained, enzymatic envi-
ronment. For example, the Bürgi-Dunitz angle has been found to be as low as 88◦ in a
fatty acid amide hydrolase.190 Combining this with the limitations of modelling, one of
which is particularly apparent in this system is treating the protein as a rigid structure,
it is fair to conclude that the thiosulfonate appears no less suited to inhibition of cysteine
proteases than the vinyl sulfones on the basis of attack angle and distance from the active
site.
Another important finding from this docking study was the potential for in situ activation
of the thiosulfonate warheads. Vinyl sulfones have long been accepted to undergo hydro-
gen bonding between active site H-bond donor residues and the H-bond acceptor of the
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(a) Thiosulfonate warhead (b) Vinyl sulfone warhead
(c) Thiosulfonate attack angle (d) Vinyl sulfone attack angle
Figure 3.4: In situ activation of warheads through H-bonding. (a) Thiosulfonate warhead, (b)
vinyl sulfone warhead, (c) Angle of attack on thiosulfonate warhead, (d) Angle of attack on vinyl
sulfone.
hexavalent sulfur centres oxygen atoms.136 Given the chemical similarity in this regard be-
tween the vinyl sulfone and thiosulfonates it is reasonable to suggest that a similar process
may take place. In this modelling study it was found that hydrogen bonding between the
sulfur oxygen atoms to His159 may prove particularly important, as this residue forms the
catalytic dyad with the active site Cys25 (as discussed in introduction section 1.1.2, figure
1.8). The combination of this H-bond donor (His159) and H-bond acceptor character of
the sulfonate oxygen atoms may in turn polarize the thiosulfonate S-S bond, thereby in-
creasing the rate of cleavage. Importantly, cysteine proteases utilise the catalytic histidine
residue as a general acid in their catalytic cycle, facilitating the H-bond donor specifically
in cysteine proteases as the His159 is in its protonated state. This is in contrast to other
proteases, such as serine proteases, which utilise a histidine residue as a general base in
their catalytic cycle.191 As such, these differing catalytic mechanisms are favourable for
the inhibitory specificity of thiosulfonates towards cysteine proteases.
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3.2 Exploring Routes Towards an Efficient Warhead syn-
thesis
Fundamental to the development and subsequent uptake of any newly emerging inhibitor
is an efficient and reproducible synthesis. As thiosulfonates are likely to find their place
amongst drug candidates targeted towards neglected tropical diseases, or as probes to bet-
ter understand biological processes, an efficient synthesis from readily accessible materials
was desired. It was envisioned that being able to access useful thiosulfonate constructs
from amino acids by robust chemistry would not only meet there criteria, but encourage
their use in future research. In the following chapter, efficient and reproducible routes
towards thiosulfonates will be explored forming the foundation of their development as
cysteine protease inhibitors.
3.2.1 A Retrosynthetic Approach
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Scheme 3.1: Retrosynthetic analysis of amino acid derived thiosulfonate warheads.
Begining with the retrosynthesis of the desired thiosulfonate inhibitors, as shown in scheme
3.1, it was clear there were two main routes which could be explored. In each case, the fi-
nal step would involve coupling the backbone to the warhead fragment by standard amide
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coupling techniques. This leads back to the key amino acid derived thiosulfonate building
block, with the potential for two clear disconnect options (scheme 3.1). Disconnection (a)
is across the carbon-sulfur bond, offering a more direct substitution route with a thio-
sulfonate salt or (b) disconnecting across the sulfur-sulfur bond back to a nucleophilic
bivalent sulfur, such as a thiol, and an electrophilic hexavalent sulfur, such as a sulfonyl
halide. Either of these routes benefit from common synthetic intermediates earlier in the
synthesis, providing redundancy in the key step of thiosulfonate formation, which can be
readily accessed by a series of functional group transformations from the commercially
available amino acid homophenylalanine. The common precursor to both of these inter-
mediates is a protected amine functionalised with a leaving group. Again, there is aparant
redundancy in this step as many possible leaving groups could be used, of which sulfonate
esters or halides are the most common and readily accessible. Either of these leaving
groups could be accessed by the corresponding alcohol which in turn could be accessed by
reduction of the corresponding amino protected homophenylalanine. This retrosynthetic
analysis also suggests that synthesis from other amino acids, not just homophenylalanine,
should be well tolerated and easily accessible allowing for expansion of inhibitor constructs
or structure-activity relationships to be explored with ease.
3.2.2 Warhead Synthesis: From Thiosulfonate Salts
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Scheme 3.2: Thiosulfonate salt synthesis from sulfinate salts.
Considering the retrosynthetic analysis in scheme 3.1, section 3.2.1, it was hypothesised
that the synthesis of thiosulfonates would be most efficient by substitution with thiosul-
fonate salts (disconnect (a), scheme 3.1). This strategy was thought to be more convergent,
allowing for a combination of two more complex fragments in fewer synthetic steps. Hence
this route was the first to be explored.
The key step of this synthetic route was the introduction of the thiosulfonate warhead with
thiosulfonate salts. As such, the formation of thiosulfonate salts was first assessed to ensure
they were easily accessible as outlined in scheme 3.2 based on the work of Sato et al . from
sulfinate salts and sulfur.192 This method provided the corresponding thiosulfonate sodium
salts 26 - 25 in good to excellent yields. Where sulfinate salts were not commercially
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available, in the case of compounds 24 and 21, they were accessed by reduction of the
corresponding sulfonyl chlorides 20 and 19 in excellent yields based on the literature
procedure by Lacour et al .193 The ability to quickly access the required thiosulfonate
salt from sulfonyl chlorides was thought to be of particular importance as the sulfonyl
chloride moiety is a common synthetic intermediate with many commercially available,
or easily accessible, potentially allowing rapid access to a wide range of thiosulfonate
warheads.
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Scheme 3.3: Homophenylalanine derived aromatic thiosulfonates from thiosulfonate salts.
With the thiosulfonate salts to hand synthesis from the amino acid starting material could
now be explored. Starting from commercially available Boc-hF-OH 29 the carboxylic acid
was first converted to the corresponding methyl ester by alkylation under basic conditions.
This method was chosen over the ubiquitous thionyl chloride / methanol approach to avoid
in situ generation of HCl, which could potentially deprotect the acid labile Boc protecting
group. This proved to be a convenient reaction as excess reagents could be removed by
evaporation (MeI) and aqueous washing (K2CO3) giving 30 in excellent yields.
Next, the methyl ester was reduced by the in situ generation of LiBH4 to the corresponding
alcohol 31 in excellent yields. Previous work in the Liskamp group found the two step
approach to amino alcohols to be higher yielding and more convenient than the direct
conversion from carboxylic acids.181 This also offers the advantage of milder reaction
conditions rather than employing more powerful reducing agents such as LiAlH4, which
may facilitate a broader substrate scope for use on more complex systems in future.
Ultimately, the alkyl bromide 33 was desired for the introduction of thiosulfonates by
substitution of their corresponding thiosulfonate salts. This was built on the previous work
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in the Liskamp group, which found the bromides offered better yields than other leaving
groups, such as mesylates.194 This could have been achieved directly by conversion of
amino alcohol 31 to alkyl bromide 33 by the Appel reaction however, previous experience
found the Appel reaction to be low yielding and the generation of triphenylphosphine
oxide by-product complicated purifications. As such the Boc protected amino alcohol 31
was first converted to mesylate 32 in excellent yields. Subsequently, mesylate 32 was
substituted for bromide 33 in good yields with the use of LiBr under reflux.
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Scheme 3.4: Employing Finkelstein conditions to improve thiosulfonate formation from thio-
sulfonate salts
Finally the key transformation forming the thiosulfonate warhead could be explored. This
involved direct substitution of bromide 33 to thiosulfonates 34 - 37. It was intended
to conduct this reaction for all four warheads presented in scheme 3.3, however when a
relatively low yield of 18% was observed for the first two attempts (towards compounds
34 and 36) it was decided to the further investigate and optimise the reaction conditions
before applying to all warhead constructs. Initial attempts at optimising the substitution
took advantage of Finkelstein conditions (scheme 3.4) to generate the more reactive alkyl
iodide in situ. Acetone was employed as the solvent to take advantage of the differing
solubilities of both sodium bromide and sodium iodide, precipitating out the generated
sodium bromide and driving the reaction towards product formation. This was met with a
moderate improvement in the yield from 18% to 29%. Although this was an improvement,
the yield was still low and not considered compatable with the search for an ‘efficient’
synthesis towards this novel warhead.
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Scheme 3.5: Impurity formation by subsequent substitution of thiosulfonates.
Furthermore, when characterising the thiosulfonate product it was clear by LC-MS analysis
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that an impurity was present, which could not be removed by standard chromatography
and has a mass increase of +32 from the desired thiosulfonate. Furthermore, NMR analysis
suggested that this impurity showed effectively identical NMR to the desired products 34
and 36, with impurity peaks overlapping with product peaks. Given the high similarity by
NMR and mass increase observed it was hypothesised that the impurity may contain an
additional sulfur, generated through the potential side reaction outlined in scheme 3.5. It
was reasoned that, upon formation of the desired warhead, an additional equivalent of the
thiosulfonate salt was attacking back on the bivalent sulfur and generating the unwanted
byproduct observed.
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Scheme 3.6: Thiosulfonate impurity formation due to impure thiosulfonate salts.
Another potential route towards formation of the undesired product 39 is displayed in
scheme 3.6. It is possible that the additional sulfur had been carried forward from the
synthesis of the thiosulfinate salt which, in turn, was incorporated during the substitution
of the alkyl halide. Either of these two mechanisms were considered to be plausible and
inherent in this synthetic approach. It was hypothesised that attempting the synthesis of
thiosulfonates by alternate methods that avoided these potential pitfalls would be prefer-
able to optimising a synthesis with inherit competing reactivity. The reason for this was
two fold: (1) the yield by direct substitution of alkyl halides by thiosulfonate salts was
considered to be poor, even after attempted optimisation. Although further optimisation
of this is possible to increase the yield, such as assessing other leaving groups, the results
may still be hampered by the presence of an inseparable impurity. (2) Determining the
exact source of the impurity, although possible, would be time consuming and challenging.
The thiosulfonate salts were not found by mass spectrometry which removed the most ob-
vious method for determining at which point the additional sulfur was being incorporated.
Other standard characterisation techniques, such as NMR, were predicted to be insignif-
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icantly different between the thiosulfonate salt and additional sulfur salt. Even if it was
found that the additional sulfur was incorporated at the thiosulfonate salt formation step,
the separation of the thiosulfonate salt from the impurity would prove difficult (separation
of two salts). Furthermore, even if pure thiosulfonate salt could be obtained and proven to
be pure, this would not prevent the potential for the same impurity to form in the follow-
ing substitution step. It was determined that the impurity observed may well be through
a combination of both routes outlined, meaning multiple reaction steps would have to be
optimised to avoid an inherit weakness in the synthesis, which was thought to be an inef-
ficient approach. As such, it was decided to explore an alternate approach to avoid these
issues rather than undertake a lengthy optimisation process which may still have proven
inefficient. Fortunately the earlier retrosynthetic analysis highlighted that this could be
achieved by the common intermediate 32 which appeared to offer a synthetic route which
could circumvent these issues.
3.2.3 Warhead Synthesis: Oxidative Cleavage of Disulfides
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Scheme 3.7: Thiosulfonate S-S disconnect with synthon options (top) and possible reagents
(middle and bottom)
Considering the previously discussed impurity observed in section 3.2.2 a new route was
desired. Based on the earlier retorsynthetic analysis (scheme 3.1) the most obvious route
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to attempt was thiosulfonate synthesis from sulfonyl chlorides and thiols. However, now
armed with the information that a secondary attack on the thiosulfonate by sulfur cen-
tred nucleophiles may be possible, as shown previously in scheme 3.5, it was proposed
that a similar side reaction may occur (scheme 3.7). This was because the synthesis of
thiosulfonates from a thiol and sulfonyl chloride shared the same fundamental problem,
generating an electrophile in the presence of a nucleophile. As shown in scheme 3.7 it was
hypothesised that reversing the reactivity of the synthons such that the hexavalent sulfur
acted as the nucleophile may overcome this issue, even if such a side reaction occurred
(nucleophile attacking the desired product) this would only reform the desired product. As
such, it was determined that this offered a more elegant and likely higher yielding approach,
however the intended starting material (surfuryl chloride 42) would itself be difficult to
access as a highly reactive intermediate. As such, a literature study was first conducted to
assess the potential merits of each option. Firstly the method from sulfonyl chlorides was
explored to assess if any previous literature had reported the potential disulfide forming
side reaction. It was found that Mahieu et al . reported the potential of this side reac-
tion suggesting that product formation could be controlled by the stoicheometry of the
reaction.195 More recently, Pham et al . have shown that when using a sulfonyl chloride,
the major product tends to be the symmetrical disulfide rather than the thiosulfonate.196
With these literature studies in mind it was considered that sulfonyl chlorides offered a
somewhat inelegant but plausible synthetic route where slow addition and stoichiometric
control may have been employed to yield the desired thiosulfonates.
R1
S
O
O R1
S
I
O O
I
R2
S S R
2
R2
S S R
2
S
R1
O O
I R2
S S R
1
O O R
2 S II2
R1
S
O
O
R2
S S R
1
O O
I
Scheme 3.8: Mechanism: Thiosulfonate formation by oxidative cleavage of disulfides
Assessing the second option was mainly focused on a more stable, synthetically accessible
electrophilic bivalent sulfur. Inspired by the concept of disulfide exchange, whereby a disul-
fide acts as a bivalent electrophillic sulfur centre for a sulfur centred nucleophile (thiol), the
literature was searched for potential examples utilising a sulfinate salt as the nucleophile.
This approach was in part inspired when considering how the originally intended sulfuryl
chloride 42 could have been accessed from a disulfide and thionyl chloride.197 Thus, it
was thought that a disulfide its self may offer a shelf stable, easily accessible starting
material for this transofrmation. Gratifyingly, a method reported by Fujiki et al . was
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found which utilised the iodine mediated oxidation of disulfides and subsequent cleavage
with a sulfinate salt to yield thiosulfonates in good yields, with the proposed mechanism
shown in figure 3.8.198 Although Fujiki et al . had only applied this method to simpler,
non amino acid derived systems, it was considered an ideal and more elegant approach
to access thiosulfonates for use as cysteine protease inhibitors. Importantly, it was con-
sidered that if a subsequent nucleophilic attack of the nucleophile utilised in this reaction
(sulfinate salt) took place on the desired thiosulfonate product, this would simply reform
the desired product. Based on the previous findings it was thought that this would offer a
significant synthetic advantage and allow for improved efficiency in the key transformation
of this work, which would prove fundamental to developing this novel warhead class for
future research.
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Scheme 3.9: Homophenylalanine derived aromatic thiosulfonates by oxidative cleavage of disul-
fides
This led to the new synthesis towards amino acid derived thiosulfonates as outlined in
scheme 3.9. This takes advantage of the earlier recognised redundancy towards the syn-
thesis of thiosulfonate warheads starting from the same synthetic intermediate, mesylate
32. The sulfur functionality was then introduced by substitution with thioacetic acid
yielding the thioacetate 44 in a good yield of 73%. Subsequent hydrolysis of the thioac-
etate under aerobic conditions allowed for direct conversion to disulfide 45 in a good yield
of 81%. It was also considered that, if nesessary, the thiol could be isolated through hy-
drolysis under anaerobic conditions which could provide a valuable building block if the
oxidative cleavage of disulfides was found to be unsuccessful again, offering flexibility in
the synthesis. Fortunately exploring thiol building blocks was not required as the subse-
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quent oxidative cleavage to compounds 34 - 37 proceeded in moderate to excellent yields
(44-95%).
In summary, an alternate method towards the synthesis of the thiosulfonate warhead has
been explored by the oxidative cleavage of disulfides with sulfinate salts. By considering
appropriate retrosynthetic approaches, this overcame a fundamental issue with the syn-
thesis of an electrophile in the presence of a nucleophile. Reversing the reactivity of the
synthons in use led to a significant increase in yield, which was realised by applying the
work of Fujiki et al . Furthermore, the overall synthesis shown in scheme 3.9 was believed
to offer a high yielding (24-51% over 6 steps), robust synthesis from amino acid building
blocks providing an excellent foundation for the work to follow.
3.3 Backbone Synthesis and Coupling to Warheads
With the thiosulfonate warhead building blocks to hand, focus turned to constructing the
backbone. In general, the backbone can be altered to confer specificity towards differ-
ent targets as it is responsible for the majority of the primary binding interactions. It
was hypothesised that generating peptidomimetic inhibitor constructs would in principle
facilitate a wide variety of peptidic backbones to be constructed, opening up a readily
accessible route towards other macromolecule targets of interest. As such, focus was
placed on generating a peptidic construct, which in this instance was derived from the
K11777 backbone, to highlight the suitability of thiosulfonates for incorporation into such
scaffolds by standard peptide coupling techniques. It was thought that confirming the
thiosulfonates are compatible with standard peptide coupling techniques would be funda-
mental to the uptake of this novel warhead construct by the wider scientific community.
Furthermore, this would also facilitate an ideal testing platform for comparison against
a known cysteine protease inhibitor, K11777 (6), to assess changing only the warhead
moiety. Maintaining the same backbone was considered important as the non-covalent in-
teractions it provides can contribute significantly towards inhibitor specificity and potency.
Thus, maintaining a consistent backbone motif allowed for assessment of the contribution
from the warhead.
The backbone was made according to the literature procedure of Kiemele et al . (scheme
3.10) starting from phenylalanine benzyl ester 46.199 This was first converted to the
isocyanate with the use of triphosgene before direct conversion to the N -methyl piperazine
caped urea 47 in a moderate yield of 48%. Interestingly, following the literature procedure
resulted in very low yields (8%) over these two steps. It was thought that this was due to an
error in the reported procedure, which reports performing an acid wash during the workup,
as this step would most likely extracting the tertiary amine into the aqueous phase reducing
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Scheme 3.10: Backbone synthesis and coupling to homophenylalanine derived aromatic war-
heads.
the yield. It was also noted that two solvents were being utilised, beginning with DCM,
concentrating and then suspending in THF. This was deemed to be unnecessary thus an
optimised approach, shown in scheme 3.10, was taken whereby the DCM layer was simply
carried forward after seperation of the aqueous NaHCO3 phase and drying. Removing the
reported acid wash and evaporation / resuspension in THF steps both improved the yield
and convenience of the reaction. Following on from this the C terminus was deprotected by
hydrogenolysis in preparation for the following peptide coupling. The amino acid derived
thiosulfonate warheads 34-37 were deprotected with HCl before direct coupling to the
backbone using the uronium coupling agent BOP as a representative, standard peptide
coupling technique which proceeded in good to excellent yields (82-100%). It was thought
that this represented a widely accessible, high yielding route towards peptidomimetic
thiosulfonate inhibitor constructs, which could be reasonable expected to work with a
wide variety of substrates.
3.4 Synthesis of K11777: A Reference Compound
In order to validate the newly synthesised thiosulfonates, K11777 (6) was synthesised as
a reference compound for comparison. The synthesis, displayed in scheme 3.11, was based
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Scheme 3.11: Synthesis of K11777 reference compound
on previous work towards vinyl sulfone warheads which found first converting to the wein-
reb amide, followed by reduction to the aldehyde and direct Horner Wadsworth Emmons
(HWE) reaction was an efficient approach towards the synthesis of vinyl sulfones.200 The
Weinreb amide 53 offered a shelf stable and easily accessible aldehyde precursor whilst
the HWE reagent 56 could be readily accessed by substition of diethyl chlorophosphate
with 55 yielding 56 in a good yield of 64%. The HWE reaction proceeded well giving
vinyl sulfone 54 in a quantitative yield. The subsequent amide coupling to backbone
48, synthesised previously, was low yielding at only 18%. It was thought that much of
the product was lost during the purification as the tertiary amine became protonated
and strongly adsorbed to the silica during chromatography before subsequent preperative
HPLC yielding the TFA salt. This could be easily avoided in future synthesis by adding
a base such as triethylamine to the eluent during chromatography, or perhaps direct pu-
rification by preperative HPLC. In this instance, further optimisation was not required as
sufficient material was obtained for all required testing.
3.5 Stability Testing Towards Common Nucleophiles
Of any newly defined warhead class the stability and reactivity towards common organic
nucleophiles should be considered. Not only does this prove useful for the design of new
synthetic approached to warheads of this type, by elucidating the conditions under which
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the warhead is stable, but this also proves invaluable when considering biological activ-
ity by considering biologically relevant nucleophiles. It was hypothesised that testing
the thiosulfonate warheads against a representative amine, representative thiol and pH
aqueous stability would represent nitrogen, sulfur and oxygen centred nucleophiles respec-
tively.
3.5.1 pH Dependent Aqueous Stability
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Figure 3.5: pH dependent aqueous hydrolysis of compounds 7 (left) and 10 (right) at pH 6
(blue), 7 (orange) and 8 (olive). Inhibitor degradation was determined by HPLC with peak areas
integrated against an internal standard (Ac-Phe-OH), 13 measurements were taken 1 hour apart,
representing time 0 to 12 hours. Sodium phosphate buffer (0.1mm) of the relevant pH containing
5% DMSO was utilised, initial inhibitor concentration was 245µm and internal standard (Ac-
Phe-OH) concentration was 338µm. Results were then normalised and plotted as scatter graphs
for visualisation.
Starting with the pH dependent aqueous stability three pH’s were examined (pH 6, 7 and
8) to represent a reasonable physiological pH range. Figure 3.5 represents the aqueous
stability profiles of both the para-nitro substituted thiosulfonate inhibitor 7 and the para
methoxy substituted thiosulfonate inhibitor 10 over 12 hours as monitored by HPLC. It
was anticipated that the warhead with an aromatic ring containing an electron withdraw-
ing substituent (p-NO2, 7) would lead to an increased reactivity of this warhead construct
and, conversely, the electron donating substitution of compound 10 (p-OMe) would de-
crease the reactivity of the warhead. This was thought to be due to enhancing or reducing
the leaving group ability of the sulfinate salt generated in each case. Gratifyingly, the aque-
ous stability profiles confirmed the highly tunable nature of this novel warhead construct
showing a marked difference between the most electron rich and most electron deficient
aromatic rings (7 and 10). As was anticipated, the stability was inversely proportional to
pH, with increasing pH reducing the half life of the warheads.
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Firstly, considering the stability profile of the p-NO2 substituted compound 7, it was found
to be effectively unstable at pH 7 and 8, having completely decomposed within 1 hour,
whilst at pH 6 a moderate half life of approximately 1.5 hours was observed. This would
suggest that such a warhead would be incompatible for use in a more complex biological
system, which is an important finding of this stability study. However, as a member of
a first inhibitor series the true value of this result lies in comparison with the predicted
most stable inhibitor construct 10 to demonstrate if the chemistry can be developed to
control the reactivity of the thiosulfonate warheads.
Moving forward from the predicted most reactive warhead 7, the p-OMe substituted war-
head of compound 10 was found to be significantly more stable at across the tested pH
range. This inhibitor construct was now effectively stable at pH 6 with a very reasonable
half life of approximately 24 hours at pH 7 and even displayed a reasonable half life of
approximately 1 hour at pH 8. This was a very encouraging finding, not only as this
highlighted a potentially suitable warhead construct for use in more complex biological
systems but the difference between the most reactive and least reactive warhead constructs
could be confirmed and the highly tunable nature of the thiosulfonate displayed. Often,
the ability to control the reactivity of a potential electrophillic trap is highly desirable in
medicinal chemistry and chemical biology for the generation of specific molecular probes or
inhibitors.143 Thus, this early study highlights the suitability of thiosulfonates for further
modifications and the ability to specifically tune their characteristics.
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Figure 3.6: Chiral sulfoxides formed upon aqueous hydrolysis of thiosulfonate warheads via a
sulfenic acid intermediate.
Furthermore this study was able to confirm the site of attack on the thiosulfonate warhead.
As expected, the site of attack could be confirmed to be on the bivalent sulfur of the
thiosulfonate. This was confirmed by the presence of two distinct peaks on the HPLC
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chromatogram, found to be of the same mass by LC-MS and consistent with formation
of chiral sulfoxide 57 (two peaks were observed due to separation of diastereomers). As
shown in scheme 3.6 the mechanism of formation is proposed to occur through the sulfenic
acid intermediate, generated by hydrolysis of the thiosulfonate warhead, leading to the
chiral sulfoxide product shown. Interestingly, the secondary attack on the warhead by the
generated sulfenic acid appears to outcompete further hydrolysis. This further confirms
the highly selective nature of thiosulfonates towards sulfur centred nucleophiles.
3.5.2 Stability Towards Thiols and Amines - The Benzyl Thiol
and Benzyl Amine Test System
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Figure 3.7: Stability towards BnSH and BnNH2 of compounds 7 (p-NO2 substituted, left) and
10 (p-OMe substituted, right). Inhibitor degradation was determined by HPLC in MeCN at
room temperature with 13 measurements taken 1 hour apart, representing time 0 to 12 hours.
Approximately 0.3 mg of inhibitor was accurately weighed and suspended in MeCN, to which 10
equivalents of BnSH or BnNH2 was added immediately before measurement. Results were then
normalised against time 0 and plotted as scatter graphs for visualisation.
Next the stability towards the common organic nucleophiles of interest, amines and thiols,
was to be assessed. The main consideration here was to assess the chemical stability
towards relevant nucleophiles in a chemical synthesis context. This was done for both the
most reactive compound 7 bearing the p-NO2 substituted warhead and the least reactive
inhibitor 10 bearing the p-OMe substituted warhead. Although the findings could be
extended towards biologically relevant nucleophiles, additional factors would have to be
considered, such as the pH of the local environment, which was intentionally examined as
a separate parameter in this work (section 3.5.1) to better understand the reactivity of
the thiosulfonate warheads.
Firstly, benzyl amine was taken as a representative amine which was UV active to allow
55
progress to be monitored by UV absorption thourgh HPLC analysis. 10 equivalents of
benzyl amine were added to the thiosulfonate inhibitor construct in MeCN and the reac-
tion progress monitord over 12 hours. Gratifyingly the thiosulfonates were found to be
effectively stable toward benzyl amine over a 12 hour time period, even the more reactive
p-NO2 substituted compound. Of course, amines are common nucleophiles in organic syn-
thesis so knowing that the thiosulfonate electrophilic trap displays little reactivity towards
these is an encouraging finding for future work. As such, it should be possible to develop
chemistry which requires a nucleophilic amine in the presence of the thiosulfonate, one
example of which has already been displayed in the final amide coupling step of inhibitor
constructs (section 3.3, scheme 3.10).
Moving on to the stability towards thiols, benzyl mercaptan was taken as a representative
thiol. Again, the benzylic group was chosen as it allowed the time dependent concentration
of the thiol to be monitored by UV absorption on HPLC. It was hypothesised that the
thiosulfonates would display an inherent reactivity towards sulfur centred nucleophiles, as
this is a fundamental feature believed to be beneficial towards specifically targeting biolog-
ically relevant sulfur centred nucleophiles, such as cysteine proteases. Encouragingly the
thiosulfonates were found to react with a thiol in a manner consistent with their predicted
reactivity profiles with the p-NO2 substituted inhibitor 7 reacting almost entirly over 12
hours, while the less reactive p-OMe inhibitor 7 gradually decreased to 50% of its initial
concentration. This mirrored the previously observed reactivity profiles during aqueous
stability testing in section 3.5.1, confirming that the more electron deficient thiosulfonate
warhead was more reactive towards incoming thiols and the more electron rich aromatic
ring was less reactive towards incoming thiols.
N
N N
H
O H
N
O
S S
59
Figure 3.8: Asymmetric disulfide formed by attack of benzyl mercaptan on thiosulfonate in-
hibitors
Again, it was observed by LC-MS that the site of attack on the thiosulfonate warhead was
the bivalent sulfur, as the asymmetric disulfide (compound 59, figure 3.8) was observed for
both inhibitor constructs, giving further insight into the reactivity of this novel warhead
construct. Furthermore the exceptional selectivity observed between amines and thiols
was a highly encouraging result, suggesting that the fundamental premise of utilising a
thiosulfonate as a warhead specific for sulfur centred nucleophiles was well founded. This
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reactivity profile is also complementary to current warheads being developed within the
Liskamp group, the sulfonyl fluorides, which are most reactive towards serine / threonine
OH.178,181 It is believed that developing such complementarity between warhead classes
will help to expand the chemical toolbox available for probing specific biological prob-
lems or designing new inhibitors, such as those displayed in this work, with enhanced
specificity.
Importantly, it was considered that this highly tunable nature could be pushed further,
reducing the reactivity of the thiosulfonate warhead whilst maintaining specificity towards
sulfur centred nucleophiles. In doing so, it was hoped that the thiosulfonates would be
able to withstand biologically relevant thiols, such as circulating thiols, and upon binding
to a target be able to illicit the desired effect. This was in part thought to be possible
due to the specific environment invoked upon binding a target molecule which in many
cases can enhance the reactivity of the warhead. Indeed, this very argument has been put
forward previously during docking studies in section 3.1, which displayed the potential in
situ activation of the thiosulfonate warheads. Thus the ultimate goal of this work became
a two fold issue, which was successfully addressed; (1) to design an inhibitor backbone
capable of delivering the warhead to a specific target and (2) to explore chemistry to
downregulate the warhead reactivity such that circulating thiols, and indeed aqueous
stability, were of little to no concern.
In summary, these stability studies suggested that the thiosulfonates displayed great po-
tential, and that their highly tunable nature may be a desirable quality. Further work
should be targeted towards increased stability combined with the ability to confer speci-
ficity through backbone design. Addressing these key issues would ensure the uptake, and
ultimately success, of this newly emerging warhead construct. This may be of particular
important in more complex biological systems where considerations, such as reaching the
target macromolecule before degradation, become increasingly important. With this in
mind, it was decided to move forward to simple biological testing to first assess the suit-
ability of thiosulfonates as cysteine protease inhibitors in an enzymatic study. This would
provide a baseline to work from and, if the thiosulfonates were deemed to offer suitable
characteristics, the chemistry to further regulate the reactivity could be explored leading
on to a potentially powerful new warhead moiety.
3.6 Biological Testing - Papain Enzyme Assay
Papain was selected as a prototypical cysteine protease being of the clan CA, family C1.
Importantly, papain has been widely studied and is more economically favourable over
other more specialised clan CA, family C1 proteases (such as parasitic analogues), offering
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an ideal platform as an initial protease target. It was hypothesised that the high homology
between these proteases would allow for rational conclusions to be drawn, which would
still be applicable to more biologically relevant cysteine proteases.
3.6.1 Developing a Thiol Independent Assay
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Figure 3.9: Papain assay overview: Hydroylsis of Nα-benzoyl-L-arginine 4-nitroanilide substrate
by papain yielding 4-nitro anilide chromophore (top) to be quantified by absorbance at 405 nm
with a plate reader (bottom right) in a 96 well plate (bottom left).
Thiols are commonly used in cysteine protease enzymatic assays as activators to ensure the
active site thiolate is in the reduced form. For preliminary biological testing it was thought
to be beneficial to remove thiols from the system due to potential cross reactivity with
the thiosulfonate warheads, as outlined in section 3.5.2. Previous work in the Liskamp
group, conducted by Brouwer et al .183 towards sulfonyl fluoride warheads developed a
thiol independent papain assay for similar reasons, which served as a starting point for
this work. The principle of the assay is outlined in figure 3.9 and is based on detecting
the absorbance of the 4-nitroanilide chromophore produced upon hydrolysis of a substrate
(Nα-benzoyl-L-arginine 4-nitroanilide). As initial rate of substrate hydrolysis is directly
proportional to the active enzyme concentration, this allows for quantification of active
enzyme for assay setup and subsequent inhibition studies.
As the main purpose of thiols in cysteine protease enzymatic assays is to ensure the active
site thiolate is in the active, reduced form it is possible to conduct the assay without
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Figure 3.10: Determining papain concentration for thiol independent assay. Doubling dilution
range from 40−2.5µm. From top to bottom: 40 µm (brown); 20 µm (blue); 10 µm (green); 5µm
(purple); 2.5µm (black); blank (red).
thiols present.183 This results in a significant portion of the tested enzyme being in an
inactive form thus higher enzyme concentrations can be used to counteract this. In this
instance, approximately 10% of the enzyme was thought to be active and the first step was
to define an adequate working concentration, as shown in figure 3.10. This was achieved
by assessing a dilution range of enzyme with a colorometric substrate to find the minimum
working concentration which gave an adequate response, with an enzyme concentration of
20µm being found as optimal for further testing.
3.6.2 Testing Initial Inhibitor Series
With a thiol independent enzyme assay now defined, testing of the first thiosulfonate
inhibitor series could take place (compounds 7 - 10 figure 3.11). Inhibitors were first
screened at a broad concentration range to find the concentration at which differences in
inhibition could be observed (between 100% inhibiton and 0% inhibition), which was found
to be 625 nm. As shown in figure 3.11 all inhibitors were tested at this concentration and
a clear trend could be observed between the reactivity of the warheads and the potency
of the inhibitor. More potent inhibitors reduced the enzyme activity, resulting in less
observed hydrolysis of the substrate (Nα-benzoyl-L-arginine 4-nitroanilide), which can be
visualised as a less steep gradient of the linear response in figure 3.11. Encouragingly all
inhibitors operated within the same order of magnitude as the reference compound K11777,
although this was clearly the most potent inhibitor tested. Furthermore it was observed
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Figure 3.11: Papain inhibition curved for homophenylalanine derived aromatic thiosulfonates.
From top to bottom the curves represent: No Inhibitor (red), 7 (dark blue), 8 (purple), 9 (cyan),
10 (olive), K11777 (6, maroon). All inhibitors were tested at 625 nm, 20 µm papain.
that reducing the reactivity of the warheads resulted in increasingly potent inhibitors.
This trend can be clearly observed with the most reactive p-NO2 substituted inhibitor
7 showing the least inhibition (figure 3.11, dark blue curve). This trend was observed
through the reactivity series and followed the predicted reactivity profiles with by the
next most reactive compound 8 (no substitution, purple curve) being followed by 9 (p-Me
substituted, cyan curve) and finally the least reactive inhibitor 10 (p-OMe substituted,
olive curve) being the most potent in the thiosulfonate series.
The observed trend correlated well with the earlier stability studies, suggesting that the ob-
served trend in potency may be due to partial decomposition of the thiosulfonate warheads
under assay conditions. Upon comparison of the assay conditions (incubation time of 1Hr,
pH 6.5) with the aqueous stability profiles in section 3.5.1, it was surprising that this effect
was not more pronounced. It was previously observed that increased aqueous stability of
the thiosulfonate warheads correlated with decreased pH, as expected. Compound 7 was
previously observed to have completely decomposed within 1 hour at pH 6. As such, the
fact that the inhibition falls within such a close range of other thiosulfonate warhead con-
structs, and indeed the vinyl sulfone reference compound, was remarkable. This suggests
that the thiosulfonates are very fast acting, inhibiting the papain before decomposition
can take place. This was a very encouraging finding as it suggests that the target binding
and subsequent inhibition must be highly efficient for the thiosulfonate constructs enabling
them to outcompete decomposition, even for relatively unstable warheads. Furthermore
this may be in part attributed to the in situ activation of the thiosulfonates observed in
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section 3.1, enhancing their reactivity in the binding pocket relative to the surrounding
aqueous environment. Most importantly, this study suggested that the thiosulfonates were
highly suitable warheads for cysteine protease inhibition and that further development to
control their reactivity may be able to further improve their stability and potency simul-
taneously. Having demonstrated the highly tunable nature of the thiosulfonates it was
believed that the chemistry surrounding the warhead stability could be further explored
leading to a powerful new warhead class for specific inhibition of cysteine proteases.
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Figure 3.12: IC50 determination of homophenylalanine derived aromatic warheads. Assay
buffer: sodium phosphate (100mm, pH 6.5) containing EDTA (1.5mm) and 2% DMSO. Final
concentrations in the wells were; Papain: 4µm; substrate: 1.0mm; inhibitor: doubling dilution
range starting at 10 µm giving: 10 µm, 5 µm, 2.5 µm, 1.25 µm, 0.625 µm, 0.3125 µm, 156.25 nm,
78.125 nm, 39.0625 nm. Error bars on graph display SEM across 3 independent repeats. Tabulated
± values represent the std error of the IC50 values across 3 independent repeats.
The initial inhibition studies provided an excellent visual aid between reactivity and in-
hibition, to further extend this the IC50 values were determined as shown in figure 3.12.
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Initially, the IC50 values obtained correlated very well with the earlier observed inhibition
studies when conducted with an enzyme concentration of 20µm. However, upon testing
later inhibitor series it was found that there was inconsistency in the data due to batch
variability in the active enzyme concentration of the papain. As such, a new batch of
papain was purchased and the active papain concentration screened as it was earlier in
figure 3.10, which was found to be more active than the previous batch. As such, a lower
papain concentration of 4 µm was used to correct for this resulting in an optical density
(OD) of 0.2, consistent with previous experiments. This papain batch was then made
into aliquots and stored at −80 ◦C and all inhibitors retested with the same papain batch.
The same papain batch was also used for all other inhibitors tested in this work to ensure
consistency and avoid batch variability. Looking towards the results in figure 3.12 it can
be seen that all inhibitors displayed similar IC50 values in the sub-micromolar range of
140-190 nm, similar to that of the reference compound K11777 at 80 nm. It was hypothe-
sised that the relatively consistent IC50 values represented effective titration of the enzyme
at the tested concentration range, with small difference observed in IC50 values reflecting
competing pH dependent decomposition of inhibitor constructs correlating with earlier
stability studies in section 3.5. As such, this assay offered a convenient testing platform
to optimise the reactivity profiles of tested inhibitor constructs. Once stability arguments
have been overcome, further optimisations should be made to this assay to reflect accurate
IC50 determination with suggestions made in the following section (3.6.3,Future work on
papain assay.
Moving forward there were two clear routes to be explored for the thiosulfonate derived
cysteine protease inhibitors. Firstly, improved potency by improving the binding affinity
with the target protease and secondly improved potency by improving the stability of
the warhead. Improving the binding affinity is a common technique, often forming a
large proportion of a structure-activity relationship; as such a convergent synthesis to
incorporate this with the thiosulfonate warheads was to be explored. Following on from
this, techniques to improve the inhibitor stability will be explored with the hypothesis that
these will be synergistic with the noncovalent interactions of the backbone motif, further
improving overall inhibitor design.
3.6.3 Future work on papain assay
The current papain assay offers a convenient platform to study the relationship between
warhead stability (based on reactivity) and inhibition potential. There are however lim-
itations which should be addressed once sufficiently stable warheads have been realised.
Such assay optimisation should begin with detailed characterisation of the enzymatic and
assay parameters, such as the Km and Kcat of the enzyme and substrate combination used,
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the amount of substrate turned over in the assay timeframe, the signal/background, and
the Z’ factor. Interested readers are referred towards the literature guidelines and reviews
for assay optimisation.201–203
An extension of these optimisations is that the current assay appears to be titrating the
enzyme with the inhibitor constructs, as such methods to overcome this should be con-
sidered. One area for optimisation would be the incubation time, as these inhibitors are
proposed to be covalent the current incubation time of 1 hr may not reflect inhibitor bind-
ing in the IC50 value, but rather titrate the enzyme. Taking this into consideration, with
the best compound (K11777) displaying an IC50 of 81 nm, there can not be more than
162 nm of active enzyme in the assay. This also suggests that the enzyme concentration
is too high to characterise such potent inhibitors, and the current assay is not sensitive
enough to accurately differentiate these inhibitors beyond comparing rates of decomposi-
tion vs rates of reaction with enzyme. A potential method to address these areas would
be to reduce the incubation time, potentially to 0 by adding the inhibitors as the final
assay component and observing the drop in substrate turnover. Methods to increase the
sensitivity of the assay could focus on reduced enzyme concentration, which will in turn
reduce the substrate turnover. With reduced substrate turnover increased sensitivity may
be required in the assay readout, which could be achieved by exploring fluorescent sub-
strates if required. As the inhibitors being tested are anticipated to be competitive in
nature, substrate concentration dependence of inhibition may also be explored. This will
then allow further kinetic measurements to be taken, such as determining Ki and Kinact
for the inhibitors.
3.7 Summary
The first generation of peptidomimetic thiosulfonate inhibitors have been explored. Mod-
elling studies suggested that the thiosulfonates were well placed to be explored as cysteine
protease inhibitors which would be well accommodated within the active site and also offer
potential in situ activation through the localised hydrogen bonding network. Furthermore
this hydrogen bonding network is specific to cysteine proteases, further increasing the selec-
tivity towards proteases of this class. An efficient synthesis towards thiosulfonate warheads
was developed which allowed for incorporation of a broad reactivity series by differing the
substitution on the aromatic ring of warheads. This broad reactivity series allowed a
greater understanding of the relationship between reactivity and activity of this new war-
head class. It was found that the thiosulfonate warhead was highly tunable, thought to be
one of the key strengths of this warhead class, and that the predicted reactivity profiles
correlated well with those observed in stability studies. A thiol independent enzyme assay
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was developed to allow for testing of this initial inhibitor series which showed that the
thiosulfonates were promising inhibitors of the cysteine protease papain. This assay also
highlighted that future warhead development may be centred around warhead reactivity
and stability. From this, a new inhibitor series can be developed to further improve on the
potential of the thiosulfonates. This approach will be two fold, first targeting increased
binding (led by modelling studies) and exploring new chemistry surrounding the warhead
moiety to further improve the aqueous stability profiles of the thiosulfonates.
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Chapter 4
Second Generation Inhibitors: A
Convergent Strategy to Improved
Binding
The ability to specifically target and differentiate between enzymes is of the utmost im-
portance when designing a new inhibitor construct. As the thiosulfonates in this work
are peptidomimetic in nature, and derived from amino acids, altering the amino acid used
should have a direct impact on the binding of the final inhibitor constructs. This has been
incorporated by design to facilitate an easily accessible method to improve the primary
binding event of thiosulfonate inhibitors which in turn should correlate with an increased
potency. To illustrate this, a modelling study was conducted to uncover a residue for
improved binding of the thiosulfonates against papain. It was hypothesised that this
improved binding would correlate with an improved potency, which would be have an
additive effect when combined with the more stable (and potent) thiosulfonate warheads
observed previously.
4.1 Docking Study: Targeting Residues Introduced with
Warhead Fragments
It has been well documented for papain like cysteine proteases that the P1 residue plays
an important role in the specificity of the inhibitor towards the target protease (see section
1.1.1. In the case of thiosulfonate inhibitors, the P1 residue is incorporated along with
the thiosulfonate moiety. Thus, it was thought to be important to highlight that alter-
nate building blocks could be utilised to increase the binding affinity towards a specific
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Figure 4.1: Docked pose of arginine-derived thiosulfonate inhibitor 14 with papain. 4 possible
docked poses, all highlight coordination between backbone carbonyls of Cys63, Ser21 and the
arginine side chain.
protease.
In order to identify a suitable amino acid residue to incorporate, the crystal structure of
papain (PDB code 1CVZ) was examined. As shown in figure 4.1, it was clear that the
bottom of the P1 binding pocket offered two potential H-bond acceptors (backbone car-
bonyls of Cys63 and Ser21). The nature of having two H-bond acceptors in close proximity
to each other suggested that a complementary residue, with two potential H-bond donors
in close proximity, would offer an ideal residue. Considering the naturally occurring amino
acids, arginine was the obvious candidate for this. The proposed suitability of arginine
was further supported by a literature study whereby Turk et al .16 proposed that the elec-
trostatic environment at the bottom of the S1 binding pocket, largely dominated by the
backbone carbonyls, would be suitable for coordination to an arginine residue. To further
explore this, and provide a visual cue to the suitability of the chosen residue in the P1
position, DrawToDock was utilised to dock inhibitor 14 with Papain (PDB 1CVZ).
It was noted that the introduction of an arginine residue in the P1 position placed the
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arginine in close proximity to the backbone carbonyls of Cys63 and Ser21, facilitating H-
bonding (figure 4.1). Another distinct feature observed was the overall binding mode of the
inhibitor had been altered. The P3 N -methylpiperazine cap was no longer predicted to be
solvent facing. This is likely due to the docking software placing a greater importance on
the H-bonding which is now present in the P1 binding site. In any case, it was hypothesised
that enhancing the initial binding event would improve the potency of the inhibitors as
the subsequent covalent bond formation is likely to be under kinetic control, thus any
improvement in the initial binding (and bringing the warhead into closer proximity with
the active site nucleophile) will likely result in an improved potency. Having proposed
that an arginine residue is a suitable candidate to improve the non-covalent interactions
of the warhead fragment, subsequent synthesis and testing could now take place.
4.2 Arginine Derived Thiosulfonates: Exploiting a Flex-
ible Synthesis
4.2.1 Synthesis of Arginine Derived Warheads
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Scheme 4.1: Arginine derived aromatic thiosulfonates by oxidative cleavage of disulfides
Based on the earlier work towards thiosulfonate warheads, which defined a robust synthesis
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towards amino acid derived thiosulfonates, a similar synthesis was conducted. This began
with the protected arginine derivative Boc-Arg(Pbf)-OH (60). The Pbf group was selected
as a suitable protecting group for this synthesis as the deprotection conditions (acidic)
were known to be compatible with the thiosulfonate warhead from the previous synthesis.
Following the same protocol as previously the carboxylic acid 60 was converted to the
methyl ester 61 before reduction to the corresponding alcohol 62 in excellent yields of 93
and 99% respectively. Next, alcohol 62 was converted to mesylate 63 before introducing
the thioacetate by substitution with thioacetic acid in a good to excellent yield of 63
and 90% respectively. Subsequent hydrolysis and oxidation to disulfide 65 proceeded in
good yields (73%), although it was observed that the oxidation step from thiol to disulfide
was less efficient than in the case of the homophenylalanine derivative. This was thought
to be due to the increased sterics of the bulky Pbf protecting group on the side chain,
as remaining thiol was observed by TLC and separated out during purification. Finally,
the thiosulfonate warheads were isolated by the oxidative cleavage of disulfide 65 giving
warhead building blocks 66 - 69 in moderate to good yields (32-55%).
4.2.2 Final Inhibitors: Coupling Warheads to the Backbone
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Scheme 4.2: Backbone synthesis and coupling to arginine derived aromatic warheads.
Moving towards final inhibitor constructs, the protected warhead fragments were first
deprotected with TFA, which was required in the case of arginine constructs to effectively
remove the Pbf protecting group as well as the Boc group. Previously, HCl was chosen
to remove the Boc group as the subsequent coupling reaction could potentially take place
between the carboxylic acid of the TFA salt rather than the desired backbone. Subsequent
68
coupling to the backbone 48 proceeded with good yields of 61-88% giving inhibitors 13 -
16 as TFA salts after preperative HPLC.
4.2.3 Biological Testing: Papain Enzyme Assay
Figure 4.2: Papain inhibition curved for homophenylalanine derived aromatic thiosulfonates.
From top to bottom the curves represent: No Inhibitor (red), 13 (maroon), 14 (green), 15 (blue),
16 (purple), K11777 (6, turquoise). All inhibitors were tested at 625 nm, 20 µm papain.
The arginine derived inhibitors were first screened against papain as before for the homo-
phenylalanine constructs at 625 nm to visualise any differences between each warhead.
As can be seen in figure 4.2 the same trend was observed between warhead reactivity
and potency, with the most reactive p-NO2 substituted warhead being the least potent
while the least reactive p-OMe substituted warhead was the most potent. Gratifyingly,
all inhibitor constructs appeared to perform better than the previous homo-phenylalanine
constructs being grouped closer to the reference compound K11777 (6, turquoise line),
suggesting that more potent inhibitors have been generated. Although screening at the
same concentration offers a great visual aid for comparison of warhead constructs, the IC50
values were then determined to allow a more quantitative comparison between warhead
constructs.
In order to determine the IC50 values of the warhead arginine derived warheads each
inhibitor was screened against papain at a doubling dilution range. This was conducted
with the same batch of papain as used previously to remove any batch to batch variability
in the active enzyme concentrations. All arginine-derived inhibitors performed better
than the homophenylalanine-derived warheads with an approximate improvement of 20 nm
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Warhead Arginine Arg Homo-Phe Homo-Phe
S1’ substituent Compound number IC50 nm Compound number IC50 nm
14 168 ± 3 8 190 ± 6
15 162 ± 18 9 182 ± 5
OMe
16 124 ± 1 10 148 ± 6
NO2
13 129 ± 2 7 186 ± 11
N/A N/A 6 (K11777) 81 ± 2
Figure 4.3: IC50 determination of arginine-derived aromatic warheads. Assay buffer: sodium
phosphate (100mm, pH 6.5) containing EDTA (1.5mm) and 2% DMSO. Final concentrations
in the wells were; Papain: 4µm; substrate: 1.0mm; inhibitor: doubling dilution range start-
ing at 10 µm giving: 10 µm, 5 µm, 2.5 µm, 1.25 µm, 0.625µm, 0.3125µm, 156.25 nm, 78.125 nm,
39.0625 nm. Error bars on graph display SEM across 3 independent repeats. Tabulated ± values
represent the std error of the IC50 values across 3 independent repeats.
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seen for all warhead construct when compared with their homophenylalanine counterparts
(figure 4.3). This suggested that the modelling studies were correct and an improvement in
potency has been achieved by increasing the initial binding event (Ki), leading to inhibition
before competing aqueous degradation, although further studies would be required to
accurately determine Ki values. The hypothesis that inhibitor binding is out competing
degradation to improve the IC50 values is also supported by the least reactive (most stable)
warhead of compound 16 exhibiting a marginally improved potency compared with other
warhead constructs. Interestingly, the p-NO2 substituted warhead of inhibitor 13 was
found to be equipotent to 16 in this study. This could, in part, be explained by the
warheads contributing towards the Ki which would improve the initial binding. This
supports the hypothesis that the inhibitor potency is determined by the initial binding
event as well as the reactivity of the warheads. Furthermore, the p-NO2 group of compound
13 offers an additional polar contact which may improve the binding of inhibitor constructs
and explain the ability of the more reactive warheads to offer improved inhibition over the
less reactive warheads. This leads on to the hypothesis that all warhead constructs must
be fast acting, outcompeting aqueous degradation, which would be largely controlled by
the initial binding event (Ki). However further assay development and experiments would
be required to fully interpret and discuss any kinetic effects, such as those outlined in
section 3.6.3.
Although the variation observed between each warhead tested in this this assay is relatively
small (1.3 fold), it is reasonable to suggest that this may become exaggerated in more
complex biological systems, for example, a biological system whereby the time taken to
reach the desired target will be significantly longer. Furthermore, the inhibitor constructs
will have to safely negotiate numerous biologically relevant nucleophiles such as circulating
thiols as well as the surrounding aqueous environment. Thus, future efforts focused on
downregulating the reactivity of the thiosulfonate warhead as it was believed this would
be favourable for selective target engagement in a more complex biological system where
competing degradation pathways would be of greater significance.
4.3 Summary
In summary, modelling studies suggested that introducing an arginine side chain in the
P1 position, simultaneously with the warhead fragment, would improve the binding of
thiosulfonate derived inhibitors towards papain. This was hypothesised to result in an
improved potency highlighting the suitability of the thiosulfonate warhead for rational
modifications in a medicinal chemistry SAR like study. The previously described synthe-
sis towards amino acid derived thiosulfonates has been expanded to encompass arginine
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derivatives. Subsequent enzymatic studies suggested that the modelling studies hold true
with a marginally improved potency observed for all arginine derived inhibitor constructs.
This led on to the argument that the inhibitory potential of thiosulfonate inhibitors may
be largely under kinetic control with the initial binding event (Ki) being the major con-
tributing factor, in combination with warhead reactivity. With this being said, warhead
stability was observed to correlate with potency. This trend is expected to become exag-
gerated moving on to more complex biological systems whereby the influence of pH and
other nucleophiles is anticipated to have greater impact. As such, future thiosulfonates
will focus on both improving the initial binding event and downregulating reactivity which
is expected to lead on to highly interesting inhibitors.
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Chapter 5
Third Generation Inhibitors:
Modulating Leaving Group Ability to
Control Reactivity
BocHN
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BocHN
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74 75 76
Figure 5.1: Target compounds for improved stability by reduced leaving group ability of the
liberated sulfinate, two key strategies: (1) Increasing the electron density on the aromatic ring
(compound 74) and (2) loss of aromaticity (compound 75 and compound 76)
From the results observed in the previous chapters it can be concluded that reduced re-
activity of the thiosulfonate warhead leads improved stability with retention, or marginal
improvement in potency. In this chapter, methods to reduce the reactivity of the thiosul-
fonate warhead by reducing the leaving group ability of the liberated sulfinate salt will be
explored. It was hypothesised that modulating the leaving group ability could be achieved
by tuning the electronic properties of the sulfinate liberated upon nucleophilic attack.
As such, this chapter explores two key methods to influence the sulfinate leaving group
ability. Firstly, generating a more electron rich aromatic ring by further substitution (as
demonstrated by compound 74, figure 5.1) will be considered. Then, expanding on this,
loss of aromaticity to the aliphatic (cyclohexane) counterpart (compound 75, figure 5.1)
and introducing an aliphatic linker to an aromatic ring (76, figure 5.1) will be explored.
Considering the wider implications of warhead reactivity, this may also offer improved
pharmacodynamic properties of future thiosulfonate derived inhibitors when moving to-
73
wards more complex biological systems than the papain assay described earlier in section
3.6.1.
5.1 Improved Stability by Further Substitution: Tris-
Methoxybenzene Analogues
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Scheme 5.1: 2,4,6-trimethoxybenzene sodium sulfinate synthesis by reduction of sulfonyl chlo-
ride.
The first target building block to be considered was the 2,4,6-tri-methoxybenzene deriva-
tive 74 (Figure 5.1). One noteworthy consideration of this building block is that the
increased steric bulk may have a significant impact on initial inhibitor binding (Ki). This
could be either beneficial or detrimental, the outcome of which would be highly dependent
on the specific protease being targeted, as it must be able to accommodate the bulkier
substituent in the S1’ binding site. It was hypothesised that, from a chemical reactivity
standpoint, this offers an interesting substrate which merits further investigation and fu-
ture SAR considerations could follow if an improved stability was realised. Hence, the
synthesis towards this building block was first explored.
The original intended synthesis towards building block 74 aimed to take advantage of
the earlier developed oxidative cleavage of disulfides by sulfinate salts as described in sec-
tion 3.2.3, scheme 3.9. As such, the first step was to form the desired sulfinate salt 79a
(scheme 5.1). Previously the sulfinate salts were found to be readily accessible form sul-
fonyl chlorides, therefore early attempts to access the sulfinate salt involved formation of
the corresponding sulfonyl chloride 78 from 2,4,6-trimethoxybenzene 77 with chlorosul-
fonic acid, which proceeded with a moderate yield of 49%. The subsequent reduction to a
74
sulfinate salt appeared high yielding, however the characterisation was considered ambigu-
ous by convenient characterisation techniques. The NMR of the product was consistent
with the structure but no mass data could be obtained as the product did not ionise. It
was considered that the NMR of potential by products, such as the sulfonic acid which
may be produced by hydrolysis of the sulfonyl chloride, or even the starting material sul-
fonyl chloride were expected to be effectively identical with only slight differences in the
chemical shift. As such, it was decided to subject what was believed to be the sodium
sulfinate salt to the subsequent oxidative cleavage which, if successful, would confirm the
production of the sulfinate salt. Unfortunately the following oxidative cleavage towards
compound 74 did not yield any of the desired thiosulfonate, with the quality of sulfinate
salt 79a being considered the most likely cause for failure.
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Scheme 5.2: 2,4,6-trimethoxybenzene sodium sulfinate synthesis by directed ortho lithation and
SO2.
It was hypothesised that an alternative synthesis towards the sulfinate salt may circumvent
the problems associated with potential side reactions and characterisation. As such, a new
route was devised as outlined in scheme 5.2 towards the sulfinate salt by ortho lithation
followed by nucleophilic addition of SO2. The main advantage of this route was that the
formation of the sulfonic acid, which could occur by hydrolysis of the sulfonyl chloride
previously, could be avoided. Furthermore the anticipated change in the characteristic
NMR peaks between 2,4,6-trimethoxybenzene and the sulfinate salt was expected to be
significantly easier to observe than the change from the sulfonyl chloride to the sulfinate
salt (which may be so close they are difficult to differentiate). The ability to follow reaction
progress by NMR would prove particuarly useful if the product was again found to not
ionise for mass spectrometry analysis. The first step, which involved ortho-lithation, was
achieved with BuLi and N,N,N’,N’-tetramethylethylenediamine (TMEDA). TMEDA was
utilised as an additive which is widely reported to improve the efficiency of lithations with
a mechanism which is likely to involve forming a coordination complex with the Li cations
enhancing the reactivity of the BuLi. Next, SO2 was generated ex situ from Na2SO3 and
conc. sulfuric acid, to be utilised as the electrophilic SO2 source, which was bubbled
through the reaction. Unfortunately only starting material 77 was isolated. Given the
method of isolating the desired sulfinate salt involved extraction into water and washing
with diethyl ether followed by freeze drying, which was intended to remove any excess
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starting material, isolation of only the hydrophobic starting material 77 was unexpected.
This observation lead to the hypothesis that the the sulfinate salt was potentially unstable,
owing to the electon rich aromatic ring and possibility to liberate gaseous SO2. This would
allow for extraction of the sulfinate salt into the aqueous phase before decomposition back
to the starting material during the reduced pressure of the freeze drying process.
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Scheme 5.3: 2,4,6-trimethoxybenzene sodium sulfinate synthesis by directed ortho lithation and
DABSO.
Another potential mechanism for the decomposition of sulfinate salt 79b may first involve
protonation of the salt to the less stable sulfinic acid.204 To test the hypothesis of salt
decomposition, the reaction was re-run using DABSO (scheme 5.3) as the SO2 source and
monitored at various stages. DABSO was chosen rather than generating SO2 ex situ as
a more convenient SO2 source.205 This would also prevent the potential for acid, used in
ex situ SO2 generation, from protonating the sulfinate salt yielding the less stable sulfinic
acid. The reaction progress was followed by LC-MS at the crude reaction mixture stage,
post extraction and finally post-freeze drying. The sulfinate salt was observed to form, be
present in the aqueous layer and degrade after freeze drying. This was consistent with the
hypothesis that sulfinate salt 79 was forming and decomposing upon freeze drying.
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Scheme 5.4: Synthesis of 2,4,6-Trimethoxybenzene thiosulfonate warhead (compound 81) by a
one pot sulfinate salt formation followed by oxidative cleavage of disulfide 45
Having confirmed the apparent instabillity of the 2,4,6-trimethoxybenzene sulfinate 79b,
a one pot method was attempted. As shown in scheme 5.4 no product was isolated from
this reaction. It was determined that the inherit instability of the intermediate sulfinate
salt 79b was unsuitable for further exploration at this stage. It was considered that, al-
though the electron rich nature of 2,4,6-trimethoxybenzene analogue 81 was anticipated
to improve stability and therefore potency, the bulky sterics may be detrimental to in-
hibitor binding. Combining the potential for decreased binding with the difficulty in the
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synthesising compound 81, synthesis efforts were ended here. It was decided to focus on
what now appeared to be the more promising cylclohexane and benzylic analogues 75 and
76 respectively.
5.2 Improved Stability by Loss of Aromaticity
5.2.1 The Cyclohexane Warhead
Combining the apparent instability of the 2,4,6-trimethoxybenzene sulfinate salt 79, with
the likelihood that the increased steric bulk would reduce its utility, new derivatives were
desired in which the leaving group character of the sulfinate moiety was diminished. It was
hypothesised that exploring the aliphatic analogue 75 (figure 5.1), bearing a cyclohexane
ring rather than an aromatic ring, would reduce the leaving group ability of the liberated
sulfinate salt. This, in turn, was proposed to offer a potential increase in stability, in a
similar sense to the tri-methoxy analogues, with minimal increase in steric bulk at the S1’
position.
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Scheme 5.5: Synthesis of cyclohexane thiosulfonate warhead (compound 75) by oxidative cleav-
age of disulfide 45
Again, it was thought that this synthesis could build on the previous success of oxidative
cleavage of disulfide 45 with sulfinate salts as shown in scheme 5.5. Starting from cylo-
hexane thiol 82 the sulfonyl chloride 83 was isolated in a good yield (69%) by oxidative
chlorination with N -chlorosuccinimide / 2m HCl, as described by Nishiguchi et al .206 The
following reduction of sulfonyl chloride 83 to sulfinate salt 84 was achieved with Na2SO3 /
NaHCO3 and 84 was used directly in the oxidative cleavage of disulfide 45. Unfortunately,
this method did not yield any desired thiosulfonate 75, only recovering unreacted disulfide
77
45. Interestingly, no aliphatic sulfinate salts were reported in the synthetic procedures by
Fujiki et al . for the oxidative cleavage of disulfides.198 This may well be due to intrin-
sic differences in reactivity which result in the aliphatic analogues being ineffective. One
potential explanation would be that aliphatic sulfonyl iodides, generated as reactive inter-
mediates, may be unstable due to competing β-elimination, which is not possible for the
aromatic analogues. As such, an alternative method was desired for the efficient synthesis
of aliphatic thiosulfonates.
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Scheme 5.6: Proposed synthesis of cyclohexane thiosulfonate 75 from a sulfonyl chloride 83
The earlier explored synthesis towards aromatic thiosulfonates avoided the use of sulfonyl
chlorides as starting materials due to competing reactivity, as shown in scheme 5.6. One
of the first thoughts was that moving from an aromatic to aliphatic system, the previously
disregarded sulfonyl chlorides may now offer a sensible synthetic strategy. It was reasoned
that the aliphatic thiosulfonate formed should have a reduced leaving group ability, en-
hancing its stability towards incoming nucleophile and in turn having a favourable impact
on the ratio of k1:k2 towards product formation (scheme 5.6). Hence, it was hypothesised
that slow addition of a thiol to an excess of cyclohexanesulfonyl chloride 83 in the presence
of DiPEA offered a plausible synthetic route, which was not previously possible for the
aromatic analogues.
Having identified a potential method for the key transformation towards aliphatic thio-
sulfonates, the complete synthesis has been outlined in scheme 5.7. As previous work
(chapter 4) had demonstrated the arginine derived warheads were highly potent, the argi-
nine analogue was also synthesised along side the homophenylalanine derivative. Scheme
5.7 highlights the synthesis of the aliphatic thiosulfonate warheads starting from their
respective amino acids. The key thioacetate building blocks 44 and 64 were isolated by
the earlier reported synthesis in chapters 3 and 4 respectively.
Next, the corresponding thiols 40 and 85 were isolated by hydrolysis under an inert
atmosphere. It was noted that, for the arginine derived construct, the reaction proceeded
slower than that of the homophenylalanine counterpart. This was thought to be due to
the increased sterics of the system, bearing a large Pbf protecting group on the arginine
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Scheme 5.7: Synthesis of the cyclohexane thiosulfonate warhead.
Boc(H)N SAc
R
Boc(H)N SH
R
, ,
LiAlH4, THF,
-78oC - RT
Used directly
in following reaction
, DiPEA, DCM
0oC - RT
100% (    )
96% (    )
Boc(H)N S
R
S
O O
,44 64 40 85
75
75
86
86
87
Scheme 5.8: Synthesis of thiols by reduction and subsequent thiosulfonate formation.
side chain. As a result, when hydrolysing thioacetate 64 to thiol 85, an increased quantity
of the undesired disulfide formed. This was considered to be inherent in the method used,
as the extended reaction time exposed the desired thiol to basic conditions for longer,
promoting disulfide formation. As such, an alternate method was applied (scheme 5.8)
involving reduction with LiAlH4. The reduction was found to be higher yielding and
also more convenient owing to the reduced reaction time (<30 min). As such, reduction
was also applied to the homophenylalanine constructs and became the method of choice
moving forward.
With the desired thiols to hand these were then used directly in the subsequent thiosul-
fonate formation with cyclohexane sulfonyl chloride 83. Unfortunately, when first trialled
for the homophenylalanine analogue, this resulted in isolation of only the symmetrical
disulfide 45 (scheme 5.6). This suggested that initial avoidance of sulfonyl chlorides for
the earlier aromatic analogues was well founded. Fundamentally, the issue remained the
relative rate of k2 to k1, as shown in scheme 5.6, thus it was hypothesised that enhancing
the reactivity of the sulfonyl halide would enhance k1 relative to k2 favouring product
formation. As such, sulfonyl bromide 87 was isolated in good yields by adapting the
oxidative chlorination method of Nishiguchi et al .206 with brominated, rather than chlo-
rinated reagents (scheme 5.8). Gratifyingly, the subsequent reaction with thiols 40, 85
79
(scheme 5.8) and sulfonyl bromide 87 was highly successful offering yields of 100% and
96% respectively for the homophenylalanine and arginine derivatives. This was ultimately
achieved by a combination of slow addition, lowered temperature and enhanced reactivity
all favouring product formation over competing product decomposition.
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Scheme 5.9: Cyclohexane warhead coupling to backbone yielding final inhibitors 11 and 17
With the key cyclohexane derived warhead building blocks now to hand they were incor-
porated into a greater inhibitor construct as shown in scheme 5.9. The warheads were first
deprotected and then directly coupled to the backbone yielding inhibitors 11 and 17 in
good yields of 54% and 55% respectively. The only notable difference between the synthe-
sis of each analogue was the conditions used for deprotecting warhead fragments 75 and
86. In general, HCl was favoured for removal of the Boc protecting group as this generated
the HCl salt. This offered the advantage over the TFA salt as it is possible, having been
observed through previous experience, that the carboxylic acid of the TFA salt can couple
to the amine, rather than the desired carboxylic acid of the backbone fragment during the
amide coupling step. Hence, HCl was used where possible with TFA being utilised for the
arginine constructs to also cleave the less labile Pbf protecting group.
5.2.2 Aliphatic Linker to Aromatic Ring: The Best of BothWorlds?
In the previous section, reducing the leaving group ability by loss of aromaticity was
discussed. In theory, this is a valid method to improve stability of the thiosulfonate
warheads. However, such structural changes not only alter the chemical reactivity of the
warhead constructs but also their target engagement and binding characteristics. As such,
it was considered that the loss of aromaticity may also be met with an altered binding
affinity (Ki), which is highly dependent on the target protease. In the case of papain
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like cysteine proteases (Clan CA, Family C1) there is a conserved aromatic residue in
the S1’ region (Trp177, papain numbering). As the thiosulfonates are being developed to
selectively target cysteine proteases, which display this conserved residue, modifications
which have the potential to target this may increase inhibitor binding and the resultant
potency. As such, this section aims to explore introducing an aliphatic linker, to alter
the reactivity of the thiosulfonates to be closer to the aliphatic analogues, joining on to
an aromatic ring. It was hypothesised that this may enable targeting of a potential pi
stacking interaction, which would be specific to cysteine proteases of this class. This aims
to build on the previously observed stability trends whilst accommodating rational SAR
for enhanced target engagement. Ultimately, it is envisioned that combining rational SAR
alongside tuning of reactivity would reinforce the suitability of this novel warhead class in
specific engagement of cysteine proteases.
Modelling Study: Targeting Conserved Active Site Residues in the S1’ Pocket
Figure 5.2: Active site residues of papain (PDB code 1CVZ) highlighting the conserved tryp-
tophan residue (Trp-177, papain numbering) of papain like cysteine proteases.
Upon examination of the active site of papain like cysteine proteases, it was noted that the
primed side of the active site contains a conserved tryptophan residue (figure 5.2). It was
hypothesised that this may offer a good pi-stacking interaction with potential inhibitor
constructs which may in turn further increase the specificity of the thiosulfonate warheads
towards cysteine proteases. With the previous hypothesis that an aliphatic substituent at
the primed side of the warhead may offer a favourable reactivity profile, it was proposed
that an aliphatic linker to an aromatic ring may offer an ideal combination of chemical
reactivity and pi-stacking ability.
In order to direct the chemistry to undertake, DrawToDock was used to screen for suitable
warhead constructs. As shown in figure 5.3, docking warheads with additional methylene
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Figure 5.3: Varying the number of methylene units between the thiosulfonate warhead and
aromatic ring in the S1’ region, screened compounds (left) with docked model of compound 12
shown on right, highlighting pi stacking ability.
units between the hexavalent sulfur and aromatic moiety (8, 12, 90, 91) suggested that a
single methylene unit (compound 12) would be optimal. This was based on the fact that
compound 12 allowed a suitable proximity of the aromatic ring to Trp-177 to facilitate
pi-stacking whilst conserving the key hydrogen bonding network surrounding the active
site thiolate and inhibitor sulfone oxygen atoms, as discussed earlier in section 3.1.
Synthesis of Methylene Spaced Aromatic Warhead
SH S Br
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2M HBr
MeCN
Thiol ,
DiPEA, DCM
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BocHN S S
OO
BocHN S
(not isolated)
92 93 76 94
40
Scheme 5.10: Original intended route towards benzyl thiosulfonate warhead building block 76,
from sulfonyl bromide 93
As the reactivity of the benzylic thiosulfonate warhead 76 was anticipated to be closer
to the aliphatic than aromatic analogues, the initial synthesis was based on the previous
success towards aliphatic thiosulfonates. It was hypothesised that warhead synthesis from
benzyl sulfonyl bromide (93) would be more suitable than oxidative cleavage of disulfides
with a sulfinate salt, which was found to be most applicable to aromatic analogues (see
chapter 3). As such, scheme 5.10 outlines the intended route towards benzylic thiosulfonate
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building block 76. Starting from benzyl mercaptan 92, synthesis towards the correspond-
ing sulfonyl bromide was attempted by oxidative bromination with NBS / 2m HBr based
on the previous success towards cyclohexane derivatives (see section 5.2.1). The freshly
prepared sulfonyl bromide was then used directly in the subsequent reaction with thiol
40, which was isolated by reduction of the corresponding thioacetate discussed previously
in scheme 5.8. Direct use of sulfonyl bromide was chosen as it was considered likely to be
a unstable synthetic intermediate. Unfortunately, the reaction did not yield the desired
thiosulfonate but rather thioether 94 was identified as the major product.
SH S BrBr
O O
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O O
BrBr2 SO2
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2M HBr
MeCN
N
Br
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HBr Br Br
H
N OO 2Br
Br
NBS radical initiation
heat / light
Scheme 5.11: Proposed radical decomposition pathway of benzylsulfonyl bromide.
Suspecting that the previously observed thioether 94 arose from the quality of the sulfonyl
bromide, the sulfonyl bromide was isolated and characterised. The characterisation was
consistent with benzyl bromide, rather than sulfonyl bromide 93. This was also consistent
with the isolation of thioether 94, which would form upon alkylation of thiol 40 with benzyl
bromide. Benzyl bromide formation could occur via desulfuration of the sulfonyl bromide
93, however King et al .207 previously reported this desulfuration required heating at 80 ◦C
for 5 days, resulting in only 50% conversion. Given the short reaction time (<10 min.),
reagents used and no observable sulfonyl bromide it has been proposed that decomposition
to benzyl bromide was likely accelerated through a radical mechanism as shown in scheme
5.11. NBS is a known radical initiatior, hence it has been incorporated into the potential
mechanism shown in scheme 5.11, with stabilisation of the radical product (benzylic) as
well as liberation of SO2 being recognised as potential driving forces.
SH S Cl
O O
NCS
2M HCl
MeCN
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Scheme 5.12: Benzyl thiosulfonate warhead synthesis from benzylsulfonyl chloride via sulfene
intermediate
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Moving forward it was decided that the differing reactivity profile of the benzylic ana-
logues, which facilitated the proposed radical mechanism, could be utilised rather than
problematic towards the synthesis of thiosulfonates. As shown in scheme 5.12, it was
proposed that the benzylic position, having more acidic protons, would favour sulfene
formation under basic conditions which may be accessable through the more stable sul-
fonyl chlorides. The sulfene formed, being a highly reactive intermediate, allowed for the
required increase in reaction rate to out compete the side reaction involving attack of
thiol 40 on the warhead fragment (shown previously in scheme 5.6). Gratifyingly this
yielded the benzylic thiosulfonate warhead derivative 76 with a moderate yield of 35%.
The reduced yield was due to the competing symmetrical disulfide formation, occurring
by attack of thiol 40 on the generated thiosulfonate warhead 76, however the quantity
isolated was sufficient to carry forward for further testing.
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Scheme 5.13: Final inhibitor coupling: Coupling the benzyl derived thiosulfonate warhead
building block to backbone.
With the benzylic thiosulfonate warhead building block (compound 76) now to hand it was
incorporated into the overall inhibitor construct. As shown in scheme 5.13 the warhead
fragment was first deprotected with HCl followed by direct coupling to the backbone 48
yielding final inhibitor construct 12 in 25% over two steps, which was isolated as a TFA
salt after purification by preperative HPLC before biological testing.
5.2.3 Stability Testing Towards Common Nucleophiles
It was hypothesised that the inhibitors bearing the cyclohexane warhead (11) and the
benzylic warhead (12) would show increased stability towards incoming nucleophiles when
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compared with the previous aromatic warheads. To test this, each inhibitor construct was
assessed for its stability towards amines, thiols and pH dependent hydrolysis. This followed
the same testing undertaken for the earlier warhead constructs in section 3.5, allowing for
a direct comparison.
Stability Towards Thiols and Amines
!"#$%&'()*+*',
0 2 4 6 8 10 12
0.0
0.5
1.0
!"#$%&'()*+
,-
&
,.
,/
'
)$
)#
"
0
,-
,-
1
$%
2
+
!"-.$/%#'()*+*',
0 2 4 6 8 10 12
0.0
0.5
1.0 !"#34
5
$%0+
!"#46#$$%12+
Cyclohexane (11)
Bn (12)
!"#$%&'()*+
,-
&
,.
,/
'
)$
)#
"
0
,-
,-
1
$%
2
+
Figure 5.4: Cyclohexane warhead stability towards benzyl thiol (left) and benzyl amine (right).
Inhibitor degradation was determined by HPLC in MeCN at room temperature with 13 measure-
ments taken 1 hour apart, representing time 0 to 12 hours. Approximately 0.3 mg of inhibitor
was accurately weighed and suspended in MeCN, to which 10 equivalents of BnSH or BnNH2
was added immediately before measurement. Results were then normalised against time 0 and
plotted as scatter graphs for visualisation.
Gratifyingly, both new inhibitor designs were significantly more stable than the previously
synthesised aromatic analogues. In each case, stability towards amines (represented by
benzylamine in this study, figure 5.4) was maintained, reinforcing the selective nature of
the thiosulfonates towards sulfur centred nucleophiles. A remarkable improvement in sta-
bility towards thiols (benzyl mercaptan in this study, figure 5.4) was observed for both of
the new inhibitor constructs when compared with the previous aromatic analogues. Cy-
clohexane derivative 11 displayed no significant thiol dependent degradation, whilst the
benzylic derivative 12 displayed <10% degradation over the 12 hour time period. This was
a significant improvement from the previously prepared aromatic warheads which displayed
close to complete degradation (for the p-NO2 substituted compound 7) and 50% degra-
dation(for the p-OMe substituted compound 10) over 12 hours. The observed increase
in stability towards thiols was particuarly encouraging as thiols represent an abundant,
biologically relevant nucleophile with the potential to halt the progress of thiosulfonates
as cysteine protease inhibitors. This owes to the fact that, thiosulfonates are inherently
more selective towards sulfur centred nucleophiles. Indeed, this is one of the core concepts
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for their development into selective cysteine protease inhibitors. This does however carry
the risk of cross reactivity with circulating thiols, thus observing a significant increase in
stability towards thiols was considered to be a considerable advance in their development
as cysteine protease inhibitors. Of course, the nucleophilicity of thiols will correlate with
the local pH, which has not been accounted for in this study, and would be a significant
contributing factor towards the stability of thiosulfonates in a biological system. This does
however demonstrate a move in the right direction for further exploration, an encouraging
finding in the development of this novel warhead class.
pH Dependent Aqueous Stability
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Figure 5.5: pH dependent aqueous stability of aliphatic thiosulfonate warheads compared to the
previous aromatic thiosulfonate warheads. Inhibitor degradation was determined by HPLC with
peak areas integrated against an internal standard (Ac-Phe-OH), 13 measurements were taken 1
hour apart, representing time 0 to 12 hours. Sodium phosphate buffer (0.1mm) of the relevant
pH containing 5% DMSO was utilised, initial inhibitor concentration was 245µm and internal
standard (Ac-Phe-OH) concentration was 338 µm.Results were then normalised and plotted as
scatter graphs for visualisation.
Moving on to the aqueous stability profiles, shown in figure 5.5, the hydrolytic stability
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correlated well with the predicted leaving group ability in each case. The leaving group
ability of the liberated sulfinate was anticipated to be higher for the benzylic derivative 12
than that of the cyclohexane derivative 11. Indeed, the benzylic derivative was found to be
more prone to hydrolysis at all pH’s tested when compared with the cyclohexane anlogue,
falling between the stability of the previously most stable p-OMe substituted compound
10 and the improved stability of cylohexane analogue 11. Previously, the most stable
aromatic analogue (10) was effectively stable at pH 6 and had a half life of approximately
30 hours at pH 7, and 45 minutes at pH 8. This has been significantly improved upon with
cyclohexane analogue 11 being stable at pH 6 and displaying a half life of approximately
60 hours at pH 7 and 6 hours at pH 8. This was a very encouraging finding as hydrolytic
stability accross a reasonable physiological pH range, such as that represented here, is a
significant consideration in the development of a new warhead class.
Importantly, the above stability studies also reinforce the relative ease with which the
chemical reactivity of the thiosulfonate warheads can be controlled. Moving forward,
this may prove to be an important characteristic for controlling the reactivity of the
thiosulfonate warheads.
5.2.4 Biological Testing: Papain Enzyme Assay
Having established the aliphatic thiosulfonate construct 11 offered a significant increase
in stability over their aromatic counterparts, further biological evaluation was required. It
was hypothesised that, based on the previously observed correlation between reactivity and
potency of the aromatic warheads, this new construct would offer an enhanced potency.
Furthermore it was hypothesised that compound 12 (bearing the benzylic warhead), which
displayed a reactivity profile close to that of the most stable aromatic construct 10 (bearing
the p-OMe substituted warhead), would be equipotent on the basis of chemical reactivity.
However, it was hoped that the methylene linker to an aromatic ring may offer enhanced
target binding (Ki) by pi stacking to the conserved tryptophan residue as discussed in
section 5.2.2 resulting in an improvement in potency. To test this, the aliphatic inhibitor
constructs 11, 17 and 12 were subjected to the papain assay developed earlier in section
3.6.1.
Gratifyingly, these new aliphatic warhead constructs performed as well as or better than
the previous most promising compound (10). As shown in figure 5.6, cyclohexane de-
rived warhead 11 displayed an IC50 of 168 nm, effectively equipotent to the previous best
inhibitor (p-OMe benzene derived warhead of inhibitor 10 at 148 nm). Combining the
marked increase in stability towards thiols and pH dependent hydrolysis with retained
potency, the cyclohexane warhead bearing inhibitor 11 offers a significantly improved
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inhibitor construct. Furthermore, when the sidechain of the P1 position was altered to
arginine, rather than homophenylalanine, a further reduction in the IC50 value to 106 nm
was observed. This enhanced potency was consistent with the previously observed trend in
chapter 4 when installing an arginine rather than homophenylalanine side chain. Arginine
derived inhibitor 17, bearing a cyclohexane warhead, was also slightly more potent than
the p-OMe aromatic warhead counterpart (inhibitor 16 which had an IC50 of 124 nm),
again suggesting this warhead offers an overall improvement in inhibitor design.
Interestingly, inhibitor 12, bearing a benzylic group in the P1’ position, was found to be
equipotent with its cyclohexane counterpart (inhibitor 11) at 164 nm. This is contrary to
the observed correlation between stability and potency observed for all other inhibitor con-
structs, which would suggest the benzylic derivative (12) should be less potent rather than
equipotent with the cyclohexane derivative (11). This may suggest that the anticipated
reduction in potency (based on stability arguments) is being offset by an improvement in
potency due to improved target binding (Ki), potentially through pi stacking of the war-
head aromatic ring. The above findings suggest that an additive effect is being observed
between both backbone and warhead design. This is a significant observation, highlight-
ing the potential benefits which can be derived from new electrophillic traps rather than
relying on the ubiquitous 1,4-Michael acceptors (as discussed in section 1.2).
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Figure 5.6: IC50 determination of aliphatic warheads compared with the most potent aromatic
warhead. K11777 6 reference compound (magenta curve), Homophenylalanine derived (p-)OMe
aromatic warhead 10 (orange curve), Arginine derived (p-)OMe aromatic warhead 16 (brown
curve) Homophenylalanine derived cyclohexane warhead 11 (green curve), Arginine derived cy-
clohexane warhead 17 (red curve), Homophenylalanine derived benzylic warhead 12 (blue curve).
Assay buffer: sodium phosphate (100mm, pH 6.5) containing EDTA (1.5mm) and 2% DMSO.
Final concentrations in the wells were; Papain: 4µm; substrate: 1.0mm; inhibitor: doubling dilu-
tion range starting at 10 µm giving: 10 µm, 5µm, 2.5 µm, 1.25 µm, 0.625µm, 0.3125µm, 156.25 nm,
78.125 nm, 39.0625 nm. Error bars on graph display SEM across 3 independent repeats. Tabulated
± values represent the std error of the IC50 values across 3 independent repeats.
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5.3 Summary
In summary, electron rich aromatic thiosulfonates, synthesised by further substitution
the aromatic ring, were not isolated for further development. The combination of their
difficult synthesis alongside the likelihood that the additional steric bulk would be detri-
mental to inhibitor design led to new methods of controlling reactivity, by modulating
leaving group ability, being explored. This lead on to the successful synthesis and testing
of a new class of aliphatic thiosulfonate (11, 12 and 17) bearing either a cyclohexane or
benzylic warhead. Early attempts found that the differing reactivity of the aliphatic thio-
sulfonates required an alternate synthesis to be developed, culminating in their synthessis
from sulfonyl halides, rather than the earlier described synthesis by oxidative cleavage of
disulfides. Gratifyingly, the aliphatic thiosulfonates were found to maintain, or improve
upon, the potency of the best in class aromatic thiosulfonate 10 against the cysteine pro-
tease papain. Furthermore, the aliphatic thiosulfonate 11 offered a considerable increase
in stability towards thiols and also towards pH dependent hydrolysis. Moving forward,
it was clear that improving the stability of the thiosulfonates was favourable for their
development as cysteine protease inhibitors. With this in mind, new strategies to further
improve the reactivity profile of the thiosulfonate warhead will be explored.
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Chapter 6
Fourth Generation inhibitors: A Steric
Approach for Increased Warhead
Stability
6.1 Reasoning and Target Warheads
Previously, it has been demonstrated that downregulating the reactivity of the thiosul-
fonate warheads, based on reducing the leaving group ability, has led to an improvent in
inhibitor design. Expanding on this trend, a new approach will be taken to regulate the
reactivity of the thiosulfonates based on reducing the rate of nucleophilic attack through
steric hindrance. It was hypothesised that the optimal reactivity profile of the thiosul-
fonates would be such that they could react with active site thiolates with minimal degra-
dation towards other biologically relevant nucleophiles, such as water and thiols. This was
believed to be possible due to the enchanced reactivity of the local enzymatic environment
(such as the local hydrogen bonding network demonstrated in section 3.1). Taken in com-
bination with the highly tunable nature of the thiosulfonates, which has been observed
thus far, it was believed this trend could be further improved through steric arguments
discussed herein.
BocHN
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O O
BocHN
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O O
BocHN
S S
O O
,
BocHN
S S
O O
,97 98 99 100 101 102
Figure 6.1: key building blocks to introduce steric arguments for decreased reactivity
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As such, this section will explore the synthesis and evaluation of two key modifications,
shown in figure 6.1, by introducing either one methyl or two methyl substituents to the
β-amino position of the thiosulfonate warhead building blocks. These aimed to build on
the previous success of the aliphatic warheads, thus functionalising both the cyclohexane
and benzylic warheads to their mono-methyl and di-methyl counterparts was proposed,
which shall be referred to as secondary and tertiary thiosulfonates respectively. It was
hypothesised that the order of reactivity would be in line with that of all SN2 reactions,
hence the tertiary thiosulfonates 97 and 98 were expected to display the slowest reaction
rate, corresponding to the most stable warhead construct. Following on from this the
secondary thiosulfonates 99-102 were anticipated to display the next slowest reaction rate
and corresponding stability, with the previously generated primary thiosulfonates thought
to be least stable in this series. Based on the previously observed trends between reactivity,
stability and inhibitor potency, it was hypothesised the order of potency from most potent
to least potent would be tertiary, secondary and then primary thiosulfonates.
6.2 Exploring a Route Towards β-Methyl analogues
6.2.1 Retrosynthetic Analysis - Two Key Disconnections
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Scheme 6.1: Retrosynthetic analysis: Towards the key secondary alcohol intermediate 106
Two key strategies were identified towards the secondary thiosulfonates 99-102 which both
went via the key synthetic intermediate 106 shown in scheme 6.1. These synthetic steps
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aimed to build on the previous success towards aliphatic thiosulfonates with warheads
generated from the corresponding sulfonyl halide and thiol. The thiol, in turn, could
be accessed by the reduction of the corresponding thioacetate which was thought to be
accessible by substitution of a suitable leaving group. Interestingly, altering the leaving
group used offered a divergent synthesis to each diastereomer, which could be accessed by
functionalising the corresponding alcohol (106) with retention of the stereocentre when
generating the mesylate 105, or inversion of the stereocentre when generating the bromide
109 with PBr3.
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Scheme 6.2: Retrosynthetic analysis: Towards secondary thiosulfonate warheads by reduction
/ diastereoselective addition
In retrosynthetic scheme 6.2 it has been proposed that alcohol 106 could be accessed by a
diastereoselevtive nucleophilic attack and reduction of methyl ester 30. The key advantage
to this method was that, in principle, it could be conducted from any amino acid allowing
easy access to various side chains for future SAR studies. Furthermore, this method would
allow for broader substrate scope by selection of different alkylating reagents. In principle,
this could prove interesting when invoking steric hinderance to alter reactivity as bulkier
substituents could be introduced with ease.
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Scheme 6.3: Retrosynthetic analysis: Towards secondary thiosulfonate warheads by sidechain
functionalisation
Moving on to retrosynthesis shown in scheme 6.3, this also started from the common sec-
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ondary alcohol intermediate 106. It was hypothesised that a sidechain functionalisation
approach could be employed allowing the methyl group of interest to be incorporated from
the chiral pool. Retrosynthetically this would involve a final deprotection step of the pro-
tected alcohol 110, with TBDMS proposed as a suitable protecting group. The sidechain
functionalisation was proposed to be possible by reduction on the alkene 111 which could
be accessed by either a Horner Wadsworth Emmons or Wittig olefination as a convenient
carcon-carbon bond forming reaction. The corresponding aldehyde 112, required for the
olefination, could be accessed by reduction of carboxylic acid 113. This carboxylic acid
represents the commercialy available, and relatively cheap, D-threonine starting material
(114). Although this approach involved more synthetic steps, it offers the advantage of
drawing from the chiral pool, potentially avoiding the need for diastereoselective transfor-
mations and / or seperations. It was also thought that as the side chain is functionalised
from a carboxylic acid, an excellent handle for further functional group interconversions,
multiple non natural amino acids could be accessed through this route. As each method
had apparent strengths for accessing new thiosulfonate warhead building blocks, both will
be explored.
6.2.2 Drawing From the Chiral Pool: A Sidechain Functionalisa-
tion Approach
The experimental work presented in this section (secion 6.2.2) was conducted by two
project students, started by Alin Pirvan and continued by Damon Allan as part of their
work towards their masters projects. All work was conducted under the supervision of the
author.
One of the first strategies to be explored towards the synthesis of secondary thiosulfonate
warheads involved drawing from the chiral pool, as shown in scheme 6.4. Starting from
D-threonine (114) the carboxylic acid was converted to methyl ester 115 in quantitative
yields. Next, the free N terminus was protected with a Boc group followed by masking the
secondary alcohol with a TBDMS group, with both steps proceeding in excellent yields
(quantitative and 91% respectively). Following on from this, the methyl ester 117 was
reduced to alcohol 118 with LiAlH4 in a low yield of 17%.
The subsequent oxidation to aldehyde 112 was originally trialled with a Swern oxidation
(6.5), which was met with a good yield of 63%. In an attempt to improve upon this
yield the Dess Martin oxidation was employed, using wet conditions to generate the more
reactive IBX in situ (scheme 6.5) as has been reported by Meyer et al ., resulting in an
equally good yield of 65%.208 As the yields were similar, the Dess Martin was selected as
the main route moving forward on the basis of being a more convenient reaction, with less
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Scheme 6.4: Synthesis towards secondary thiosulfonates from D-threonine, dashed arrows indi-
cate proposed synthetic steps which were not conducted.
noxious byproducts that the DMS, CO and CO2 produced by the Swern oxidation.
The following Wittig reaction was anticipated to be the most synthetically challenging
step of this synthesis, owing to the predicted instability of the α-aldehyde intermediate
112. Upon first attempts (scheme 6.6) the phosphonium ylide was generated from the
phosphonium salt with NaH before addition of the aldehyde, resulting in a yield of only
17% of the desired product 119, with the elimination product 122 being identified as
shown in scheme 6.6. This was proposed to form through deprotonation of the highly acidic
alpha proton, leading to an anion, which was resonance stabilised by the neighbouring
aldehyde, before subsequent elimination as shown in scheme 6.6. As such, a weaker base,
LiHMDS, was employed to form the ylide which was met with a marginal increase to 19%
yield. When combined with the low yielding reduction of methyl ester 117 to alcohol
118 it was decided this synthesis was inefficient and would not be taken further. The
choice to end the synthesis here was largely based on recognising the alternate synthetic
strategy, highlighted by retrosynthesis in scheme 6.2. The alternate synthetic strategy
offered increased simplicity, and circumvented the unstable aldehyde intermediate.
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Scheme 6.5: Methods of oxidation to aldehyde 112. (a) Swern oxidation: Oxalyl chloride,
DMSO, NEt3, dry DCM, −78 ◦C-RT. (b) Dess Martin oxidation: Dess Martin Periodinane, wet
DCM (washed with water before use).
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Scheme 6.6: Wittig reaction and competing elimination
6.2.3 Reduction & Diastereoselective Addition: Introduction of
A Chiral Secondary Alcohol
Having found the previous side chain functionalisation approach (section 6.2.2) to be lim-
ited by unstable synthetic intermediates and low yields, a new approach was desired. This
was based on the retrosynthetic analysis shown in scheme 6.2 to include a reduction /
diastereoselective addition to introduce the methyl group into amino acid starting mate-
rials.
As shown in scheme 6.7 this approach started from methyl ester 30. The diastereoselective
reduction / alkylation was based on the earlier work of Nyong et al .209 and achieved a
reasonable yield of 46%. The main route for loss of product was overreduction to the
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Scheme 6.7: Secondary thiosulfonates by diastereoselective alkylation
corresponding primary alcohol 31 rather than the desired alkylation step which it may be
possible to further optimise through addition times. The following mesylation proceeded
in excellent yields (90%) to mesylate 105.
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Scheme 6.8: Oxazolidinone formation through alcohol by-product
Following on from mesylate formation was substitution to thioacetate 104, as shown in
scheme 6.8, early attempts led to the undesired ozazolidinone formation. The conditions
used were based on the earlier transformation of primary mesylates to thioacetates with
thioacetic acid and caesium carbonate. Initially the reaction did not proceed, yielding
only the mesylate starting material when conducted at room temperature. It was con-
cluded that the rate of substitution for the secondary mesylate was significantly slower
than the primary mesylates used in the eralier synthesis of thiosulfonate warheads. As
such, the reaction was conducted at an elevated temperature of 70 ◦C which gave rise to
oxazolidinone 124 as the major product. It was proposed that the increased sterics of the
system, which led to increased reaction times, placed greater significance on the competing
substitution with water (which had not been observed previously). As this reaction was
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conducted with hygroscopic reagents, which had not been dried, the water content was
likely significant leading to the proposed mechanism of oxazolidinone formation in scheme
6.8. The secondary alcohol, which formed by substitution of mesylate 105 with water,
was able to perform an intramolecular cyclisation to generate oxazolidinone 124 under
the basic conditions present. This was easily overcome by using dry solvents and KSAc,
rather than the hygroscopic Cs2CO3 and HSAc method employed previously, resulting in
a reasonable yield of 55% shown in scheme 6.7.
With thioacetate 104 in hand it was reduced to thiol 103 with LiAlH4, which was used di-
rectly in the following thiosulfonate warhead formation. Thiol 103 was diversified out into
thiosulfonates 100 and 101 using the earlier developed methods with cyclohexane sulfonyl
bromide and benzylsulfonyl chloride methods in moderate yields of 38% and 50% respec-
tively. Unfortunately, time constraints prevented the corresponding diastereomer synthesis
from being explored, which would involve isolating the corresponding bromide 109 from
alcohol 106 followed by applying the same conditions above for all subsequent transfor-
mations from thioacetate to the thiosulfonate warheads. In terms of the development of
the thiosulfonate warheads, this was not considered to be detrimental as the chemical
reactivity, and subsequent stability, was considered to be the same for each diastereomer.
However, for future work, it would be interesting to generate the corresponding diastere-
omer for biological testing as it may offer an increase, or decrease in binding to the target
protease with the corresponding change observed in the inhibitor potency.
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Scheme 6.9: Coupling the Secondary Thiosulfonate Warheads to their Backbone
At present these newly developed secondary thiosulfonate warheads, with a methyl sub-
stituent anti to the amino acid side chain, were sufficient to test the hypothesis of increased
stability leading on to improved potency. With each warhead fragment now to hand they
were incorporated into the peptidic backbone as shown in scheme 6.9 in low to moder-
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ate yields of 25% (128) and 55% (127). The inhibitors were isolated as the TFA salts
after purification by preperative HPLC before further stability and biological testing was
conducted.
6.3 Exploring a Route Towards β-Gem-DiMethyl ana-
logues
6.3.1 Substitution of a Hindered Tertiary Centre
H2N
SH
O OH
BocHN
STrt
BocHN
STrt
H2 Pd/C
potential cat.
poisoning
129 130 131
Scheme 6.10: Synthesis towards tertiary thiosulfonates starting from D-penicillamine (129).
In an effort to further expand upon steric arguments to alter the reactivity profile of the
thiosulfonate warheads, tertiary thiosulfonate warheads were desired to complement the
previously discussed secondary thiosulfonate warheads. Similar to the previous synthesis
towards the secondary thiosulfonates, discussed in section 6.2.2, two potential synthetic
routes were identified. The first involved a ‘sidechain functionalisation’ approach starting
from penicillamine and the second involved starting from an amino acid and methylating.
The merits of each route were considered to be analogous to that of the mono-methyl
derivatives with one key difference for the ‘sidechain functionalisation’ approach. It was
thought that the presence of a bivalent sulfur may poison the Pd catalyst during the
reduction of the alkene, as shown in scheme 6.10. Considering the potential for catalyst
poisoning, combined with the previously observed instability of the aldehyde intermediate,
this route was considered to be unsuitable.
As such, it was hypothesised that the tertiary thiosulfonate warheads could be obtained
by di-methylation of an ester (scheme 6.11). Starting from methyl ester 30 tertiary al-
cohol 132 was obtained in good yields (72%) by alkylation with the Grignard reagent
MeMgBr. Based on the previous success of the primary and secondary thiosulfonates,
it was intended to functionalise the tertiary alcohol to mesylate 137 before substitution
to introduce the sulfur functionality. Unfortunatly, mesylate 137 was not found to form
under these conditions, thus optimisation to find a suitable leaving group began.
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Scheme 6.11: Synthesis towards tertiary thiosulfonates by a tertiary alcohol intermediate
As shown in scheme 6.12 functionalisation of alcohol 132 to tosylate 133 was then at-
tempted. Unfortunately, this led to no reaction, recovering only starting material. This
was not entirely unexpected given the similarity with the previously attempted mesylation.
Based on this it was decided to move away from sulfonate esters.
As generating the leaving group appeared to be the limiting step, it was hypothesised
that phosperous reagents may offer a viable alternative, as the phosphorous oxygen bond
is known to be one of the strongest and an excellent driving force in synthesis.197 As
such, functionalising with diphenylphosphine chloride was attempted based on the work
of Pluempanupat et al . who reported using this method to functionalise tertiary alcohols
before substitution with sulfur based nucleophiles.210 Unfortunately a very low yield of
only 8% was achieved.
Encouraged by the finding that phosphorous reagents were able to functionalise the tertiary
alcohol, albeit in very low yields, this method was explored further. Lawesson’s reagent
(shown in scheme 6.12), which also derives its driving force through phosphorous-oxygen
bond formation, has been reported to convert tertiary alcohols directly to tertiary thiols.211
As such, this method was initially attempted in THF under reflux (65 ◦C), with no product
identified as forming. It was thought that the reaction may not proceed due to the sterics
of the tertiary alcohol, thus the reaction was attempted at an elevated temperature by
reflux in toluene (110 ◦C). This led to a complex mixture of by-products, with none of the
desired thiol isolated or observed. Encouraged by the consumption of the alcohol starting
material, the reaction was then attempted at a lower temperature (50 ◦C) in an effort to
reduce the formation of by-products. Unfortunately the outcome of this was the same, only
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Scheme 6.12: Synthesis of tertiary thiosulfonates by di-methylation
observing a complex mixture of products with none of the desired thiol observed.
As shown in scheme 6.13, it was attempted to isolate the desired tertiary thiol via substi-
tution of a trifluoroacetate with resin bound thiol, based on the work of Bandgar et al .212
Bandgar et al . reported using this method to generate tert-butyl thiol directly from tert-
butanol in a 75% yield. The reported high yield combined with the direct isolation of
the desired thiol made this method appear highly attractive. It was reported that the
enchanced nucleofugal character of the trifluoroacetate moiety, in combination with the
enhanced nucleophilicity of the resin bound thiol were favourable for this reaction. This
argument was considered reasonable, with the resin bound thiol thought to be comparable
to techniques such as employing crown ethers to enhance nucleophilicity (when compared
with NaSH). As shown in scheme 6.13 the intermediate triflouroacetate was observed to
form by TLC however upon addition of resin bound thiol only the alcohol starting material
was found to form and be isolated. It is proposed that competing addition to the car-
bonyl of the TFA moiety led to reforming of the starting material and trifluorothioacetic
acid.
Finally, It was then hypothesised that functionalising the tertiary centre may be possible
through an SN1 mechanism. As such, conc. HBr (Aq.) was thought to offer a viable
option to isolate the corresponding bromide. This method was initially avoided as it was
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Scheme 6.13: Attemted synthesis of tertiary thiol by direct substitution of a trifluoroacetate
with resin bound thiol.212 Proposed side reaction leading to reformation of alcohol 132 shown
(bottom).
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Scheme 6.14: Converting tertiary alcohol to tertiary bromide under acidic conditions
incompatible with the Boc protection group, thus the Boc group was first deprotected and
exchanged for an Fmoc protecting group (scheme 6.14). Then, Fmoc protected compound
141 was subjected to 48% HBr however no product was isolated, yielding only unreacted
starting material. In hindsight, this reaction may have been more efficient if conducted
in non-aqueous solvents such as HBr / AcOH, which would offer a suitable polar protic
solvent for the SN1 reaction whilst taking advantage of Le Chatelier’s principle to drive
the reaction to completion (as water should be liberated).
As functionalising the alcohol appeared to be the limiting step in the synthesis, rather
than the following substitution, a new approach was trailed. Based on the previously
observed oxazolidinone formation, which occurred accidentally during the synthesis to-
wards secondary thiosulfonates (section 6.2.3, scheme 6.8), the method in scheme 6.15
was proposed. It was hypothesised that oxazolidinone 143 could be generated under ba-
sic conditions, which occurred in an excellent yield of 93% with the use of potassium
tert-butoxide. Following on from this, the reactivity of the oxazolidinone, being a cyclic
carbamate, was compared with that of a Boc group, being a linear carbamate. It was
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Scheme 6.15: Attempted ring opening of oxazolidinone 143 under acidic conditions. TIPS and
BnSH were trialed as carbocation scavengers to determine if ring opening under acidic conditions
was possible.
thought that the same driving forces for Boc deprotection under acidic conditions also
exsisted for oxazolidinone 143. Namely, stabilisation of the generated carbocation by
a tertiary centre, as well as liberation of CO2, which could drive the reaction forward.
Hence, it was hypothesised that under acidic conditions the oxazolidinone 143 could be
ring opened, generating a carbocation that could be captured with a suitable carbocation
scavenger (ideally sulfur based, leading to a thiol). To test this hypothesis oxazolidinone
143 was subjected to increasingly strong acidic conditions, eventually leading to reflux
in conc. HBr / AcOH. Either TIPS, or BnSH, were introduced as a carbocation scav-
engers, with the intention of optimising the scavenger used if the reaction was seen to
progress. In each case only unreacted oxazolidinone 143 was recovered, with no other
products observed. It was thought that acetic acid, being a polar protic solvent, would
be optimal for this transformation and the generated carbocation would be scavenged by
either the bromide, leading to the corresponding tertiary bromide or BnSH, leading to the
thioether 145. Surprisingly, oxazolidinone 143 was found to be very stable under acidic
conditions, offering no detectable decomposition. A final attempt was made with the use
of a Lewis acid (BF3.OEt2) under dry conditions, with the main reasoning being exclusion
of water from the reaction, however this was also unsuccessful in opening the ring with
only unreacted oxazolidinone 143 being observed. It was reasoned that, being a cyclic
system, the reactivity of 143 was significantly different to the linear (Boc) counterpart.
This may be explained by poor orbital overlap, which is required to push electrons into
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the σ* antibonding orbital, breaking the bond and open the ring system.
Due to time constraints, attempts towards the synthesis of tertiary thiosulfonates ended
here. It is clear that further optimisation can be done and it is believed that the tertiary
thiosulfonates will be accessible by one of the methods, or a close analogue, presented
above. A next obvious step would be to attempt the synthesis with a triflate, which also
offers enchanced nucleofugal character similar to the trifluoroacetate presented, however
would not suffer from the corresponding side reaction (attack on the carbonyl). This, in
combination with resin supported thiol, may offer a suitable synthesis towards the required
tertiary thiol intermediate to continue towards tertiary thiosulfonates.
6.3.2 Stability Testing Towards Common nucleophiles
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Figure 6.2: Structure of primary thiosulfonate inhibitors and their secondary thiosulfonate coun-
terparts. Also included are the first generation aromatic inhibitors, to highlight the progression
of the thiosulfonate inhibitors.
As the core reasoning for introducing steric arguments was to improve the stability of
the thiosulfonate warheads, the stability of the secondary thiosulfonates towards common
nucleophiles was assessed. It was hypothesised that these warheads would mimic the trend
seen earlier with the cyclohexane derivative being most stable, followed by the benzylic
derivative. It was also expected that introduction of a methyl group, to generate the
secondary thiosulfonates in each instance, would further improve the warhead stability.
As such, comparisons will be drawn with the respective primary thiosulfonate warheads
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to deduce the effect steric arguments have upon thiosulfonate warhead stability in this
section. Figure 6.2 has been provided for reference to the structure of each compound
discussed in the following section.
Stability Towards Thiols and Amines - The benzyl Thiol and Benzyl Amine
test system
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Figure 6.3: Stability of inhibitor 127 (left) and 128 (right) towards benzyl amine and benzyl
mercaptan. Inhibitor degradation was determined by HPLC in MeCN at room temperature with
13 measurements taken 1 hour apart, representing time 0 to 12 hours. Approximately 0.3 mg of
inhibitor was accurately weighed and suspended in MeCN, to which 10 equivalents of BnSH or
BnNH2 was added immediately before measurement. Results were then normalised against time
0 and plotted as scatter graphs for visualisation.
To begin with, the stability of the secondary thiosulfonates 127 and 128 towards amines
and thiols was assessed. Based on the previous success of the primary thiosulfonate bearing
an aliphatic warhead (compounds 11 and 12, section 5.2.3) it was expected that the
secondary thiosulfonates would display very high stability towards both amines and thiols.
Testing was conducted by the earlier described method with benzyl amine and benzyl thiol,
used for the primary thiosulfonates, for comparison (section 5.2.3). As can be seen in figure
6.3 the secondary thiosulfonates were stable towards both amines and thiols over the 12
hour test period. When compared with the earlier aromatic thiosulfonate warheads, this
was a significant improvement. However, when compared against the primary, aliphatic
thiosulfonates this was expected, hence the main issue to be addressed was the aqueous
stability profiles.
pH Dependent Aqueous Hydrolysis
Moving on to the aqueous stability profiles, comparison of the newly developed secondary
thiosulfonates (127 and 128) with their primary thiosulfonate counterparts (11 and 12)
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Figure 6.4: pH dependent aqueous stability of secondary thiosulfonate warheads compared to
the previous primary aromatic and aliphatic thiosulfonate warheads. Inhibitor degradation was
determined by HPLC with peak areas integrated against an internal standard (Ac-Phe-OH), 13
measurements were taken 1 hour apart, representing time 0 to 12 hours. Sodium phosphate buffer
(0.1mm) of the relevant pH containing 5% DMSO was utilised, initial inhibitor concentration
was 245 µm and internal standard (Ac-Phe-OH) concentration was 338µm.Results were then
normalised and plotted as scatter graphs for visualisation.
106
there was a clear improvement, as shown in figure 6.4.
Looking towards the cyclohexane warhead analogues, the primary thiosulfonate warhead
of compound 11 was known to be stable at pH 6, display minimal degradation at pH 7
(half life approximately 60 hours) and had a half life of approximately 6 hours at pH 8.
Now, with the secondary thiosulfonate warhead of compound 127 the inhibitor was stable
at both pH 6 and pH 7, with a greatly increased half life of approximately 24 hours at pH
8.
A similar trend was observed when comparing the benzylic warheads of compounds 12
and 128. Previously, the primary thiosulfonate warhead of compound 12 showed a half
life of approximately 40 hours at pH 6, 5 hours at pH 7 and 45 minutes at pH 8. Now, with
the incorporation of a methyl group to form the corresponding secondary thiosulfonate
warhead of inhibitor 128 the warhead was effectively stable at pH 6 and 7, with a greatly
increased half life of approximately 11 hours at pH 8.
As expected, the cyclohexane derived warhead (11) was more stable than the benzylic
counterpart (12), as had been observed previously for the primary thiosulfonates (section
5.2.3). However, in both cases the thiosulfonates were now found to be significantly more
stable towards aqueous hydrolysis, especially at the relatively basic pH of 8 (in terms of
physiological pH). This was considered a significant step forward, as a half life in the order
of hours at higher physiological pH levels would offer a wider potential therapeutic window.
The earlier aromatic warheads 7 and 10 have also been displayed in figure 6.4 to highlight
the progression of the thiosulfonate warheads from the early aromatic constructs.
6.4 Biological evaluation - Papain assay
Moving on from the success of the stability testing towards common nucelophiles, the inhi-
bition of papain was to be assessed. It was hypothesised that, based on the trends observed
in the work thus far, the increased stability of the new secondary thiosulfonate warheads
would offer improved potency in the papain assay. Figure 6.5 displays the newly made
secondary thiosulfonates (127 and 127) compared with their primary thiosulfonate coun-
terparts (11 and 12). In accordance with the hypothesis, both secondary thiosulfonate
warheads offered an improved potency when compared with their primary thiosulfonate
counterparts (approximately 40 nm, 1.3 fold increase). Furthermore, the most stable war-
head of compound 127 (secondary thiosulfonate with a cyclohexane warhead) was again
observed to be the most potent at 121 nm. The inhibitor bearing a secondary thiosulfonate,
benzylic warhead (12 was close to follow, with an IC50 value of 137 nm).
It can be concluded that secondary thiosulfonate warheads of 127 and 128 retained, or
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Figure 6.5: Papain IC50 values of the secondary thiosulfonate warheads 127 and 128 compared
to their primary thiosulfonate counterparts (inhibitors 11 and 12). Assay buffer: sodium phos-
phate (100mm, pH 6.5) containing EDTA (1.5mm) and 2% DMSO. Final concentrations in the
wells were; Papain: 4µm; substrate: 1.0mm; inhibitor: doubling dilution range starting at 10 µm
giving: 10 µm, 5µm, 2.5µm, 1.25 µm, 0.625 µm, 0.3125µm, 156.25 nm, 78.125 nm, 39.0625 nm. Er-
ror bars on graph display SEM across 3 independent repeats. Tabulated ± values represent the
std error of the IC50 values across 3 independent repeats.
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slightly improved upon the previous IC50 values of their primary thiosulfonate counterparts
(11 and 12). When combined with the significant increase in stability towards common
nucleophiles displayed in section 6.3.2, this displays a significant advance in the develop-
ment of thiosulfonates as cysteine protease inhibitors. Of particular significance was the
increased stability towards aqueous hydrolysis, with a substantial increase in half life even
at higher pH values. As it is believed the aqueous stability will become more significant
in increasingly complex biological settings, the findings of improved potency in the papain
assay are anticipated to become exaggerated with increasing biological complexity.
6.5 Summary and Future Work
In summary, controlling the reactivity by introducing steric arguments to reduce the rate
of nucleophillic attack on the thiosulfonate warhead has been explored. This led to the
successful synthesis, stability and biological testing of the secondary thiosulfonates, bear-
ing an additional methyl group adjacent to the site of attack. It was found that increasing
the sterics surrounding the thiosulfonate warhead successfully down regulated their reac-
tivity, which was met with an improved IC50 against papain. Efforts towards the synthesis
of tertiary thiosulfonates were made to further expand upon this trend, however they were
were unsuccessful. Based on the observed results, future work should include accessing
the tertiary thiosulfonates and assessing their reactivity profiles. Furthermore, the oppo-
site diastereomer of the secondary thiosulfonates presented could be made to assess the
potential impact of chirality on the function of the thiosulfonates. With the thiosulfonates
having a substantially improved reactivity profile, compared with the early aromatic pri-
mary thiosulfonate warheads, it was decided to move on to more complex and relevant
biological testing targeting the neglected tropical disease Schistosomiasis.
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Chapter 7
Applying Thiosulfonates to target a
Neglected Tropical Disease:
Schistosomiasis
The work presented in this chapter was conducted in collaboration with the research group
of Dr. Andrea Kriedenweiss at The Institute of Neglected Tropical Diseases, Tubingen
University, Germany. All viability testing presented herein was conducted by Mr Erik
Koehne with the author providing compounds for testing.
Parts of this chapter have been published: D.J. Ward, H. Van de Langemheen, E. Koehne,
A. Kreidenweiss, and R.M.J. Liskamp. Highly tunable thiosulfonates as a novel class of
cysteine protease inhibitors with anti- parasitic activity against Schistosoma mansoni.
Bioorganic & Medicinal Chemistry, 27(13):2857 - 2870, 2019.
Having explored the reactivity profiles of the thiosulfonate warheads and proven their
suitability as cysteine protease inhibitors in a model (papain) system, it was decided to
expand testing towards a more biologically relevant target. It was hypothesised that mov-
ing towards increasingly complex biological systems, such as S. mansoni (the parasite
responsible for schistosomiasis) the earlier observed stability and potency trends would
become exaggerated. S. mansoni is a trematode blood fluke causing acute and chronic
intestinal schistosomiasis (bilharzia) in humans. Schistosomiasis is widely prevalent in
Africa, Middle East, and South America affecting >200 million people. Large-scale elim-
ination activities are ongoing and praziquantel, the only schistosomiasis medication, is
widely deployed by mass drug administration programs. New anti-schistosomal drug can-
didates are urgently needed since reduced susceptibility to praziquantel has been reported
for many decades.91,92 Research on candidate antischistosomal targets has focused on di-
gestive enzymes in S. mansoni since the parasite feeds on the haemoglobin of red blood
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Figure 7.1: Structure of all thiosulfonate inhibitors tested in this chapter. Homophenylala-
nine derived primary thiosulfonates (left), arginine derived primary thiosulfonates (middle) and
homophenylalanine derived secondary thiosulfonates (right)
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cells, essential for the parasite’s growth, development, and reproduction.93 Papain like
cysteine proteases play a major role in haemoglobin degradation and have become an
important drug target.44,213,214 Namely, the cathepsin B like cysteine protease SmCB1.
The reference compound in this study (6, K11777) has shown a high efficacy against the
S. mansoni parasite in the murine model.101 Furthermore, K11777 (6) has been utilised
to probe the structural basis for inhibition of SmCB1, providing a foundation for the
thiosulfonate derivatives presented.187
First, the structural basis for targeting S. mansoni was explored with DrawToDock before
viability testing was conducted. Then, conclusions will be drawn which relate back to
earlier observed trends in the papain assay test system between reactivity and potency,
as well as new considerations such as permeability. A total of 13 thiosulfonate deriva-
tives (figure 7.1) were tested in vitro against S. mansoni, of which 8 compounds showed
high activity. The first 10 compounds were tested at the same point in time with the
final 3 compounds being tested at a later date. The most potent thiosulfonate from the
first 10 was tested alongside the final 3, to account for any variation between biological
assays.
7.1 Modelling Study: Applying Thiosulfonates Inhibitors
to SmCB1
As mentioned previously, SmCB1 ia a major cysteine protease in S. mansoni, validating it
as a suitable target. SmCB1 is a papain like cysteine protease, being of the Clan CA fam-
ily C1, the active site shares many common features with papain used in the earlier test
system. There are however a few key differences surrounding the active site, most notable
a feature named the occluding loop which can be seen in figure 7.2. The occluding loop is
a feature of cathepsin B and cathepsin B like proteases that is defined as a loop extending
beyond the C-terminus of the peptidic substrate in the active site. A notable feature of
the occluding loop is the presence of two histidine residues, His-180 and His-181 shown
in figure 7.2, which allow Cathepsin B like proteases to anchor the C-terminus through
H-bonding to these key His residues (see section 1.1.1). As such, cathepsin B like proteases
can function as di-peptidal carboxypeptidases in addition to their endopeptidase activity,
with the occluding loop anchoring the C-terminus in such a way that the scissile bond is
placed two amino acids residues back from the C terminus. This di-peptidal carboxypep-
tidase activity has been reported as being highly pH dependent. The occluding loop of
mammalian cathepsin B was found to alter its position and thus C-terminal anchoring
ability in a pH dependent manner, whilst the parasitic variant SmCB1 was reported to
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be less flexible through stabilisation by two salt bridges.28,215 It was hypothesised that
the occluding offered a unique H-bonding partner amongst the cysteine proteases, which
could be exploited to improve binding of the thiosulfonate inhibitors.
Figure 7.2: Crystal Structure of S. mansoni cathepsin B like Cysteine Protease SmCB1 with
K11777 bound in active site; PDB code: 3S3R.
A further key difference between papain and SmCB1 is found at the bottom of the S1
binding pocket. SmCB1 has a glutamic acid residue at the bottom of the S1 binding pocket,
again shown in figure 7.2, which offers an excellent H-bond partner for basic residues. As
such, it was expected that the basic arginine residue of inhibitors 13-17 would offer an
ideal partner for optimal binding. Indeed, the ability for Cathepsin B as well as SmCB1 to
accept basic residues in this position has been reported.216 Gratifylingly, it was anticipated
that this would correlate well with the earlier observed trends in the papain test system
that arginine derived warheads would offer improved inhibition (section 4.2.3). In this
case, the preference for arginine is due to coordination towards a slightly different residue
(Glu-142 in this case) rather than coordinating backbone carbonyls of Cys-63 and Ser-21
(in the case of Papain, see chapter 4 section 4.1). It was hypothesised that Glu-142 would
offer a more favourable H-bonding partner with arginine than the electrostatic environment
created by backbone carbonyls of Cys-63 and Ser-21 in the papain test system previously,
thus the arginine constructs were anticipated to enhance target binding to SmCB1.
Initially all inhibitor constructs were screened against SmCB1 with the use of DrawToDock
to determine if these inhibitors would offer reasonable binding towards this new target.
Gratifyingly, the overall binding mode observed mirrored that of K11777, based on the
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Figure 7.3: Docked pose of thiosulfonate inhibitor 7 with SmCB1. 2 possible docked poses
(top left and top right) and the overlay with K11777 from the crystal structure (bottom left and
bottom right). K11777 is shown with blue carbon backbone, thiosulfonate 7 is shown with green
carbon backbone.
crystal structure of K11777 bound to SmCB1 (PDB code 3S3R). Two noteworthy obser-
vations were made during this screening. Firstly, as shown in figure 7.3, it was found that
the p-NO2 substituted warheads offered a favourable H-bonding pair with His-180 and His-
181 of the occluding loop. When compared with K11777 (bound in the original crystal
structure) the overall binding mode correlated well with the homophenylalanine residue
occupying the same S1 region, the phenylalanine residue occupying the S2 region and the
N-methylpipirazine cap occupying the S3 region. The greatest difference was observed in
the S1’ region where the p-NO2 substituted warhead of compound 7 coordinated His-181
of the occluding loop. This was a very encouraging find, suggesting that the p-NO2 moiety
may serve as a suitable mimic of the C-terminus of natural substrates. Thus, it was ex-
pected that the p-NO2 substituted warheads may perform better than others on the basis
of the initial binding event, Ki. Earlier studies correlated the decreased stability of the
p-NO2 warheads with reduced potency (section 3.6), which may counteract the potential
contribution to enhanced binding.
Secondly, it was found that arginine constructs 14-13 all offered H-bonding between the
arginine side chain and Glu-142 at the base of the S1 binding pocked. Furthermore, it
was observed that compound 13 bearing the p-NO2 substitution displayed H-bonding
between the His-181 of the occluding loop and the nitro group. It was hypothesised that
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Figure 7.4: Docked pose of thiosulfonate inhibitors 14 (top left), 15 (top right), 16 (bottom left)
and 13 (bottom right) with SmCB1. All inhibitor constructs show coordination of the arginine
side chain towards Glu-142. Compound 13 (bottom right) also shows coordination of the p-NO2
group towards His of the occluding loop.
the additional H-bonding partners presented here would enhance the initial binding of
inhibitor constructs and translating through to more potent inhibitors, as was previously
demonstrated in the papain assay.
7.2 Viability Testing Against Schistosomula: The Lar-
val Form of Schistosomiasis
For the first 10 thiosulfonate inhibitors tested (7-11 and 13-17), viability testing was con-
ducted at a set concentration of 30µm to screen for active compounds, as shown in figure
7.5. Mefloquine and auranofin were used as control compounds and K11777 (6 included
as a reference compound for comparison. Interestingly all arginine derived constructs
(13-17), which were anticipated to be more potent based on earlier papain studies and
modelling towards SmCB1, exhibited effectively no activity. This was in contrast to the
homophenylalanine derivatives 7-11), which were found to be highly active. Based on this,
it was believed that the lack of activity of the arginine derived inhibitors was likely due
to poor permeability of the parasitic tegument. The parasitic tegument is the outer body
covering the parasite, which is highly hydrophobic potentially reducing the permeability
115
Figure 7.5: In vitro drug susceptibility screen of schistosomula. Mean % viability of schisto-
somula after drug exposure for 1 day, 3 days and 7 days. Derivatives (7-11 and 13-17) and
K11777 (6) control were tested at 30 µm, MQ (mefloquine) at 100µm, and AU (auranofin) at
1µm. ND (no drug, medium only) and DMSO control for schistosomula viability. Assay was
done in triplicate.
of the more polar arginine derivatives, carrying a positive charge at physiological pH.217
There are many other factors which may account for the selective uptake, or increased
permeability, of the homophenylalanine derivatives tested here. For example, it has been
reported that lipids are of particular interest in the research of S.mansoni with some ex-
traordinary lipids, such as ∆5-octadecanoic acid, and large amounts of lysophospholipids
being found in the tegument.218 Interestingly, S.mansoni worms are unable to synthesise
sterols and fatty acids de novo,.219 Recent reports on the lipid topography of the oral and
ventral suckers (involved in the uptake of nutrients) suggesting an enhanced lipid concen-
tration in this region.217 These characteristics of the parasite biology may be significant in
the design of inhibitors, resulting in the loss of potency moving from homophenylalanine
(7-11) to arginine constructs (13-17).
Following on from this, the trend observed for all active compounds (7-11) broadly fol-
lowed the earlier observed trends between warhead reactivity and potency in the papain
test system. To further confirm this all active constructs (7-11) were carried forward to de-
termine their EC50 values, as shown in figure 7.6. Most notably, the cyclohexane analogue
11 was found to be the most potent in this early screen with the p-NO2 substituted war-
head 7 appearing almost equipotent. Interestingly, this suggests that the potency mirrors
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Compound Concentration range 3 Day Mean 7 Day Mean
number (µm) tested IC50 (SD) (µm) IC50 (SD) (µm)
MQ 200-0.27 2.4 (0.6) 0.4 (0.1)
AU 10-0.014 0.2 (0.1) 0.1 (0.1)
K11777 6 100-0.14 59.9 (23.5) 7.3 (3.3)
8 300-0.14 64.4 (19.3) 21.4 (3.5)
9 300-0.14 41.1 (7.6) 26.9 (4.7)
10 300-0.14 44.9 (27) 13.6 (1.0)
7 300-0.14 29.3 (12.6) 14.7 (1.1)
11 300-0.14 25.4 (16.7) 13.5 (1.2)
Figure 7.6: Schistosomula viability dose-response curves for compounds 7-11. Viability (%) is
displayed per compound concentration (log10, µm). Drug exposure: blue: 1 day, red: 7 days.
Dots and triangles represent individual data points per drug concentration (triplicates) from one
exemplary assay. Lines represent the modelled curve fit. MQ (mefloquine), AU (auranofin).
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stability, with the lest reactive cyclohexane analogue 11 being the most potent inhibitor
at 25.4 and 13.5 µm after 3 and 7 days respectively. An exception to this trend is the most
reactive inhibitor (p-NO2) substituted warhead, compound 7, which was equipotent with
the least reactive inhibitor (cyclohexane analogue 11) at 29.3 and 14.7 µm after 3 and 7
days respectively. Considering the anticipated stability under these assay conditions (pH
7.3), when combined with earlier stability tests (section 3.5), compound 7 was expected
to decompose rapidly under these conditions. This led to the belief that the thiosulfonate
analogues must be fast acting, with a rate capable of overcoming the competing pH de-
pendent hydrolysis of compound 7. Combining this with the earlier modelling studies,
which suggested the p-NO2 may be able to anchor the inhibitors by coordinating His-180
and His-181 of the occluding loop, may explain this unanticipated increase in the observed
potency, despite its low stability.
With the previous finding that arginine analogues were not effective in targeting S. man-
soni in this system, future inhibitor constructs focused only on the homophenylalanine
analogues. These represent the benzylic warhead 12 and the secondary thiosulfonates 127
and 128. It was hypothesised that the correlation between increased warhead stability
and inhibitor potency would continue, as such the cyclohexane derived warhead (inhibitor
11) was anticipated to be more potent than the benzylic warhead (inhibitor 12) and the
secondary thiosulfonates (127 and 128) were anticipated to be more potent that their pri-
mary thiosulfonate counterparts (11 and 12). As testing was taking place on a different
batch of S. mansoni, a number of months apart, the previous most potent thiosulfonate in-
hibitor 11 was run alongside K11777 (6) as a control to account for any potential biological
variability in the assay. In agreement with the hypothesis based on stability arguments,
the secondary thiosulfonate warheads were found to be more potent than their primary
thiosulfonate counterparts, with approximately a 2 fold increase observed in this assay
(figure 7.7, comparing compound 11 and 12 with 127 and 128 respectively). A marked
improvement from the previous most potent thiosulfonate inhibitors was observed. One
interesting finding was that, in this assay, the previous most potent thiosulfonate (11)
offered reduced potency of 43.4 and 38.9 µm over 3 and 7 days respectively when com-
pared with the previous assay (at 29.3 and 14.7 µm respectively). This was considered
to be consistent with biological variation, hence the importance of inclusion of this as a
control compound for comparison between assays. Comparing this with the secondary
thiosulfonate (127), derived from the same cyclohexane warhead, showed a considerable
improvement to 15.9 and 14.1 µm over 3 and 7 days respectively. A similar trend was
observed for the benzylic warhead (12) with an EC50 of 43.4 and 26.3 µm over 3 and 7
days respectively, which was equipotent with the previous best primary thiosulfonate (cy-
clohexane derivative 11). When moving to the secondary benzylic thiosulfonate derivative
128 there was again a significant improvement in EC50 to 22.0 and 13.2 µm over 3 and 7
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Compound Concentration range 3 Day Mean 7 Day Mean
number (µm) tested IC50 (SD) (µm) IC50 (SD) (µm)
MQ 200-0.27 3.3 (0.5) 1.1 (0.2)
AU 10-0.014 0.3 (0.1) 0.2 (0.1)
K11777 6 100-0.14 26.7 (10.1) 10.8 (1.8)
11 100-0.14 43.4 (1.3) 38.9 (3.8)
127 100-0.14 15.9 (2.6) 14.1 (0.4)
12 100-0.14 43.4 (1.2) 26.3 (10.4)
128 100-0.14 22.0 (6.7) 13.2 (2.6)
Figure 7.7: Schistosomula viability dose-response curves for compounds 11 and 12 compared
to 127 and 128. Viability (%) is displayed per compound concentration (log10, µm). Drug
exposure: blue: 1 day, red: 7 days. Dots and triangles represent individual data points per drug
concentration (triplicates) from one exemplary assay. Lines represent the modelled curve fit. MQ
(mefloquine), AU (auranofin).
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days respectively. Possibly the most interesting find was that, when moving to the sec-
ondary thiosulfonate warheads, these were now approximately equipotent with the known
vinyl sulfone reference compound K11777 6, suggesting the thiosulfonates are well placed
as cysteine protease inhibitors for further investigation and application towards treatment
of schistosomiasis.
7.3 Summary
Modelling studies were used to understand the suitability of thiosulfonate constructs for
application towards S. mansoni cathepsin B like cysteine protease SmCB1. Thiosulfonate
derived inhibitors (7-17,127 and 128) were tested against larval stage S. mansoni and
compared against the known cysteine protease inhibitor K11777 (6). Gratifyingly, thio-
sulfonates 7-12, 127 and 128 were found to be highly active and followed a similar trend
between reactivity and potency observed in the previous papain assay test system. It
is believed that the increased charge of the arginine derived constructs lead to reduced
permeability, correlating with the composition of the parasitic tegument, which in turn
greatly decreased the potency of these constructs. Upon considering the assay conditions,
namely pH and time, with the earlier explored stability profiles, it was determined that
the thiosulfonates must be fast acting inhibitors with long lasting effects. Namely, It was
suggested that inhibitor 7 bearing p-NO2 substitution may offer a suitable mimic of the
C-terminus, enhancing its target binding and resultant potency to outcompete hydrolysis
based on the warheads earlier observed aqueous stability profile. A significant increase
in potency, which again correlated with stability, was realised for the secondary thiosul-
fonate warheads 127 and 128 which were comparible with the activity of the vinyl sulfone
reference compound K11777 (6).
Moving forwards, these results suggest that the thiosulfonates are well suited for use as
cysteine protease inhibitors in targeting schistosomiasis. One potential area for improve-
ment would be to generate arginine mimics with increased permeability, as modelling
suggested basic residues would be well accepted in the P1 position. This may facilitate
improved target engagement (Ki) through rational SAR, whilst accounting for the required
improvement in permeability.
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Chapter 8
Strategy to Improve Permeability:
Towards a Benzyl Amine-Derived
Arginine Mimic
TrtHN
S
NHBoc
S
O O
146
Figure 8.1: Warhead building block with a benzyl amine arginine mimic side chain.
Previous work has shown that inhibitors bearing an arginine residue in the P1 position
are highly potent in the papain test system. Both modelling and literature suggested
that a similar response could be expected when targeting the cathepsin B like cysteine
protease of SmCB1 in schistosomaiasis. Interestingly, testing of arginine derived constructs
on S.mansoni found them to be highly ineffective leading to on to the hypothesis that
permeability, rather than selectivity and binding, was reducing the inhibitor potency.
As such, this chapter will explore the synthesis towards an arginine mimic with improved
permeability. Figure 8.1 shows the key building block for this work, the non-natural amino
acid derivative bearing a benzylamine side chain. this building block was chosen based on
the work of Geurink et al . who successfully exploited the benzylamine side chain as an
arginine mimic with improved cell permiability.220 The amine of the side chain offers a
suitable H-bond donor to mimic that of arginine, while the benzylic amine offers a reduced
pKa, reducing the charge at physiological pH and improving the permeability.
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8.1 Attempted Synthesis of Benzyl Amine-DerivedWar-
heads
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Scheme 8.1: Synthesis towards the arginine mimic benzyl amine derived non natural amino
acid building block 146.
The intended synthesis towards the benzylamine-derived non natural amino acid was based
largely on the earlier work of Geurink et al ., which incorporated this non-natural amino
acid into inhibitor constructs for improved permeability.220 Starting from phenylalanine
147 the para substituted N -chloroacetamide moiety was introduced followed by sequential
Cbz protection of the N terminal amine to compound 148. This first step was met with
low yields of 30%, mainly due to the difficult separation of the di-substituted by-product
(ortho and para substitution) on the aromatic ring. The following hydrolysis of the N-
trichloroacetamide was followed by direct Boc protection yielding the free carboxylic acid
149 in a moderate yield of 57%. The carboxylic acid was then converted to the corre-
sponding methyl ester for two reasons, (1) to aid purifications as the polar carboxylic acid
tends to be poorly resolved by normal phase column chromatography and (2) to allow for
a mild reduction to the corresponding alcohol later in the synthesis (as employed previ-
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ously in section 3.2.2, scheme 3.3). At this stage the Cbz protecting group was exchanged
for the trityl protecting group, as the reducing conditions required for its removal were
considered to be incompatible with the final thiosulfonate warhead. This was achieved
over two steps, first by hydrogenolysis with H2 Pd/C (99% yield) followed by protection
with TrtCl under basic conditions (92% yield).
TrtHN
OMs
NHBoc
TrtHN OH
NHBoc NHBoc
TrtHN
MsCl, NEt3,
DCM
158 154 159
Scheme 8.2: Intramolecular cyclisation and aziridine formation.
The route forward from the primary alcohol aimed to take advantage of the previously
explored synthetic routes towards thiosulfonate warheads. This involved the conversion of
the primaty alcohol to a mesylate for subsequent substitution with thioacetic acid. Once
thioacetate 155 was to hand it was intended to access thiol 156 by reduction rather than
hydrolysis as this was found to be the more efficient method, especially when preparing
analogues with increasingly bulky side chains such as that of arginine attempted previously.
Once the thiol was to hand it was intended to incorporate the cyclohexane thiosulfonate
warhead, as this was found to be the most promising warhead construct previously, with
sulfonyl bromide 157. However, as shown in scheme 8.2 this route was not successful, it
was found that upon generating mesylate 154 a rapid intramolecular substitution occured
generating aziridine 159. This is likely due to the available lone pair on the nitrogen
accelerated by the aziridine formation placing the steric bulk of the trityl group away
from other substituents. A subsequent literature search concluded that the combination
of a bulky trityl group and neighbouring mesylate is common for aziridine formation.
With the above aziridine formation in mind, along with the suggestion that the sterics
and reactivity of the trityl protected amine accelerated the reaction, a new synthetic route
has been proposed in scheme 8.3. The key difference with this approach is to replace
the trityl protecting group with a carbamate, Fmoc, which will still allow for orthogonal
deprotection whilst delocalising the lone pair of the nitrogen into the carbamate and pre-
venting the intramolecular cyclisation. One potential weakness of this route is that Fmoc
deprotection may occur during the final step to form thiosulfonate warhead 165 generat-
ing the free amine. This was not considered a significant issue as previous studies have
shown the thiosulfonate to be stable in the presence of amines and the subsequent reac-
tion would involve Fmoc removal before coupling to a peptidic backbone. Unfortunately
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Scheme 8.3: Revised synthesis towards the arginine mimic benzyl amine derived non natural
amino acid building block 165
time constraints prevented this route from being fully explored as it was felt improving
cell permeability with the use of non natural amino acids was interesting but not a key
milestone towards developing the thiosulfonates as cysteine protease inhibitor. As such,
work focused on the other key milestone which has been realised throught this work, fur-
ther controlling the reactivity of the thiosulfonate warhead. However, the above synthesis
should be considered and the final compound is likely to be highly interesting for future
work.
8.2 Summary
The synthesis towards an arginine mimic non natural amino acid building block to be
incorporated as a thiosulfonate inhibitor was attempted. This synthetic approach was
unsuccessful due to aziridine formation when attempting to generate the key mesylate
synthetic intermediate. A new synthesis has been proposed which may overcome this
side reaction however time constraints prevented the full exploration of this route. It
was determined that increasing the permeability of with arginine mimics may provide
interesting future inhibitor constructs but this work was not deemed to be fundamental
to the development of the thiosulfonate warhead its self. Rather, focus turned to further
controlling the reactivity of the thiosulfonate warheads, which was believed to be of greater
significance for the overall development of this new warhead class.
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Chapter 9
Conclusions
In conclusion, the thiosulfonate moiety has been developed as a novel electrophillic trap
to be utilised as cysteine protease inhibitors. A convenient platform for running virtual
screening direct from ChemDraw, named DrawToDock, was also developed and applied
to the thiosulfonate inhibitors. This highlighted the suitability of thiosulfonates as cys-
teine protease inhibitors, displaying their ability to take advantage of the local hydrogen
bonding network of cysteine proteases through hydrogen bonding through the sulfoxide
oxygens. This resulted in rational SAR, leading on to the incorporating of arginine in the
P1 position which improved inhibitor potency towards papain, a representative cysteine
protease. Stability studies with common nucleophiles, such as amines, thiols and pH de-
pendent hydrolysis, displayed the highly tunable nature of the thiosulfonates. Although
some of the first generation inhibitors, namely 7 with an electron withdrawing p-NO2
substituent on the aromatic ring, were found to be unstable towards aqueous hydroly-
sis. There was a marked difference with inhibitor 10 (p-OMe substituted) highlighted the
ease with which the reactivity could be controlled. This led on to a second generation of
aliphatic inhibitors, with significantly improved stability through reduced leaving group
ability of the liberated sulfinate salt. This was achieved by replacing the previous aromatic
rings with aliphatic (cyclohexane) or benzylic motifs. Again, it was found that increasing
the stability of the thiosulfonate warhead improved the potency.
Encouraged by the highly tunable nature of the thiosulfonates, steric arguments were then
introduced, to improve stability by reducing the rate of nucleophilic attack. It was found
that generating secondary thiosulfonates, by introduction of a methyl group, significantly
improved the warhead stability (even at the relatively high pH 8). It is believed that the
thiosulfonates now offer highly suitable warhead constructs to be used as cysteine protease
inhibitors, which may find potential use as chemotherapeutics in human diseases such as
cancer and osteoporosis. Another potential application is towards neglected tropical dis-
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eases, with 8 of the final inhibitor constructs being found to be active towards S.mansoni,
the parasite responsible for schistosomiasis. At the time of writing, interest in the thio-
sulfonates is growing and testing (by request) is ongoing against the malaria parasite P.
falciparum.
From the early stages, where the thiosulfonates were a concept derived from the simple
methyl methane thiosulfonate found in plants such as cauliflower and garlic, significant
advances have been made. It is believed that the chemoselectivity of the thiosulfonate
motif offers a valuable addition to the currently available warheads, moving away from the
over-represented Michael acceptors. Future work to further improve upon this may involve
the synthesis of tertiary thiosulfonates, as an extension of the steric stability arguments
put forward, which may prove to be a powerful new warhead class.
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Chapter 10
Experimental
10.0.1 Materials and Methods
Reagents: All reagents and starting materials (were applicable) were obtained from either
Sigma Aldrich R© or Fluorochem Ltd. of the highest available quality, and utilised without
further purification.
Solvents: All solvents were obtained from Fisher Scientific. Where necessary (under strict
anhydrous conditions) solvents were obtained from a dry source. All deuterated solvents
for NMR were obtained from Cambridge Isotope Laboratories, Inc.
Reactions: Air and moisture sensitive reactions were performed under a nitrogen atmo-
sphere. All glassware used was dried under reduced pressure with heating (250 ◦C) from
a heat gun. All reactions were conducted in septa sealed vessels with equipped with a
nitrogen balloon, unless otherwise stated, and stirred with the use of a magnetic stirrer
bead. A glass stopper replaced the rubber septum in strongly acidic reaction conditions,
such as Boc removal with TFA.
Thin Layer Chromatography (TLC): All TLCs were conducted on aluminium backed TLC
plates coated (0.25 mm), with silica gel 60 F254 obtained from Merck. Compounds were
then detected by fluorescent quenching at 254 nm, by UV light from a UV Minerallight R©
lamp. Non-fluorescent quenching substances were visualised by oxidative staining with
KMnO4 (2.00 g in 400 mL water), or Ninhydrin (1.5 g in 100 mL n-Butanol, 3 mL AcOH)
for staining amines. Stained TLC plates were developed by heating with a heat gun
(250 ◦C), on a hot plate (250 ◦C) or a combination of both as required.
Automated column chromatography: was conducted with the Biotage R© Isolera One R©
automated chromatograph. Products were purified on Biotage R© SNAP Ultra cartridges
pre packed with Biotage R© HP-sphereTM Spherical silica. UV absorption was detected
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with Biotage R© IsoleraTM Spektra UV detector at both UV1 (254 nm) and UV2 (280 nm)
to identify fractions for collection in combination with TLC analysis.
Preparative HPLC: was conducted with the Angilent Technologies 1260 Infinity Preparative-
scale Purification system. Separation was achieved on a Phenomenex Gemini R©, 10 µ C18
110Å AXIA, 250 x 21.2 mm. A linear gradient of 5 → 95% MeCN in Ultra pure water
with 0.1% TFA was utilised. All runs were conducted over 80 minutes with a flow rate of
12.5 mL/Min. Fraction collection was based on UV absorption detected at both 214 and
254 nm. LC-MS: was conducted with a Thermo Scientific, Dionex UltiMate 3000 stan-
dard LC system coupled to a Thermo Scientific LCQ FleetTM Ion trap mass spectrometer.
Separations were achieved with a Dr. Maisch GmbH Reprosil Gold 120 C18, 3 µm, 150
x 4 mm column with a flow rate of 1 mL/Min. A linear gradient of 5 → 95% MeCN in
Ultra pure water with 0.1% TFA over either 40 min. or 10 min. was utilised and retention
times given. UV absorption was detected at 214 nm.
Nuclear Magnetic Resonance (NMR): characterization employed a Bruker R© 400 MHz and
a Bruker R© 500 MHz spectrometer measuring1H,13C, COSY and HSQC as required. Chem-
ical shifts are given in parts per million (ppm). Shifts were downfield of a TMS reference
(δTMS = 0 ppm) and the resonances of the rest protons of the deuterated solvents served
as internal standard.221 CDCl3 7.24 ppm (1H-NMR), 77.0 ppm (13C-NMR); Methanol-d4
3.31 ppm (1H-NMR), 49.0 ppm (13C-NMR); DMSO-d6: 2.49 ppm (1H-NMR), 39.5 ppm
(13C-NMR). 1H-1H COSY experiments and 1H-13C HSQC experiments were also conducted
for correct signal assignment as required.
10.0.2 General Procedures
(1) General procedure for amino acid derived methyl esters: the Boc protected amino acid
(1.00 equiv.) and K2CO3 (3.00 equiv.) were slurried in DMF (3.5 mL/mmol) for 1.5 hrs.
under a nitrogen atmosphere. Methyl iodide (3.00 equiv.) was added dropwise and the
solution stirred overnight. TLC (0.1% AcOH in a suitable mixture of EtOAc and Pet-
ether 40-60) confirmed reaction completion and the solution was evaporated to dryness.
The residue was taken up in EtOAc (10 mL/mmol), washed with water (10 mL/mmol),
aqueous back extracted with EtOAc (3×10 mL/mmol) The combined organic layers were
washed with 5% aq. Na2SO3 (3×20 mL/mmol), brine (50 mL/mmol) and dried over
MgSO4. Concentration in vacuo yielded the title compound with no further purification
required unless otherwise stated.
(2) General procedure for obtaining amino alcohols by methyl ester reduction: The pre-
viously formed methyl ester (1.00 equiv.) and LiCl (2.50 equiv.) were stirred in dry THF
(3.00 mL/mmol) and cooled to 0 ◦C for 15 min. under a nitrogen atmosphere. NaBH4
128
(2.50 equiv.) was added and stirred for 15 min. followed by the addition of EtOH (4
mL/mmol). The solution was stirred for 1 hr. at 0 ◦C before removal of the ice bath. TLC
(suitable eluent mixture of EtOAc and pet-ether 40-60) confirmed reaction completion
after 3 hrs. Water (1.5 mL/mmol) was added followed by addition of sat. NH4Cl (2.5
mL/mmol) and EtOAc (10 mL/mmol). The aqueous and organic layers were separated
and the aqueous layer was back extracted with EtOAc (3×10 mL/mmol). The combined
organic layers were washed with brine (50 mL/mmol) and dried over MgSO4. Concen-
tration in vacuo yielded the title compound without further purification unless otherwise
stated.
(3) General procedure for preparation of mesylates: The previously formed alcohol (1.00
equiv.) was dissolved in DCM (10 mL/mmol) and cooled to 0 ◦C. Triethylamine (5.00
equiv.) was added followed by MsCl (3.50 equiv.) and stirred overnight. Completion of
the reaction was confirmed by TLC (suitable concentration of EtOAc, pet-ether) and the
solution washed with 1m KHSO4 (2×5 mL/mmol), water (2×15 mL/mmol), brine (30
mL/mmol) and dried over MgSO4. Concentration in vacuo yielded the title compound
with no further purification required unless otherwise stated.
(4) General procedure for preparation of thioacetates by mesylate substitution: CsCO3
(1.00 equiv.) was suspended in DMF (10mL/mmol) and thioacetic acid (2.00 equiv.)
was added under an N2 atmosphere before stirring for 15 min. In a separate flask the
previously formed mesylate (1.00 equiv.) was dissolved in DMF (2 mL/mmol) and added
dropwise to the CsCO3/HSAc solution before DMF (2 mL/mmol) was used to rinse any
remaining mesylate into the CsCO3/HSAc solution. The reaction vessel was then covered
with aluminium foil and stirred overnight, TLC confirmed completion (suitable mixture of
EtOAc and pet-ether 40-60). The reaction mixture was evaporated to dryness and taken up
in EtOAc (10 mL/mmol), washed with water (3×mL/mmol), back extracted with EtOAc
(4×5 mL/mmol). The combined organic layers were washed with brine (7.5 mL/mmol)
and dried over MgSO4. Purification by column chromatography (using a suitable gradient
of EtOAc and pet-ether 40-60) yielded the title compound.
(5) General Procedure for the preparation of a disulfide from a thioacetate: The previously
prepared thioacetate (1.00 equiv.) was dissolved in EtOH (25 mL/mmol) and KOH (3.00
equiv.) was added followed by DMSO (1% by volume) and water (2% by volume). Air was
bubbled through the solution for 30 min. before stirring vigorously in an open topped flask
overnight. TLC (suitable eluent mixture of EtOAc, pet-ether 40-60) confirmed reaction
completion. The thiol formation was always observed as a spot on TLC with a higher
Rf value than the disulfide, which tends to have an Rf value close to that of the starting
material thioacetate. The solution was then evaporated to dryness, taken up in EtOAc
(20 mL/mmol), washed with water (3×20 mL/mmol), brine (20 mL/mmol), dried over
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MgSO4 and concentrated in vacuo to yield the title compound which was used without
further purification unless otherwise stated.
(6)(a) General procedure for preparation of a thiol from a thioacetate: All solvents used
in this procedure were first degassed by bubbling N2 gas through for 30 min. Under a
N2 atmosphere the previously prepared thioacetate (1.00 equiv.) was dissolved in EtOH
(25 mL/mmol) and KOH (3.00 equiv.) was added and stirred overnight. TLC (suitable
eluent mixture of EtOAc, pet-ether 40-60) confirmed reaction completion. The solution
was then evaporated to dryness on a rotary evaporator fitted with a N2 balloon to ensure
a N2 atmosphere was maintained upon removal from the rotary evaporator. The resultant
residue was taken up in EtOAc (20 mL/mmol), washed with water (3×20 mL/mmol), brine
(20 mL/mmol), dried over MgSO4 and concentrated in vacuo to yield the title compound
which was used without further purification.
(6)(b) Under a N2 atmosphere the previously prepared thioacetate (1.00 equiv.) was
dissolved in dry THF (10 mL/mmol), cooled to -78 ◦C and LiAlH4(2m in THF, 1.00 equiv.)
was added. The reaction was stirred for 10 min. before allowing to warm to 0 ◦C. TLC
(suitable eluent mixture of EtOAc, pet-ether 40-60) confirmed reaction completion within
30 min. to the reaction was added EtOAc (2 mL/mmol), water (2 mL/mmol) and sat.
NH4Cl (2 mL/mmol). The solution was then diluted with EtOAc (20 mL/mmol), washed
with 1mKHSO4 (20 mL/mmol), brine (20 mL/mmol), dried over MgSO4 and concentrated
in vacuo to yield the title compound which was used without further purification.
(7) General procedure for thiosulfonate formation from the disulfide: The previously
formed disulfide (1.00 equiv.) was dissolved in DCM (10 mL/mmol) and the respective
sodium sulfinate salt (3.20 equiv.) was added followed by iodine (2.00 equiv.). Completion
was confirmed by TLC (relevant concentration of EtOAc, pet-ether) after 1.5 hrs. The
reaction mixture was diluted with DCM (10 mL/mmol), washed with 1m Na2SO3 (2×10
mL/mmol), water (20 mL/mmol), back extract aqueous with DCM (10 mL/mmol), com-
bine organic and wash with brine (10 mL/mmol) and dry over MgSO4. Purification by
column chromatography (relevant gradient of EtOAc, pet-ether) yielded the title the title
compound.
(8) Thiosulfonate formation from Sulfonyl bromide: Cyclohexane sulfonyl bromide, which
was prepared by modification of the procedure of Nishiguchi et al .206 (1.2 equiv.) was
stirred in DCM (10 mL/mmol) and DiPEA was added (1.2 equiv.). The solution was
cooled to 0 ◦C in an ice bath and the relevant thiol dissolved in DCM (10 mL/mmol) was
added dropwise. Reaction completion was confirmed by TLC after 30 min., the solution
was diluted with 10 mL/mmol DMF and evaporated to dryness before being taken up
in EtOAc (10 mL/mmol) and washed with (3×10 mL/mmol) 1m KHSO4, Brine (1×10
mL/mmol), dried over MgSO4 and concentrated in vacuo to yield the title compound.
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(9) Peptide coupling of the warhead containing derivative to backbone peptides - Method
1: The free amine hydrochloride salt was prepared from the relevant Boc protected amine
by stirring in 2m HCl/dioxane (10 mL/mmol) for 1 hr. and completion confirmed by TLC
(15% EtOAc, n-Hexane). The solution was then evaporated to dryness and co-evaporated
with toluene (2×10 mL/mmol) yielding the unprotected amine as the hydrochloride salt.
The amine was then taken up in DCM (10 mL/mmol) and BOP (1.20 equiv.) was added
followed by DiPEA (initially 2.00 equiv. with more added as necessary to maintain basic
conditions) and reaction progress followed by TLC (10% MeOH in DCM). Coupling was
usually complete within 3 hrs. at which point the solution was diluted with EtOAc (100
mL/mmol), washed with water (2×50 mL/mmol), brine (2×50 mL/mmol), dried over
MgSO4 and purified by column chromatography (0→10% MeOH, DCM) yielding the title
compounds. Purification by preparative HPLC yielded the title compounds as fluffy white
TFA salts after lyophilisation.
(10) Peptide coupling of the warhead containing derivative to backbone peptides - Method
2: The free amine TFA-salt was prepared from the relevant Boc-Arg(Pbf)-warhead by
stirring in TFA (10 mL/mmol) with 2% water and 1% TIPS for 2 hr. and completion con-
firmed by LCMS to ensure both Boc and Pbf removal. The solution was then evaporated
to dryness and co-evaporated with toluene (2×10 mL/mmol) yielding the unprotected
amine as the bis-TFA salt. The amine was then taken up in DCM (10 mL/mmol) and
HCTU (1.20 equiv.) was added followed by DiPEA (initially 2.00 equiv. with more added
as necessary to maintain basic conditions) and reaction progress followed by TLC (10%
MeOH, DCM). Coupling was usually complete within 3 hrs. at which point the solution
was diluted with DMF (10mL/mmol) and evaporated to dryness. The residue was taken
up in 0.1% TFA in water and freeze dried before purification by reverse phase column
chromatography (5→40% MeCN, water, 0.1% TFA) yielding the title compounds. Fur-
ther purification by preparative HPLC yielded compounds as fluffy white TFA salts after
lyophilisation.
10.0.3 Chemistry
BocHN
OMe
O
Boc-HomoPhe-OMe (30): Literature compound.222 Methyl ester was prepared according
to general procedure 1 on a 1 mmol (279 mg) scale. Yield: 280 mg, 0.955 mmol, 96%.
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1H NMR (400 MHz, CDCl3) δ 7.24-7.09 (m, 5H), 5.00 (d, J = 8.4 Hz, 1H), 4.29 (dd, J =
12.5, 7.5 Hz, 1H), 3.64 (s, 3H), 2.65-2.55 (m, 2H), 2.14-2.03 (m, 1H), 1.93-1.82 (m, 1H),
1.38 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 173.16, 155.35, 140.77, 128.48, 128.40, 126.15, 79.94, 53.25,
52.27, 34.40, 31.64, 28.33.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.91 (ESI-MS
(m/z): 293.66 (M+)).
BocHN
OH
Boc-HomoPhe-CH2OH (31): Literature compound.223 Reduction to the alcohol was
achieved according to general procedure 2 on a 0.933 mmol (272 mg) scale. Yield: 239
mg, 0.901 mmol, 97%.
1H NMR (400 MHz, CDCl3) δ 7.23-7.07 (m, 5H), 4.73 (d, J = 8.0 Hz, 1H), 3.57 (d, J =
10.2 Hz, 2H), 3.48 (br s, 1H), 2.75 (s, 1H), 2.68-2.53 (m, 2H), 1.82-1.72 (m, 1H), 1.72-1.60
(m, 1H), 1.38 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 156.47, 141.55, 128.45, 128.36, 125.98, 79.65, 65.71, 52.49,
33.32, 32.40, 28.42.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.21 (ESI-MS
(m/z): 265.75 (M+)).
HRMS: calcd. for C15H23NO3Na, 288.1570 [M+Na+]; found 288.1559.
BocHN
OMs
Boc-HomoPhe-CH2OMs (32): Literature compound.224 Prepared according to general
procedure 3 on a 1 mmol (263 mg) scale. Yield: 335 mg, 0.976 mmol, 98%.
1H NMR (400 MHz, CDCl3) δ 7.35-7.18 (m, 5H), 4.66 (d, J = 8.7 Hz, 1H), 4.29 (dd, J =
9.9, 4.0 Hz, 1H), 4.23 (dd, J = 10.1, 4.1 Hz, 1H), 3.90 (br s, 1H), 3.03 (s, 3H), 2.83-2.64
(m, 2H), 1.99-1.81 (m, 2H), 1.48 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 155.30, 140.78, 128.57, 128.37, 126.22, 71.14, 49.42, 37.56,
32.98, 32.09, 28.34.
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LC-MS (Linear gradient 5 →95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.59 (ESI-MS
(m/z): 366.08 (M+Na+)).).
HRMS: calcd. for C16H25NO5Na, 366.1346 [M+Na+]; found 366.1343.
BocHN
SAc
Boc-HomoPhe-CH2SAc (44): Literature compound.225 Prepared according to general
procedure 4 on a 23.5 mmol (8.07 g) scale. Purified by column chromatography 0 âĘŠ
10% EtOAc, Hexane. Yield: 5.55 g, 17.2 mmol, 73%.
1H NMR (400 MHz, CDCl3) δ 7.24-7.08 (m, 5H), 4.46 (d, J = 9.1 Hz, 1H), 3.73 (br s,
1H), 3.05 (dd, J = 13.9, 4.8 Hz, 1H), 2.97 (dd, J = 13.9, 7.0 Hz, 1H), 2.69-2.53 (m, 2H),
2.28 (s, 3H), 1.81-1.70 (m, 1H), 1.70-1.61 (m, 1H), 1.38 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 155.58, 141.52, 128.58, 128.49, 126.11, 79.54, 50.45, 36.33,
34.06, 32.49, 30.72, 28.51.
LC-MS (Linear gradient 5 →95% MeCN, 0.1% TFA, 40 min): Rt (min): 22.14 (ESI-MS
(m/z): 323.67 (M+)).
HRMS: calcd. for C17H25NO3SNa, 346.1447 [M+Na+]; found 346.1437.
BocHN
S S NHBoc
Boc-HomoPhe-Disulfide (45): Prepared according to general procedure 5 on a 2.67 mmol
(864 mg) scale. Yield: 605 mg, 1.08 mmol, 81%.
1H NMR (500 MHz, CDCl3) δ 7.23-7.08 (m, 10H), 4.90 (br s, 2H), 3.81 (br s, 2H), 2.92
(d, J = 11.9 Hz, 2H), 2.72 (dd, J = 14.2, 6.3 Hz, 2H), 2.65 (dd, J = 9.8, 5.0 Hz, 2H),
2.57 (ddd, J = 13.8, 9.8, 6.6 Hz, 2H), 1.86 (br s, 2H), 1.70 (br s, 2H), 1.39 (s, 18H).
13C NMR (101 MHz, CDCl3) δ 155.50, 141.46, 128.44, 125.98, 49.96, 45.05, 35.10, 32.44,
28.49.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 8.36 (ESI-MS
(m/z): 860.89 (M+), 883.20 (M+Na+)).
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HRMS: calcd. for C30H44N2O4S2Na, 583.2635 [M+Na+]; found 583.2610.
BocHN
SH
Boc-HomoPhe-CH2SH (40): Prepared according to general procedure (6) on a 1.20 mmol
(684 mg) scale. Yield: Quant. Due to air sensitivity the thiol was not characterized and
used directly in following reaction.
BocHN
S S
O O
Boc-Homo-CH2SSO2-Ph (34): Prepared according to general procedure 7 on a 0.196 mmol
(110 mg) scale. Purified by automated column chromatography 5→25% EtOAc, pet-ether
40-60. Yield: 90 mg, 0.213 mmol, 54%.
1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 8.3, 1.4 Hz, 2H), 7.60 (tt, J = 7.3, 1.3 Hz,
1H), 7.52 (tt, J = 7.5, 1.5 Hz, 2H), 7.29-7.23 (m, 2H), 7.18 (tt, J = 7.4, 1.3 Hz, 1H), 7.11
(dd, J = 8.3, 1.5 Hz, 2H), 4.67 (d, J = 8.7 Hz, 1H), 3.86-3.74 (m, 1H), 3.22 (dd, J = 13.4,
4.9 Hz, 1H), 3.15 (dd, J = 13.1, 6.3 Hz, 1H), 2.70-2.60 (m, 1H), 2.56 (ddd, J = 13.9, 9.2,
7.0 Hz, 1H), 1.83-1.67 (m, 2H), 1.43 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 155.24, 144.64, 140.91, 133.83, 129.39, 128.56, 128.37,
127.01, 126.18, 79.79, 49.42, 40.91, 35.62, 32.26, 28.41.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 23.52 (ESI-MS
(m/z): 421.57 (M+), 444.07(M+Na+)).
HRMS: calcd. for C21H27NO4S2Na, 444.1274 [M+Na+]; found 444.1260.
BocHN
S S
O O
Boc-HomoPhe-CH2SSO2-(p-Me)Ph] (35): Prepared according to general procedure 7 on
a 0.212 mmol (119 mg) scale. Purified by automated column chromatography 5→25%
EtOAc, pet-ether 40-60. Yield: 157 mg, 0.266 mmol, 63%.
1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.4 Hz, 2H), 7.32-7.28 (m, 2H), 7.28-7.23 (m,
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2H), 7.21-7.14 (m, 1H), 7.13-7.09 (m, 2H), 4.71 (d, J = 8.7 Hz, 1H), 3.87-3.76 (m, 1H),
3.20 (dd, J = 13.1, 4.2 Hz, 1H), 3.14 (dd, J = 13.2, 6.2 Hz, 1H), 2.70-2.60 (m, 1H), 2.56
(ddd, J = 13.9, 9.2, 7.0 Hz, 1H), 2.41 (s, 3H), 1.81-1.68 (m, 2H), 1.43 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 155.25, 144.92, 141.80, 140.95, 129.94, 128.51, 128.35,
127.08, 126.13, 79.70, 49.41, 40.79, 35.59, 32.25, 28.39, 21.69.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.56 (ESI-MS
(m/z): 435.65 (M+), 458.07(M+Na+)).
HRMS: calcd. for C22H29NO4S2Na, 458.1430 [M+Na+]; found 458.1417
BocHN
S S
O O
OMe
Boc-HomoPhe-SSO2-(p-OMe)Ph (36): Prepared according to general procedure 7 on a
0.212 mmol (119 mg) scale. Purified by automated column chromatography 5→25%
EtOAc, pet-ether. Yield: 158 mg, 0.350 mmol, 83%.
1H NMR (400 MHz, CDCl3) δ 7.88-7.80 (m, 2H), 7.31-7.24 (m, 2H), 7.22-7.15 (m, 1H),
7.15-7.10 (m, 2H), 7.01 -6.93 (m, 2H), 4.62 (d, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.86-3.77
(m, 1H), 3.20 (dd, J = 13.6, 4.2 Hz, 1H), 3.15 (dd, J = 13.3, 6.0 Hz, 1H), 2.72-2.63 (m,
1H), 2.58 (ddd, J = 13.9, 9.1, 7.1 Hz, 1H), 1.86-1.70 (m, 2H), 1.44 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 163.75, 155.25, 140.96, 136.28, 129.43, 128.52, 128.35,
126.13, 114.43, 79.69, 55.80, 49.40, 40.75, 35.61, 32.26, 28.39.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.39 (ESI-MS
(m/z): 451.62 (M+), 474.06 (M+Na+)).
HRMS: calcd. for C22H29NO5S2Na, 474.1379 [M+Na+]; found 474.1366.
BocHN
S S
O O
NO2
Boc-HomoPhe-CH2SSO2-(p-NO2)Ph] (37): Prepared according to general procedure 7 on
a 1 mmol (560 mg) scale. Purified by automated column chromatography 5→25% EtOAc,
pet-ether. Yield: 520 mg, 1.11 mmol, 56%.
1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 8.9 Hz, 2H), 8.08 (d, J = 8.9 Hz, 2H), 7.31-7.23
(m, 2H), 7.22-7.16 (m, 1H), 7.14 -7.08 (m, 2H), 4.52 (d, J = 8.4 Hz, 1H), 3.82-3.69 (m,
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1H), 3.27 (dd, J = 13.6, 5.4 Hz, 1H), 3.21 (dd, J = 13.9, 6.2 Hz, 1H), 2.68 (ddd, J =
14.6, 9.1, 5.9 Hz, 1H), 2.59 (ddd, J = 13.9, 9.0, 7.1 Hz, 1H), 1.86-1.76 (m, 1H), 1.76-1.66
(m, 1H), 1.43 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 155.18, 150.46, 149.72, 140.59, 128.62, 128.35, 128.27,
126.34, 124.72, 80.04, 60.47, 49.38, 41.52, 35.54, 32.18, 28.39, 21.12, 14.28.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.32 (ESI-MS
(m/z): 466.31 (M+)).
HRMS: calcd. for C21H26N2O6S2Na, 489.1124 [M+Na+]; found 489.1119.
S
Br
OO
Cyclohexane sulfonyl bromide (87) was prepared by adapting the method if Nishiguchi
et al . for the synthesis of sulfonyl chlorides:206 N-Bromosuccinimide (7.12g, 40 mmol, 4
equiv) was added to MeCN/2m HBr (1:1, v/v) at 0 ◦C. To this was added cyclohexane
thiol (1.225 mL, 10 mmol, 1.00 equic.) and the reaction allowed to stir for 10 minutes.
Completion was confirmed by TLC (100% pet ether, 40-60), the reaction was filtered over
a silica plug which was rinsed with DCM (10 mL). The title compount was isolated as a
slightly yellow oil after evaporation in vacuo (2.828 g, quant.)
1H NMR (400 MHz, Chloroform-d) δ 3.50 (tt, J = 11.9, 3.6 Hz, 1H), 2.41 (dddt, J = 11.8,
3.8, 2.6, 1.3 Hz, 2H), 1.99 (ddt, J = 12.1, 4.2, 2.4 Hz, 2H), 1.80-1.62 (m, 3H), 1.47-1.33
(m, 2H), 1.28 (tt, J = 12.7, 3.3 Hz, 1H).
13C NMR (101 MHz, CDCl3) δ 78.92, 27.60, 25.01, 24.84.
BocHN
S S
O O
Boc-HomoPhe-CH2SSO2-cHex] (75): Prepared according to general procedure 8 on a 0.500
mmol (141 mg) scale. Purified by column chromatography 3→30% EtOAc, pet-ether 40-
60. Yield: 214 mg, Quant.
1H NMR (400 MHz, CDCl3) δ 7.31-7.25 (m, 2H), 7.22-7.15 (m, 3H), 4.68 (d, J = 8.8 Hz,
1H), 3.90-3.82 (m, 1H), 3.39 (dd, J = 13.4, 4.1 Hz, 1H), 3.18 (dd, J = 13.8, 7.0 Hz, 1H),
3.17-3.11 (m, 1H), 2.77-2.61 (m, 2H), 2.31-2.22 (m, 2H), 1.95-1.87 (m, 2H), 1.87-1.76 (m,
2H), 1.75-1.67 (m, 1H), 1.63-1.49 (m, 2H), 1.46 (s, 9H), 1.37-1.26 (m, 2H), 1.26-1.15 (m,
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1H). 13C NMR (101 MHz, CDCl3) δ 155.36, 140.96, 128.53, 128.38, 126.14, 71.37, 50.07,
41.17, 35.88, 32.26, 28.38, 26.36, 26.21, 25.17, 25.11, 25.04.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.39 (ESI-MS
(m/z): 427.75 (M+)).
HRMS: calcd. for C21H33NO4S2Na, 450.1743 [M+Na+]; found 450.1746.
BocHN
S S
O O
Boc-HomoPhe-CH2SSO2-MePhe] (76): Benzyl sulfonyl chloride (216 mg, 1.13 mmol, 2
.26 equiv.) was dissolved in dry DCM (5 mL) and cooled to 0 ◦C followed by the addition
of DiPEA (87 µL, 0.5 mmol, 1.00 equiv.). The solution was stirred for 5 min. before Thiol
40 (0.5 mmol, 1.00 equiv) was taken up in dry DCM (5 mL) and added dropwise. The
reaction was allowed to stir for 30 min before a second addition of DiPEA (87 µL, 0.5
mmol, 1.00 equiv.). TLC confirmed reaction completion before diluting with EtOAc (15
mL), washing with 1m KHSO4 (2×10 mL), NaHCO3 (2×10 mL), water (1×10 mL), brine
(1×10 mL) and drying over MgSO4. The crude product was concentrated in vacuo before
purification by column chromatography (3→30% EtOAc / pet-ether 40-60) yielding the
title compound after concentration in vacuo (76 mg, 0.17 mmol, 35%).
1H NMR (400 MHz, CDCL3) δ 7.47-7.43 (m, 2H), 7.41-7.36 (m, 3H), 7.27 (t, J = 7.5 Hz,
2H), 7.22-7.16 (m, 1H), 7.14 (d, J = 7.6 Hz, 2H), 4.59 (d, J = 9.0 Hz, 1H), 4.53 (s, 2H),
3.74 (br s, 1H), 3.04-2.95 (m, 1H), 2.84 (dd, J = 13.8, 7.3 Hz, 1H), 2.69-2.52 (m, 2H),
1.80-1.65 (m, 2H), 1.45 (s, 9H).
13 NMR (101 MHz, CDCl3) δ 155.31, 140.91, 131.45, 130.65, 129.44, 129.13, 128.97, 128.85,
128.55, 128.45, 128.37, 127.78, 126.18, 79.86, 68.98, 56.31, 49.90, 41.45, 35.91, 32.19,
28.40.
HRMS: calcd. for C22H29NO4S2Na, 458.1430 [M+Na+]; found 458.1428.
BocHN
OH
Boc-HomoPhe-CH(Me)OH (106): Methyl ester 30 (5.866 g, 20 mmol, 1.00 equiv.) was
dissolved in dry DCM (200 mL) under a N2 atmosphere and cooled to -78 ◦C. MeMgBr
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(3m in diethyl ether, 13.2 mL, 40 mmol, 2.00 equiv.) was added dropwise over 15 minutes
followed by the slow addition of DiBAlH (1m in THF, 40 mL, 40 mmol, 2 equiv.) over 2
hours. A further portion of MeMgBr (3m in diethyl ether, 20 mL, 60 mmol, 3.00 equiv.)
was added dropwise over 10 minutes and the reaction allowed to stir for a further 1 hour
before removal from cooling and stirring overnight. The reaction mixture was slowly added
to sat. NaHCO3, diluted with DCM (200 mL) and washed with Rochelles salt (sat. 400
mL) before seperating the layers and back exrtacting the aqueous with DCM (4×100
mL). The organic layer was dried over MgSO4, concentrated in vacuo and purified by
column chromatography (5→60% EtOAc / pet ether 40-60) yielding the title compound
after concentration in vacuo (2.558 g, 9.156 mmol, 46%) Product contained 12% anti
diastereomer by NMR.
1H NMR (400 MHz, CDCl3) δ 7.31-7.23 (m, 2H), 7.21-7.14 (m, 3H), 4.77 (d, J = 9.5 Hz,
1H), 3.79 (br s, 1H), 3.54-3.42 (m, 1H), 2.81-2.56 (m, 2H), 2.32-2.22 (m, 1H), 1.88 -1.76
(m, 2H), 1.46 (s, 9H), 1.17 (d, J = 6.3 Hz, 3H).
13 NMR (101 MHz, CDCl3) δ 156.57, 141.85, 128.48, 128.40, 126.02, 125.91, 79.37, 70.64,
69.70, 58.95, 55.59, 34.39, 32.99, 32.12, 31.82, 28.40, 20.49.
HRMS: calcd. for C16H25NO3Na, 302.1727 [M+Na+]; found 302.1719.
[α]D20=-8.3 (c 1.00, CHCl3)
BocHN
OMs
Boc-HomoPhe-CH(Me)OMs (105): Prepared according to general procedure (3) on a 1
mmol (279 mg) scale. Purified by automated column chromatography 10→50% EtOAc,
pet-ether 40-60. Yield: 278 mg, 0.778 mmol, 90%.
1H NMR (400 MHz, cdcl3) δ 7.32-7.24 (m, 2H), 7.22-7.13 (m, 3H), 4.81 (qd, J = 6.4, 2.5
Hz, 1H), 4.61 (d, J = 9.8 Hz, 1H), 3.79-3.68 (m, 1H), 2.99 (s, 3H), 2.78-2.63 (m, 2H),
1.91-1.73 (m, 2H), 1.46 (d, J = 1.4 Hz, 9H), 1.41 (d, J = 6.4 Hz, 3H).
13C NMR (101 MHz, CDCl33) δ 155.79, 141.09, 128.53, 128.50, 128.47, 128.37, 126.11,
80.89, 79.75, 53.72, 38.77, 34.10, 32.17, 28.36, 18.10.
HRMS: calcd. for C17H27NO5SNa, 380.1502 [M+Na+]; found 380.1499
[α]D20=-14.0 (c 1.02, CHCl3)
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BocHN
SAc
Boc-HomoPhe-CH(Me)SAc (104): Mesylate 105 (272 mg, 0.761 mmol, 1 equiv.) was
dissolved in dry DMF under a N2 atmosphere. KSAc (104 mg, 0.913 mmol, 1.2equiv.)
was added and the reaction heated to 60 ◦C. after 1 hour, a further portion of KSAc (156
mg, 1.37 mmol, 1.8 equiv) was added and TLC (20% EtOAc, pet ether 40-60) confirmed
reaction completion after a further 2 hours. The reaction mix was evaporated to dryness
in vacuo, the residue taken up in EtOAc (10 mL), washed with brine (1×10 mL), dried
over MgSO4 and concentrated in vacuo. Purification by column chromatography (3→25%
EtOAc/ pet ether 40-60) gave yielded the title compound (62 mg, 0.421 mmol, 55%).
Note: at this stage chiral resolution was achieved during chromatographicseperation from
the other diastereomer (which eluted sooner, with a higher Rf value).
1H NMR (400 MHz,CDCl3) δ 7.27 (d, J = 8.5 Hz, 2H), 7.22-7.15 (m, 3H), 4.52 (d, J =
9.7 Hz, 1H), 3.90 âĂŞ 3.72 (m, 1H), 2.73 (td, J = 12.4, 10.4, 5.1 Hz, 1H), 2.68-2.56 (m,
1H), 2.32 (s, 3H), 1.88 (dddd, J = 13.9, 10.1, 6.5, 3.4 Hz, 1H), 1.56 (s, 2H), 1.47 (s, 9H),
1.27 (d, J = 7.1 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 155.57, 128.45, 128.36, 125.99, 53.93, 44.06, 34.18, 32.67,
30.80, 28.39, 17.68.
HRMS: calcd. for C18H27NO3SNa, 360.1604 [M+Na+]; found 360.1602
[α]D20=+17.9 (c 1.2, CHCl3)
BocHN
SH
Boc-HomoPhe-CH(Me)SH (103): Prepared according to general procedure (6.a) on a
0.174 mmol (59 mg) scale. Yield: Quant. Due to air sensitivity the thiol was not charac-
terized and used directly in following reaction.
BocHN
S S
O O
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Boc-HomoPhe-CH(Me)SSO2cHex (100): Prepared according to general procedure 8 on
a 0.154 mmol (52 mg) scale. Purified by automated column chromatography 3→30%
EtOAc, pet-ether 40-60. Yield: 26 mg, 0.059 mmol, 38%.
1H NMR (400 MHz, CDCL3) δ 7.32-7.25 (m, 2H), 7.23-7.14 (m, 3H), 4.70 (d, J = 9.6 Hz,
1H), 3.89 (dq, J = 10.0, 5.2, 3.5 Hz, 1H), 3.73 (qd, J = 7.2, 3.2 Hz, 1H), 3.14 (tt, J =
12.2, 3.5 Hz, 1H), 2.76 (ddd, J = 14.7, 9.9, 5.2 Hz, 1H), 2.62 (ddd, J = 13.9, 9.5, 6.8 Hz,
1H), 2.34-2.20 (m, 2H), 1.92 (dd, J = 12.0, 4.5 Hz, 2H), 1.88-1.80 (m, 1H), 1.75-1.67 (m,
1H), 1.65-1.51 (m, 3H), 1.47 (s, 9H), 1.43 (d, J = 7.3 Hz, 3H), 1.38-1.13 (m, 4H).
13C NMR (101 MHz, CDCl3) δ 155.49, 141.04, 128.53, 128.37, 126.16, 79.81, 71.25, 54.28,
52.41, 33.34, 32.58, 28.40, 26.44, 26.09, 25.24, 25.14, 25.08, 18.94.
HRMS: calcd. for C22H35NO4S2Na, 464.1900 [M+Na+]; found 464.1894
[α]D20=+3.3 (c 0.575, CHCl3)
BocHN
S S
O O
Boc-HomoPhe-CH(Me)SSO2MePh (101): Phenylmethane sufonyl chloride (67 mg, 0.350
mmol, 2.00 equiv.) was dissolved in dry DCM (2 mL) and cooled to 0 ◦C. DiPEA was
then added (61 µL, 0.350 mmol, 2.00 equiv.) before the addition of freshly prepared thiol
103 (0.175 mmol, 1.00 equiv.). The reaction was allowed to stir for 1 hour before addition
of a second portion of phenylmethane sulfonyl chloride (34 mg, 0.175 mmol, 1.00 equiv.)
followed by DiPEA (61 µL, 0.350 mmol, 2.00 equiv.). The reaction mix was then diluted
with EtOAc (10 mL) before wshing with 1m KHSO4 (2×10 mL), brine (1×10 mL) and
drying over MgSO4. Purification by column chromatography (3→30% EtOAc, Pet ether
40-60) yielded the title compound (39 mg, 0.087 mmol, 50%).
HRMS: calcd. for C23H31NO4S2Na, 472.1587 [M+Na+]; found 472.1589
[α]D20=+9.0 (c 0.74, CHCl3)
BocHN
OMe
HN
HN NHPbf
O
Boc-Arg(Pbf)-OMe (61): Prepared according to general procedure 1 on a 10 mmol (5.27 g)
scale. Purified by automated column chromatography 20→100% EtOAc, pet-ether 40-60.
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Yield: 5.02 g, 9.29 mmol, 93%.
1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 6.18-6.04 (m, 2H), 5.26 (d, J = 8.3 Hz, 1H),
4.35-4.19 (m, 1H), 3.73 (s, 3H), 3.35-3.25 (m, 1H), 3.23-3.13 (m, 1H), 2.96 (s, 2H), 2.58
(s, 3H), 2.52 (s, 3H), 2.09 (s, 3H), 1.87-1.75 (m, 1H), 1.70-1.55 (m, 3H), 1.46 (s, 6H), 1.42
(s, 9H).
13C NMR (101 MHz, CDCl3) δ 173.07, 158.83, 156.29, 156.08, 138.47, 133.05, 132.39,
124.70, 117.59, 86.49, 80.46, 52.81, 52.60, 43.37, 40.85, 30.71, 28.74, 28.45, 25.30, 19.40,
18.03, 12.61.
LC-MS (Linear gradient 5→ 95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.70 (ESI-MS
(m/z): 541.12 (M+H+)).
HRMS: calcd. for C25H40N4O7SNa, 563.2510 [M+Na+]; found 563.2501.
BocHN
OH
HN
HN NHPbf
Boc-Arg(Pbf)-CH2OH (62): Prepared was achieved according to general procedure 2 on
a 9.29 mmol (5.02 g) scale. Yield: 4.72 g, 9.21 mmol, 99%.
1H NMR (400 MHz, CDCl3) δ 6.39-6.12 (m, 3H), 5.16 (d, J = 7.9 Hz, 1H), 3.64-3.51 (m,
3H), 3.31-3.15 (m, 3H), 2.95 (s, 2H), 2.56 (s, 3H), 2.50 (s, 3H), 2.09 (s, 3H), 1.64 -1.51 (m,
4H), 1.46 (s, 6H), 1.41 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 158.92, 156.80, 156.47, 138.46, 132.88, 132.37, 124.77,
117.67, 86.56, 79.74, 65.12, 43.37, 41.20, 29.03, 28.74, 28.55, 25.75, 19.43, 18.09, 12.62.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.15 (ESI-MS
(m/z): 513.08 (M+H+)).
HRMS: calcd. for C24H40N4O6SNa, 535.2561 [M+Na+]; found 535.2543.
BocHN
OMs
HN
HN NHPbf
Boc-Arg(Pbf)-CH2OMs (63): Prepared according to general procedure 3 on a 9.21 mmol
(4.72 g) scale. Purified by automated column chromatography 20→100% EtOAc, pet-ether
40-60. Yield: 3.42 g, 5.79 mmol, 63%.
1H NMR (400 MHz, CDCl3) δ 6.20-5.98 (m, 3H), 5.03 (d, J = 9.0 Hz, 1H), 4.23 (dd, J =
141
10.2, 4.2 Hz, 1H), 4.16 (dd, J = 10.2, 4.4 Hz, 1H), 3.90-3.79 (m, 1H), 3.32-3.15 (m, 2H),
3.04 (s, 3H), 2.96 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.10 (s, 3H), 1.70-1.53 (m, 4H), 1.46
(s, 6H), 1.42 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 159.07, 156.19, 155.96, 138.53, 132.48, 124.90, 117.74,
86.65, 79.97, 71.52, 49.69, 43.29, 40.95, 37.39, 28.71, 28.67, 28.47, 25.50, 19.42, 18.06,
14.30, 12.59.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.40 (ESI-MS
(m/z): 591.08 (M+H+)).
HRMS: calcd. for C25H42N4O8S2Na, 613.2336 [M+Na+]; found 613.2312.
BocHN
SAc
HN
HN NHPbf
Boc-Arg(Pbf)-CH2SAc (64): Prepared according to general procedure 5 on a 5.79 mmol
(3.42 g) scale. Purified by automated column chromatography 20→100% EtOAc, pet-ether
40-60. Yield: 2.98 g, 5.23 mmol, 90%.
1H NMR (400 MHz, CDCl3) δ 6.19-6.02 (m, 3H), 4.71 (d, J = 9.2 Hz, 1H), 3.78-3.64 (m,
1H), 3.32-3.20 (m, 1H), 3.20-3.09 (m, 1H), 2.95 (s, 2H), 3.03-2.86 (m, 2H), 2.58 (s, 3H),
2.52 (s, 3H), 2.35 (s, 3H), 2.09 (s, 3H), 1.63-1.53 (m, 2H), 1.53 -1.46 (m, 2H), 1.46 (s, 6H),
1.41 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 158.81, 156.52, 156.21, 138.50, 132.44, 124.69, 117.58,
86.47, 80.04, 50.19, 43.39, 41.12, 34.15, 32.44, 30.72, 28.75, 28.52, 25.60, 19.41, 18.04,
12.63.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.74 (ESI-MS
(m/z): 571.08 (M+H+)).
HRMS: calcd. for C26H42N4O6S2Na, 593.2438 [M+Na+]; found 593.2408.
BocHN
S
HN
S NHBoc
NH
NHPbfHN
HN NHPbf
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Boc-Arg(Pbf)-Disulfide (65): Prepared according to general procedure 5 on a 4.21 mmol
(2.40 g) scale. Purified by automated column chromatography 20→100% EtOAc, pet-ether
40-60. Yield: 1.62 g, 1.54 mmol, 73%.
1H NMR (400 MHz, CDCl3) δ 6.47-6.18 (m, 6H), 3.91-3.77 (m, 2H), 3.40-3.13 (m, 4H),
2.96 (s, 4H), 3.04-2.81 (m, 4H), 2.57 (s, 6H), 2.51 (s, 6H), 2.10 (s, 6H), 1.76-1.50 (m, 8H),
1.46 (s, 12H), 1.41 (s, 18H).
13C NMR (101 MHz, CDCl3) δ 158.90, 156.76, 156.69, 138.45, 132.98, 132.42, 124.74,
117.65, 86.52, 79.65, 50.68, 43.42, 41.01, 31.53, 28.76, 28.64, 26.04, 19.49, 18.11, 12.65.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.62 (ESI-MS
(m/z): 1055.25 (M+H+)).
HRMS: calcd. for C48H78N8O10S4Na, 1077.4616 [M+Na+]; found 1077.4598.
BocHN
SH
HN
HN NHPbf
Boc-Arg(Pbf)-CH2SH (85): Prepared according to general procedure 7 on a 3.285mmol
scale. Yield: 94%. Thiol was used directly in following reaction due to air sensitivity.
BocHN
S
HN
HN NHPbf
S
O O
Boc-Arg(Pbf)-CH2SSO2-Ph] (66): Prepared according to general procedure 7 0.331 mmol
(349 mg) scale. Purified by automated column chromatography 20→80% EtOAc, pet-ether
40-60. Yield: 142 mg, 0.212 mmol, 32%.
1H NMR (400 MHz, CDCl3) δ 7.94 -7.89 (m, 2H), 7.65-7.59 (m, 1H), 7.58-7.51 (m, 2H),
6.30-6.02 (m, 3H), 5.01 (d, J = 8.8 Hz, 1H), 3.86-3.66 (m, 1H), 3.23-3.10 (m, 3H), 3.06
(dd, J = 13.7, 6.8 Hz, 1H), 2.95 (s, 2H), 2.56 (s, 3H), 2.50 (s, 3H), 2.09 (s, 3H), 1.63-1.50
(m, 2H), 1.45 (s, 6H), 1.50 âĂŞ 1.37 (m, 2H), 1.40 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 158.79, 156.16, 155.81, 144.37, 138.33, 133.90, 132.80,
132.28, 129.42, 127.02, 124.67, 117.52, 86.43, 79.92, 49.37, 43.23, 40.92, 40.82, 31.27,
28.61, 28.36, 25.60, 19.33, 17.97, 12.50.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.18 (ESI-MS
(m/z): 669.02 (M+H+)).
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HRMS: calcd. for C30H44N4O7S3Na, 691.2246 [M+Na+]; found 691.2235.
BocHN
S
HN
HN NHPbf
S
O O
Boc-Arg(Pbf)-CH2SSO2-(p-Me)Ph] (67): Prepared according to general procedure 7 on
a 0.383 mmol (404 mg) scale. Purified by automated column chromatography 20→80%
EtOAc, pet-ether 40-60. Yield: 423 mg, 0.423 mmol, 55%.
1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 6.20-
6.01 (m, 3H), 4.94 (d, J = 9.0 Hz, 1H), 3.83-3.72 (m, 1H), 3.25-3.08 (m, 3H), 3.04 (dd,
J = 13.7, 6.8 Hz, 1H), 2.95 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.44 (s, 3H), 2.09 (s, 3H),
1.63-1.47 (m, 4H), 1.45 (s, 6H), 1.40 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 158.92, 156.21, 145.25, 141.64, 138.51, 132.47, 130.14,
127.25, 124.78, 117.63, 86.54, 80.16, 49.33, 43.38, 40.98, 40.85, 31.61, 31.60, 28.75, 28.50,
25.65, 21.81, 19.44, 18.08, 12.63.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.33 (ESI-MS
(m/z): 683.01 (M+H+)).
HRMS: calcd. for C31H46N4O7S3Na, 705.2421 [M+Na+]; found 705.2402.
BocHN
S
HN
HN NHPbf
S
O O
OMe
Boc-Arg(Pbf)-CH2SSO2-(p-OMe)Ph] (68): Prepared according to general procedure 7 on
a 0.319 mmol (336 mg) scale. Purified by automated column chromatography 20→80%
EtOAc, pet-ether 40-60. Yield: 142 mg, 0.212 mmol, 33%.
1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 9.0 Hz, 2H), 7.00 (d, J = 9.0 Hz, 2H), 6.16-5.97
(m, 3H), 4.92 (d, J = 9.0 Hz, 1H), 3.88 (s, 3H), 3.85-3.73 (m, 1H), 3.29-3.08 (m, 3H), 3.04
(dd, J = 13.8, 6.7 Hz, 1H), 2.95 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.09 (s, 3H), 1.64-1.48
(m, 4H), 1.45 (s, 6H), 1.42 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 163.87, 158.77, 156.02, 138.38, 132.35, 129.49, 124.63,
117.49, 114.50, 86.40, 80.05, 55.81, 43.24, 40.86, 40.64, 31.52, 28.61, 28.36, 25.47, 19.29,
17.93, 12.48.
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LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.18 (ESI-MS
(m/z): 699.01 (M+H+)).
HRMS: calcd. for C31H46N4O8S3Na, 721.2370 [M+Na+]; found 721.2341.
BocHN
S
HN
HN NHPbf
S
O O
NO2
Boc-Arg(Pbf)-CH2SSO2-(p-NO2)Ph] (69): Prepared according to general procedure 7
0.337 mmol (355 mg) scale. Purified by automated column chromatography 20→80%
EtOAc, pet-ether 40-60. Yield: 172 mg, 0.241 mmol, 36%.
1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 8.9 Hz, 2H), 8.11 (d, J = 8.5 Hz, 2H), 6.32-6.04
(m, 3H), 5.10 (d, J = 8.9 Hz, 1H), 3.83-3.71 (m, 1H), 3.24-3.16 (m, 3H), 3.12 (dd, J =
13.6, 7.1 Hz, 1H), 2.96 (s, 2H), 2.55 (s, 3H), 2.49 (s, 3H), 2.09 (s, 3H), 1.63-1.48 (m, 4H),
1.46 (s, 6H), 1.38 (s, 9H).
13C NMR (101 MHz, CDCl3) δ 158.96, 156.15, 155.77, 150.46, 149.41, 138.32, 132.44,
132.28, 128.34, 124.82, 124.71, 117.65, 86.57, 80.02, 49.51, 43.19, 41.28, 40.80, 31.21,
28.60, 28.34, 25.69, 19.32, 17.97, 12.49.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.21 (ESI-MS
(m/z): 713.99 (M+)).
HRMS: calcd. for C30H43N5O9S3Na, 736.2115 [M+Na+]; found 736.2095.
BocHN
S
HN
HN NHPbf
S
O O
Boc-Arg(Pbf)-CH2SSO2-cHex] (86): Prepared according to general procedure 8 0.500
mmol (264 mg) scale. Purified by automated column chromatography 20→100% EtOAc,
pet-ether 40-60. Yield: 96%.
1H NMR (400 MHz, CDCl3) δ 6.28-6.06 (m, 3H), 5.12 (d, J = 8.9 Hz, 1H), 3.83-3.73 (m,
1H), 3.36-3.05 (m, 5H), 2.96 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.31-2.22 (m, 2H), 2.09 (s,
3H), 1.97-1.86 (m, 2H), 1.76-1.66 (m, 1H), 1.64-1.49 (m, 6H), 1.46 (s, 6H), 1.42 (s, 9H),
1.37-1.16 (m, 3H).
13C NMR (101 MHz, CDCl3) δ 158.75, 156.23, 156.00, 138.30, 132.87, 132.25, 124.64,
117.49, 86.41, 79.80, 71.27, 50.15, 43.24, 41.09, 40.84, 31.56, 28.62, 28.39, 26.32, 26.17,
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25.71, 25.12, 25.06, 25.02, 19.33, 17.98, 12.50.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.47 (ESI-MS
(m/z): 675.17 (M+H+)).
HRMS: calcd. for C30H50N4O7S3Na, 697.2734 [M+Na+]; found 697.2709.
Backbone Synthesis
N
N
O
N
H O
OBn
Synthesis of phenyl alanine derived Urea 47 according to the literature procedure.199 step
1, Isocyanate formation: was achieved from the TFA salt TFA.H2N-Phe-OBn (17.2 g, 48.7
mmol, 1.00 equiv.) and reaction progress was followed by TLC (5% MeOH/DCM). Step 2:
Urea formation: according to the literature procedure.199 Reaction progress was followed
by TLC (5% MeOH, DCM) and the title compound purified by column chromatography
(0→6% MeOH, DCM). Yield: (8.84 g, 23.2 mmol, 48%).
1H NMR (400 MHz, CDCl3) δ 7.35-7.30 (m, 3H), 7.30-7.26 (m, 2H), 7.21-7.17 (m, 3H),
7.02-6.97 (m, 2H), 5.16 (d, J = 12.2 Hz, 1H), 5.07 (d, J = 12.2 Hz, 1H), 5.00 (d, J = 7.6
Hz, 1H), 4.82 (dt, J = 7.6, 5.9 Hz, 1H), 3.37-3.31 (m, 4H), 3.09 (dd, J = 5.9, 3.1 Hz, 2H),
2.36-2.31 (m, 4H), 2.27 (s, 3H).
13C NMR (101 MHz, CDCl3) δ 172.51, 156.47, 136.13, 135.23, 129.34, 128.55, 128.47,
128.43, 128.42, 126.91, 67.06, 54.48, 54.38, 45.98, 43.56, 38.19.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 14.63 (ESI-MS
(m/z): 382.04 (M+H+)).
N
N
O
N
H O
OH
Carboxylic acid 48 was made according to the literature procedure.:199 Benzyl ester 47
(8.84 g, 23.2 mmol, 1.00 equiv.) was dissolved in 1% AcOH / EtOH (250 mL) and 10wt.
% Pd/C (2.3 g) used. TLC (5% MeOH in DCM) confirmed reaction completion. Yield:
7.36 g, 25.3 mmol, quant.
1H NMR (400 MHz, CDCl3) δ 7.18-7.08 (m, 5H), 5.88 (s, 1H), 4.48 (dd, J = 12.3, 6.4 Hz,
1H), 3.59-3.42 (m, 2H), 3.42-3.26 (m, 2H), 3.14 (dd, J = 13.8, 5.0 Hz, 1H), 2.99 (dd, J =
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13.8, 7.1 Hz, 1H), 2.73-2.49 (m, 4H), 2.39 (s, 3H).
13C NMR (101 MHz, CDCl3) δ 177.12, 156.91, 138.26, 129.71, 128.24, 126.60, 56.12, 53.09,
43.96, 42.02, 38.18.
Coupling warheads to backbone
N
N
O
N
H
H
N S S
O O
O
Inhibitor HomoPhe-CH2SSO2-Ph] (8): Prepared according to general procedure 9 on a
0.577 mmol (243 mg) scale. Purified by automated column chromatography 0→10%
MeOH, DCM. Yield: 281 mg, 0.472 mmol, 82%. To ensure high purity for biological test-
ing an 82 mg portion was further purified by preparative HPLC, returning 55 mg of the
title compound as a TFA salt after lyophilisation which was > 98% pure by HPLC.
1H NMR (400 MHz, Methanol-d4) δ 7.91 (d, J = 8.4 Hz, 2H), 7.70-7.63 (m, 1H), 7.62-7.55
(m, 2H), 7.26 (d, J = 4.3 Hz, 4H), 7.23-7.18 (m, 3H), 7.16-7.13 (m, 1H), 7.12-7.07 (m, 2H),
4.44 (dd, J = 9.0, 6.6 Hz, 1H), 4.21-4.06 (m, 2H), 4.01-3.91 (m, 1H), 3.49-3.36 (m, 2H),
3.19-3.10 (m, 2H), 3.07 (dd, J = 13.7, 6.6 Hz, 1H), 3.00 (dd, J = 6.4, 4.2 Hz, 2H), 2.92
(dd, J = 13.7, 9.0 Hz, 1H), 2.95-2.80 (m, 2H), 2.84 (s, 3H), 2.65-2.56 (m, 1H), 2.50-2.40
(m, 1H), 1.82-1.71 (m, 1H), 1.71-1.60 (m, 1H).
13C NMR (101 MHz, Methanol-d4) δ 174.63, 158.51, 145.98, 142.54, 138.70, 135.16, 130.66,
130.38, 129.53, 129.46, 129.40, 128.05, 127.82, 126.98, 57.98, 54.10, 49.38, 43.61, 42.38,
41.11, 39.12, 36.22, 33.00.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 17.06 (ESI-MS
(m/z): 595.13 (M+H+).
HRMS: calcd. for C31H39N4O4S2, 595.2407 [M+H+]; found 595.2397 and calcd. for
C31H39N4O4S2Na, 617.2227 [M+Na+]; found 617.2214.
N
N
O
N
H
H
N S S
O O
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Inhibitor HomoPhe-CH2SSO2-(p-Me)Ph] (9): Prepared according to general procedure 9
on a 0.485 mmol (211 mg) scale. Purified by automated column chromatography 0→10%
MeOH, DCM. Yield: 297 mg, 0.488 mmol, Quant. To ensure high purity for biological
testing a 33 mg portion was further purified by preparative HPLC, returning 13 mg of the
title compound as a TFA salt after lyophilisation which was > 99% pure by HPLC.
1H NMR (500 MHz, Methanol-d4) δ 8.09 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.4 Hz, 2H),
7.40 (d, J = 8.1 Hz, 2H), 7.31-7.18 (m, 6H), 7.15 (d, J = 7.5 Hz, 1H), 7.13-7.08 (m, 2H),
4.42 (dd, J = 9.0, 6.6 Hz, 1H), 4.25-4.04 (m, 2H), 4.01-3.89 (m, 1H), 3.52-3.35 (m, 2H),
3.21-3.07 (m, 2H), 3.03 (dd, J = 13.8, 6.7 Hz, 1H), 2.98 (t, J = 6.6 Hz, 2H), 3.04-2.92
(m, 2H), 2.90 (dd, J = 13.8, 9.0 Hz, 1H), 2.87 (s, 3H), 2.65-2.57 (m, 1H), 2.48-2.43 (m,
1H), 2.42 (s, 3H), 1.81-1.73 (m, 1H), 1.69-1.60 (m, 1H).
13C NMR (126 MHz, Methanol-d4) δ 174.69, 158.57, 146.63, 143.29, 142.61, 138.71, 131.14,
130.38, 129.55, 129.45, 129.40, 128.20, 127.84, 126.98, 57.95, 54.20, 43.65, 42.44, 41.10,
39.17, 36.25, 33.05, 21.59.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 18.29 (ESI-MS
(m/z): 609.10 (M+H+)).
HRMS: calcd. for C32H41N4O4S2, 609.2564 [M+H+]; found 609.2544.
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Inhibitor HomoPhe-CH2SSO2-(p-OMe)Ph] (10): Prepared according to general procedure
9 on a 0.441 mmol (199 mg) scale . Purified by automated column chromatography 0→10%
MeOH, DCM. Yield: 315 mg, 0.504 mmol, Quant. To ensure high purity for biological
testing an 83 mg portion was further purified by preparative HPLC, returning 60 mg of
the title compound as a TFA salt after lyophilisation which was > 99% pure by HPLC
.
1H NMR (400 MHz, Methanol-d4) δ 7.84 (d, J = 9.0 Hz, 2H), 7.28-7.18 (m, 7H), 7.16-7.05
(m, 5H), 4.43 (dd, J = 9.0, 6.5 Hz, 1H), 4.23-4.04 (m, 2H), 4.00-3.91 (m, 1H), 3.86 (s,
3H), 3.50-3.34 (m, 2H), 3.22-3.08 (m, 2H), 3.05 (dd, J = 13.7, 6.5 Hz, 1H), 2.98 (t, J =
6.2 Hz, 2H), 3.05-2.90 (m, 2H), 2.91 (dd, J = 13.6, 9.0 Hz, 1H), 2.85 (s, 3H), 2.65-2.56
(m, 1H), 2.50-2.40 (m, 1H), 1.83-1.72 (m, 1H), 1.71-1.59 (m, 1H).
13C NMR (101 MHz, Methanol-d4) δ 174.61, 165.47, 158.54, 142.58, 138.72, 137.55, 130.56,
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130.38, 129.53, 129.44, 129.39, 127.82, 126.98, 115.65, 57.96, 56.42, 54.13, 43.62, 42.40,
41.02, 39.15, 36.22, 33.04.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 17.33 (ESI-MS
(m/z): 625.11 (M+H+)).
HRMS: calcd. for C32H41N4O5S2, 625.2513 [M+H+]; found 625.2482 and calcd. for
C32H40N4O4S2Na, 647.2332 [M+Na+]; found 647.2305.
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Inhibitor HomoPhe-CH2SSO2-(p-NO2)Ph (7): Prepared according to general procedure 9
on a 0.204 mmol (95 mg) scale. Purified by automated column chromatography 0→10%
MeOH, DCM. Yield: 108 mg, 0.169 mmol, 83%. To ensure high purity for biological
testing all 108 mg was further purified by preparative HPLC, returning 36 mg of the title
compound as a TFA salt after lyophilisation which was > 98% pure by HPLC.
1H NMR (400 MHz, Methanol-d4) δ 8.36 (d, J = 9.0 Hz, 2H), 8.11 (d, J = 8.9 Hz, 2H),
7.32-7.15 (m, 7H), 7.13-7.04 (m, 3H), 4.42 (dd, J = 8.8, 6.8 Hz, 1H), 4.23-4.07 (m, 2H),
3.87-3.77 (m, 1H), 3.51-3.36 (m, 2H), 3.22-3.09 (m, 2H), 3.09-3.01 (m, 3H), 3.17-2.86 (m,
2H), 2.92 (dd, J = 13.7, 8.8 Hz, 1H), 2.86 (s, 3H), 2.66-2.57 (m, 1H), 2.50-2.39 (m, 1H),
1.80-1.70 (m, 1H), 1.68-1.57 (m, 1H).
13C NMR (101 MHz, Methanol-d4) δ 174.72, 158.55, 151.94, 151.01, 142.37, 138.65, 130.37,
129.58, 129.47, 129.46, 129.35, 127.87, 127.00, 125.89, 57.93, 54.15, 43.63, 42.42, 41.73,
39.10, 36.14, 32.84.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 17.55 (ESI-MS
(m/z): 640.11 (M+H+)).
HRMS: calcd. for C31H38N5O6S2, 640.2258 [M+H+]; found 640.2232.
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Inhibitor HomoPhe-CH2SSO2-cHex (11): Prepared according to general procedure 9 on
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a 0.391 mmol (167 mg) scale. Purified by automated column chromatography 0→10%
MeOH, DCM. Yield: 163 mg, 0.271 mmol, 69%. To ensure high purity for biological
testing all 163 mg was further purified by preparative HPLC, returning 130 mg of the title
compound as a TFA salt after lyophilisation which was > 99% pure by HPLC.
1H NMR (400 MHz, Methanol-d4) δ 8.15 (d, J = 8.5 Hz, 1H), 7.34-7.10 (m, 10H), 4.48
(dd, J = 9.2, 6.2 Hz, 1H), 4.27-4.08 (m, 2H), 4.08-3.96 (m, 1H), 3.52-3.34 (m, 2H), 3.26
(tt, J = 11.7, 3.4 Hz, 1H), 3.23-3.05 (m, 5H), 3.07-2.86 (m, 2H), 2.96 (dd, J = 13.8, 9.3
Hz, 1H), 2.86 (s, 3H), 2.71 (ddd, J = 14.4, 9.3, 5.4 Hz, 1H), 2.59 (ddd, J = 13.7, 9.1,
7.0 Hz, 1H), 2.26-2.14 (m, 2H), 1.94-1.84 (m, 3H), 1.84-1.74 (m, 1H), 1.73-1.66 (m, 1H),
1.55-1.43 (m, 2H), 1.42-1.27 (m, 2H), 1.22 (tt, J = 12.6, 3.2 Hz, 1H).
13C NMR (101 MHz, Methanol-d4) δ 174.76, 158.59, 142.66, 138.84, 130.37, 129.57, 129.55,
129.43, 127.80, 127.03, 71.85, 58.00, 54.17, 50.14, 43.63, 42.44, 41.37, 39.17, 36.65, 33.03,
27.51, 27.45, 26.23, 26.11, 26.07.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 17.97 (ESI-MS
(m/z): 601.08 (M+H+)).
HRMS: calcd. for C31H45N4O4S2, 601.2877 [M+H+]; found 601.2859 and calcd. for
C31H44N4O4S2Na, 623.2696 [M+Na+]; found 623.2672.
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Inhibitor HomoPhe-CH2SSO2-CH2Ph (12): Prepared according to general procedure 9 on
a 0.174 mmol (76 mg) scale. Purified by preperative HPLC 5→95% MeCN/Water, 0.1%
TFA. Yield: 32 mg, 0.044 mmol, 25%.
1H NMR (500 MHz, Methanol-d4) δ 8.08 (d, J = 9.1 Hz, 1H), 7.46 (dd, J = 8.0, 1.6 Hz,
2H), 7.36 (tdd, J = 8.7, 6.9, 3.7 Hz, 3H), 7.32-7.23 (m, 6H), 7.23-7.13 (m, 4H), 4.68 (s,
2H), 4.53 (dd, J = 9.4, 6.1 Hz, 1H), 4.17-4.10 (m, 3H), 3.41 (s, 2H), 3.29-3.22 (m, 1H),
3.14 (dd, J = 13.9, 6.1 Hz, 2H), 3.10 (br s, 2H), 2.96 (dd, J = 13.9, 9.4 Hz, 2H), 2.85 (s,
3H), 2.86-2.81 (br s, 2H), 2.72-2.64 (m, 1H), 2.49 (dt, J = 13.7, 8.2 Hz, 1H), 1.74 -1.63
(m, 2H), 1.10 (dd, J = 7.2, 1.1 Hz, 3H).
13C NMR (126 MHz, MeOD) δ 173.53, 173.44, 160.77, 160.41, 157.17, 141.26, 137.45,
131.32, 128.98, 128.88, 128.38, 128.33, 128.19, 128.07, 126.45, 125.67, 67.84, 60.68, 56.69,
48.65, 48.56, 42.24, 41.01, 40.19, 37.76, 35.31, 31.63
150
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 17.29 (ESI-MS
(m/z): 609.33 (M+H+)).
HRMS: calcd. for C32H41N4O4S2, 609.2564 [M+H+]; found 609.2251 and calcd. for
C32H40N4O4S2Na, 631.2383 [M+Na+]; found 631.2362
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Inhibitor HomoPhe-CH(Me)SSO2-CH2Ph (128): Prepared according to general procedure
9 on a 80µmol (36 mg) scale. Purified by preperative HPLC 5→95% MeCN/Water, 0.1%
TFA. Yield: 25 mg, 34 µmol, 25%.
1H NMR (500 MHz, Methanol-d4) δ 8.08 (d, J = 9.1 Hz, 1H), 7.46 (dd, J = 8.0, 1.6 Hz,
2H), 7.36 (tdd, J = 8.7, 6.9, 3.7 Hz, 3H), 7.32-7.23 (m, 6H), 7.23-7.13 (m, 4H), 4.68 (s,
2H), 4.53 (dd, J = 9.4, 6.1 Hz, 1H), 4.17-4.10 (m, 3H), 3.41 (s, 2H), 3.29-3.22 (m, 1H),
3.14 (dd, J = 13.9, 6.1 Hz, 2H), 3.10 (br s, 2H), 2.96 (dd, J = 13.9, 9.4 Hz, 2H), 2.85 (s,
3H), 2.86-2.81 (br s, 2H), 2.72-2.64 (m, 1H), 2.49 (dt, J = 13.7, 8.2 Hz, 1H), 1.74 -1.63
(m, 2H), 1.10 (dd, J = 7.2, 1.1 Hz, 3H).
13C NMR (126 MHz, MeOD) δ 173.80, 157.28, 141.29, 137.45, 131.34, 129.01, 128.84,
128.39, 128.28, 128.25, 128.18, 128.04, 126.38, 125.66, 68.37, 56.62, 52.75, 52.63, 51.79,
42.22, 41.05, 37.80, 33.62, 31.86, 15.98.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 17.29 (ESI-MS
(m/z): 609.33 (M+H+)).
HRMS: calcd. for C32H41N4O4S2, 609.2564 [M+H+]; found 609.2251 and calcd. for
C32H40N4O4S2Na, 631.2383 [M+Na+]; found 631.2362
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Inhibitor HomoPhe-CH(Me)SSO2cHex (127): Prepared according to general procedure 9
on a 59µmol (26 mg) scale. Purified by preperative HPLC 5→95% MeCN/Water, 0.1%
TFA. Yield: 25 mg, 25µmol, 42%.
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1H NMR (400 MHz, Methanol-d4) δ 8.17 (d, J = 9.0 Hz, 1H), 7.39-7.08 (m, 10H), 4.56
(dd, J = 9.5, 5.9 Hz, 1H), 4.29-3.96 (m, 3H), 3.61 (qd, J = 7.2, 3.8 Hz, 1H), 3.42 (br s,
2H), 3.27-3.10 (m, 2H), 3.09 (s, 2H), 3.00-2.88 (m, 2H), 2.86 (s, 3H), 2.74 (ddd, J = 13.9,
9.0, 5.0 Hz, 1H), 2.62-2.51 (m, 1H), 2.28-2.16 (m, 2H), 1.95-1.83 (m, 3H), 1.83-1.73 (m,
1H), 1.49 (tdt, J = 12.1, 7.4, 3.7 Hz, 2H), 1.41-1.31 (m, 2H), 1.29 (dd, J = 7.3, 0.9 Hz,
3H), 1.26-1.11 (m, 1H).
13C NMR (101 MHz, MeOD) δ 173.65, 157.31, 141.23, 137.52, 129.00, 128.23, 126.37,
125.65, 70.71, 56.51, 52.83, 52.77, 51.12, 42.23, 41.07, 37.76, 33.30, 31.82, 26.09, 25.96,
24.84, 24.71, 24.66, 16.75.
HRMS: calcd. for C32H46N4O4S2Na, 637.2853 [M+Na+]; found 637.2852.
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Inhibitor Arg-CH2SSO2-Ph (14): Prepared according to general procedure 10 on a 0.190
mmol (127 mg) scale. Purification directly by preparative HPLC (Linear gradient 5→40%
MeCN, 0.1% TFA, 80 min) returned the title compound as a TFA salt after lyophilisation
which was >99% pure by HPLC: Yield: 131 mg, 0.167 mmol, 88%.
1H NMR (400 MHz, Methanol-d4) δ 8.05 (d, J = 8.7 Hz, 1H), 7.98-7.93 (m, 2H), 7.77-7.70
(m, 1H), 7.69-7.61 (m, 2H), 7.27-7.15 (m, 5H), 4.33 (dd, J = 9.0, 6.6 Hz, 1H), 4.20-4.03
(m, 2H), 4.06-3.94 (m, 2H), 3.55-3.32 (m, 2H), 3.15-3.01 (m, 5H), 2.97-2.92 (m, 3H), 2.88
(s, 3H), 1.69-1.34 (m, 4H).
13C NMR (101 MHz, Methanol-d4) δ 174.99, 158.64, 158.56, 145.98, 138.64, 135.26, 130.75,
130.34, 129.56, 128.16, 127.88, 58.21, 54.13, 43.63, 42.40, 41.94, 40.93, 39.03, 31.39,
26.23.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 12.24 (ESI-MS
(m/z): 590.33 (M+H+)).
HRMS: calcd. for C27H40N7O4S2, 590.2578 [M+H+]; found 590.2557.
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Inhibitor Arg-CH2SSO2-(p-Me)Ph] (15): Prepared according to general procedure 10 on
a 0.180 mmol (124 mg) scale yielding 254 mg of crude material. Purification of a 44 mg
portion of crude material directly by preparative HPLC (Linear gradient 5→40% MeCN,
0.1% TFA, 80 min) gave the title compound as a TFA salt after lyophilisation which was
>99% pure by HPLC: Yield: 20 mg, (0.152 mmol, 84%, assuming all crude was to be
purified).
1H NMR (500 MHz, Methanol-d4) δ 8.03 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H),
7.46 (d, J = 8.4 Hz, 2H), 7.28-7.17 (m, 5H), 4.33 (dd, J = 9.1, 6.6 Hz, 1H), 4.29-3.83 (m,
2H), 4.06-3.94 (m, 1H), 3.59-3.21 (m, 2H), 3.15-3.00 (m, 3H), 2.98-2.89 (m, 3H), 2.88 (s,
3H), 2.45 (s, 3H), 1.69-1.60 (m, 1H), 1.61-1.49 (m, 2H), 1.46-1.38 (m, 1H).
13C NMR (126 MHz, Methanol-d4) δ 174.98, 158.64, 158.57, 146.77, 143.16, 138.66, 131.20,
130.34, 129.56, 128.27, 127.87, 58.21, 54.13, 43.64, 42.40, 41.95, 40.90, 39.04, 31.43, 26.24,
21.59.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 13.70 (ESI-MS
(m/z): 604.33 (M+H+)).
HRMS: calcd. for C28H42N7O4S2, 604.2734 [M+H+]; found 604.2717.
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Inhibitor Arg-CH2SSO2-(p-OMe)Ph (16): Prepared according to general procedure 10 on
a 0.094 mmol (66 mg) scale. Purification by preparative HPLC (Linear gradient 5→40%
MeCN, 0.1% TFA, 80 min) gave the title compound as a TFA salt after lyophilisation
which was >99% pure by HPLC: Yield: 50 mg, 0.61 mmol, 65%.
1H NMR (400 MHz, Methanol-d4) δ 8.05 (d, J = 8.7 Hz, 1H), 7.88 (d, J = 8.9 Hz, 2H),
7.45-7.18 (m, 5H), 7.13 (d, J = 8.9 Hz, 2H), 4.33 (dd, J = 9.1, 6.5 Hz, 1H), 4.20-4.05 (m,
2H), 4.03-3.94 (m, 1H), 3.89 (s, 3H), 3.54-3.35 (m, 2H), 3.24-3.00 (m, 5H), 2.99-2.89 (m,
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3H), 2.88 (s, 3H), 1.69-1.48 (m, 3H), 1.47-1.37 (m, 1H).
13C NMR (101 MHz, Methanol-d4) δ 175.00, 165.56, 158.61, 158.54, 138.68, 137.43, 130.66,
130.34, 129.54, 127.85, 115.70, 58.27, 56.45, 54.09, 49.02, 43.62, 42.37, 41.93, 40.87, 39.00,
31.46, 26.23.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 12.88 (ESI-MS
(m/z): 620.25 (M+H+)).
HRMS: calcd. for C28H42N7O5S2, 620.2683 [M+H+]; found 620.2656.
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Inhibitor Arg-CH2SSO2-(p-NO2)Ph (13): Prepared according to general procedure 10 on a
0.217 mmol (155 mg) scale. Purified by reverse phase automated column chromatography
(Linear gradient 5→40% MeCN, 0.1% TFA, 40 min) using a Biotage R© SNAP Ultra C18,
60 g column yielding the title compound as a TFA salt after lyophilisation which was
>98% pure by HPLC. Yield: 110 mg, 0.132 mmol, 61%.
1H NMR (400 MHz, Methanol-d4) δ 8.47 (d, J = 8.5 Hz, 2H), 8.19 (d, J = 8.5 Hz, 2H),
8.10 (d, J = 8.7 Hz, 1H), 7.31-7.17 (m, 5H), 4.33 (dd, J = 9.2, 6.4 Hz, 1H), 4.21-4.02 (m,
2H), 4.00-3.90 (m, 1H), 3.45 (br s, 2H), 3.22-2.98 (m, 7H), 2.95-2.90 (m, 1H), 2.98-2.80
(m, 2H), 2.88 (s, 3H), 1.69-1.40 (m, 4H).
13C NMR (101 MHz, Methanol-d4) δ 175.08, 158.60, 158.54, 152.09, 150.82, 138.65, 130.30,
129.62, 129.56, 127.86, 125.97, 58.21, 54.08, 43.62, 42.36, 41.89, 41.42, 38.93, 31.52,
26.22.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 13.24 (ESI-MS
(m/z): 635.33 (M+H+)).
HRMS: calcd. for C27H39N8O6S2, 635.2428 [M+H+]; found 635.2407.
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Inhibitor Arg-CH2SSO2-cHex (17): Prepared according to general procedure 10 on a 0.220
mmol (148 mg) scale. Purification directly by preparative HPLC (Linear gradient 5→40%
MeCN, 0.1% TFA, 80 min) returned the title compound as a TFA salt after lyophilisation
which was >99% pure by HPLC Yield: 93 mg, 0.118 mmol, 54%.
1H NMR (400 MHz, Methanol-d4) δ 8.11 (d, J = 8.8 Hz, 1H), 7.34-7.19 (m, 5H), 4.40 (dd,
J = 9.6, 5.9 Hz, 1H), 4.18-4.02 (m, 3H), 3.51-3.38 (m, 2H), 3.32 (tt, J = 11.8, 3.4 Hz,
1H), 3.25-3.04 (m, 7H), 2.96 (dd, J = 13.8, 9.6 Hz, 1H), 2.87 (s, 3H), 2.29-2.20 (m, 2H),
1.95-1.88 (m, 2H), 1.75-1.59 (m, 4H), 1.59-1.46 (m, 3H), 1.46-1.31 (m, 2H), 1.29-1.19 (m,
1H).
13C NMR (101 MHz, Methanol-d4) Îť 175.17, 158.63, 158.59, 138.84, 130.32, 129.55, 127.81,
71.96, 58.29, 54.10, 50.12, 42.37, 42.00, 41.29, 39.02, 31.87, 27.57, 27.43, 26.32, 26.22, 26.09,
26.05.
LC-MS (Linear gradient 5→95% MeCN, 0.1% TFA, 40 min): Rt (min): 13.65 (ESI-MS
(m/z): 596.33 (M+H+)).
HRMS: calcd. for C27H46N7O4S2, 596.3047 [M+H+]; found 596.3028.
10.0.4 Stability testing
pH dependent aqueous stability
All stability tests were carried out in 0.1m sodium phosphate buffer of the corresponding
pH with Ac-Phe-OH used as an internal standard. 70 µL of Ac-Phe-OH solution (1 mg/mL,
0.07 mg) in phosphate buffer of the relevant pH was added to 25µL of inhibitor solution
(9.8 mm stock solution in DMSO) and diluted with 880µL of pH buffer solution giving a
final volume of 1 mL with 5% DMSO. The sample was shaken for 10 min. before being
centrifuged at 13,200 rpm for 5 min. and transferred to an HPLC vial for sampling. The
sample was then analysed over 12 hrs. by HPLC using 12×60 min. gradients from (5→95%
MeCN, 0.1% TFA, 60 min.) yielding 12 measurements 1 h apart, a blank sample containing
5% DMSO in phosphate buffer was run after the analysis for subtraction from the baseline.
The inhibitor peak was integrated against the internal standard, data normalised to show
percentage degradation with time and plotted on a scatter graph for visualisation.
Stability towards benzyl amine and benzyl mercaptan
approximately 0.3 mg of the thiosulfonate inhibitor for testing was accurately weighed out
and dissolved in 1 mL MeCN. To this was added either 10 equivalents of benzyl mercaptan
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(for thiol stability testing) or 10 equivalents of benzyl amine (for amine stability testing)
in an HPLC vial. The vial was then analysed by HPLC using 13×60 min. gradients from
(5→95% MeCN, 0.1% TFA, 60 min.) yielding 13 measurements 1 h apart, a blank sample
containing only MeCN was run after the analysis for subtraction from the baseline. The
first measurement was defined as time 0. The inhibitor peak area was then taken for each
time point and normalised against time 0 to show percentage degradation with time. This
was then plotted on a scatter graph for visualisation.
10.0.5 Biology
Papain assay
All tested inhibitors were prepared as described and were >98% pure as determined by
analytical HPLC. Papain from papaya latex was purchased as a lyophilised powder from
Sigma Aldrich R©. The substrate Nα-benzoyl-L-arginine 4-nitroanilide hydrochloride was
purchased from Sigma Aldrich R©. As assay buffer sodium phosphate (100 mm, pH 6.5)
containing EDTA (1.5 mm) was used. Compounds were dissolved in DMSO (for molecular
biology grade) which was purchased from Sigma Aldrich R©. A CLARIOstar microplate
reader with Corning R© 96 well UV- transparent plates was used.
Method
Each inhibitor was screened by three separate experiments, each conducted in duplicate.
The Papain stock solution was prepared in assay buffer (40 µm), the solution shaken for
10 min. and then centrifuged at 13,200 rpm for 3 min. The substrate stock solution
(Bz-L-Arg-pNA) was prepared in DMSO (50 mm mM). Stock solutions of inhibitors were
prepared in DMSO (9.8 mm) and a 1:1 dilution made with buffer solution (4.95 mm), from
which relevant serial dilutions with 1:1 DMSO:Buffer solution were made to achieve the
desired concentrations of inhibitor solutions for the assay. To each well was added in-
hibitor solution (4.0µL), buffer solution (172.0µL) and papain solution (20.0 µL) followed
by thorough mixing (15 times by pipette upon papain addition). For the positive control
a DMSO/buffer solution (1:1) was used instead of the inhibitor solution and the negative
control (blank) was taken by replacing papain solution with assay buffer. After 1 h in-
cubation with shaking (shaker plate set to 100 rpm) a sample (98.0 µL) was taken from
each well and added to wells containing substrate solution (2.0µL), Mixed thoroughly by
pipette (15 times), the plate covered with a lid and centrifuged at 1000 rpm for 1 min (to
remove any air bubbles) and the subsequent liberation of p-nitroaniline was measured over
a 1h. time frame with 1 measurement per well per minute. Final concentrations in the
wells were: enzyme: 4µm; substrate: 1.0 mm; inhibitor: Doubling dilution range starting
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at 10 µm giving: 10µm, 5µm, 2.5 µm, 1.25µm, 0.625µm, 0.3125µm, 156.25 nm, 78.125 nm,
39.0625 nm.
Processing: As the liberation of p-nitroaniline was linear, the response was measured by
applying a line of best fit to the blank corrected data and taking the gradient as a measure
of the response. The gradients were normalized against the gradient of the positive control
(100% response in the absence of inhibitor). The normalized response was used to calculate
the IC50 value by plotting log(inhibitor) vs. normalized response with the GraphPad Prism
software suite.
S. mansoni bio-assay
Preparation of schistosomula
S. mansoni life cycle is maintained at the Institute of Tropical Medicine, University Hos-
pital Tübingen/Germany. S. mansoni infected vector snails were exposed to day-light to
induce shedding of cercariae. Schistosomula were obtained by mechanical transformation
of cercariae by vortexing following published procedures.101 Schistosomula were kept in
48-well plates in schistosomula culture medium (SCM; phenol-red free medium 199 [M199;
catalog number 11043-023; Gibco], 5.5 mM d-glucose, 200 U/ml penicillin, 200µg/ml strep-
tomycin, 1% heat-inactivated FCS [iFCS]) at 400 schistosomula/1 ml SCM/well for 24 h
to allow maturation before being further processed.
Schistosomula in vitro drug susceptibility assay
All compounds were tested in vitro against mature schistosomula. Thiosulfonate com-
pounds were dissolved in DMSO at a stock concentration of 10 mM. Mefloquine hydrochlo-
ride (MQ, Sigma-Aldrich) and auranofin (AU, Sigma-Aldrich) were dissolved in DMSO at
36 mM and 14.7 mM, respectively. All compounds were stored at -20 celsiusuntil further
use. 96 well, sterile, flat bottom plates were predosed with compounds at respective con-
centrations. Drug dilutions were done in SCM. Schistosomula were distributed at a density
of 100 worms/well. The number of worms was counted for each individual well. Final vol-
ume/well was 225 µL. In vitro cultures were kept at 37 ◦C and 5% CO2. Each experiment
included MQ and AU to control for schistosomula inhibition. Worm viability during in
vitro culture was controlled using ‘medium only’ and DMSO (1%), respectively. Viability
of worms per drug concentration was analysed by an inverted microscope (Nikon Eclipse
Ti) using 40× magnification. On the basis of motility and morphology, the parasites were
classified as viable (movement and normal appearance) or dead (no movement within 10
s and/or severe morphological changes of any kind compared to the morphology of un-
treated parasites, e.g., granularity, blebbing). Data analysis: Viability of schistosomula is
reported as the proportion of viable schistosomula to the total number of schistosomula
157
per respective well. Viability in % and log concentration of the drug were used to estimate
the IC50 by GraphPad Prim 6 applying the built-in 4 parametric regression analysis to
model curve fit.
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#!/bin/bash
#System requirements and notes: designed and tested on MacOS. 
Require install of Open Babel and install of Python 2.7. for 
script to operate.
#input parameters here:
pH=6.5 # Input the pH for protonation of ligands.
steps=3000 # Input the number of energy minimisation steps 
used for generation of ligand 3D coordinates (for conversion 
to .pdb)
echo Running ligand conversion … # all echo commands give a 
readout to the user in terminal to update on the process
echo
echo parameters:                                             
echo protonation state \(pH\) = $pH                            
echo energy minimisation steps = $steps                      
echo Energy minimisation method: MMF94\, steepest descending  
#these parameters can be altered in line 19, this is assumed 
to be the standard required.
for f in ligand_*.cdx; do #this for loop converts all .cdx 
files starting with the name ligand_ to corresponding .pdb 
files
    b=`basename $f .cdx`
    echo
    echo Processing $b to .pdb format ...
    echo
    obabel $f -O ${b}.pdb --gen3d -p $pH --minimize --steps 
$steps --sd # This line contains the presets used by Open 
Babel for file conversion
    echo
    echo $b conversion complete.
    echo
done
echo All ligands converted to .pdb
for f in ligand_*.pdb; do #this for loop converts all .pdb 
files starting with the name ligand_ to corresponding .pdbqt 
files
    b=`basename $f .pdb`
    echo
    echo Processing $b to .pdbqt format ... 
    echo
    python ./prepare_ligand4.py -l ${f} # this line calls on 
the python script to prepate .pdbqt files from the 
corresponding .pdb files. python version 2.7 is required for 
this.
    echo
    echo $b conversion to .pdbqt complete.
    echo
done
echo All ligands converted to .pdbqt
for f in ligand_*.pdbqt; do #this for loop rund the docking 
simulation for each of the previously prepared ligand .pdbqt 
files
    b=`basename $f .pdbqt`
    echo Docking ligand $b ... 
    mkdir -p $b
    ./vina --config config.txt --ligand $f --out ${b}/${b}
_out.pdbqt --log ${b}/${b}_log.txt #this is the vina 
executable to run docking. vina.exe must be present in the 
directory for this to function along with a configuration file 
named config.txt
done
# The following code is to 'clean' the apperance of the 
results and files generated
mkdir chemdraw\ files # makes a new directory named Chemdraw 
files
mv *.cdx chemdraw\ files # moves all Chemdraw files to new 
directory
mkdir pdb\ files # makes a new directory named pdb files
mv ligand_*.pdb pdb\ files # moves all pdb files to new 
directory
mkdir pdbqt\ files # makes a new directory named pdbqt files
mv ligand_*.pdbqt pdbqt\ files # moves all .pdbqt files to new 
directory
mkdir results # makes a new directory named results
mv ligand_* results # moves all docking result files to new 
directory
echo All ligands docked.
echo Job Complete.
cat DrawtoDock1.0.sh >> scriptlog.txt # saves a copy of the 
DrawtoDock1.0.sh script used to a log file for future 
reference
mv scriptlog.txt results # Moves the DrawtoDock script log 
file into the results folder.
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